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Fatty acid nomenclature and abbreviations
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18:2/i-6
18:3/i-3
20:3/i-6
20:3/i-9
22:3/i-9
20:4/i-6
22:4/>-6
20:5«-3
22:5/1-6
22:6/»-3
AF
BPD
C
CADI
CASI
C-AF
CZS
EDTA
EFA
EFADI
ERG
FAME
FL
GA
HC
HM
IV
IVH
LCP
LCP-AF
MDI
MUFA
ND
NS
PC
PDI
PE
nonadecanoic acid
oleic acid
linoleic acid
a-linolcnic acid
dihomo-y-linolcnic acid
Mead acid
dihomo-Mcad acid
arachidonic acid
adrcnic acid
eicosapentacnoic acid
Osbond acid
docosahexacnoic acid (ccrvonic acid)
artificial formula
bronchopulmonary dysplasia
capillary
ccrvonic acid deficiency index (22:5«-6/22:4/>-6)
cervonic acid sufficiency index (22:6/1-3/22:5/1-6)
conventional artificial formula
centraal zenuwstelsel (central nervous system)
ethylenediaminetetracetic acid
essential fatty acid
essential fatty acid deficiency index (20:3n-9/20:4/j-6)
electroretinogram
fatty acid methyl ester
fosfolipide (phospholipid)
gestational age
head circumference
human milk
intravenous
intraventricular haemorrhage
long-chain polyunsaturated fatty acid (long-chain polyene)
artificial formula enriched with long-chain polyunsaturated fatty
acids
(Bayley) Mental Development Index
monounsaturated fatty acid
none detected
not significant
phosphatidylcholine
(Bayley) Psychomotor Development Index
phosphatidylethanoline
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Nomenclature and abbreviations
PC prostaglandin
PL phospholipid
PUFA polyunsaturated fatty acid
RBC red blood cell
SAFA saturated fatty acid
SO standard deviation
SOA small for gcstational age
Ul unsaturation index [sum of (number of double bonds * % level
of fatty acid)]
v venous
VEP visual evoked potential
Introduction
In the Netherlands, about 7<* of live-born infants are born preterm. that is within 37
weeks of gestation [ 1 ]. Over the past few decades, the overall prognosis of these vulnerable
infants, born as early as after 26 weeks of pregnancy, has improved substantially thanks to
medical and technical advances in perinatal care, especially regarding the management of
cardio-respiratory problems in the early neonatal period |2-4). Another factor which has
contributed to the decreased mortality and morbidity of prelerm infants is the increased
knowledge of their particular nutritional needs, for the prctcrm infant's gastrointestinal tract
and metabolic make-up are immature and insufficiently prepared to properly digcsl, absorb
and metabolize nutrients. To achieve optimal growth and development, prelerm infants do
not only have special requirements for fluid, amino acids, vitamins, minerals and energy,
but also for specific, so-called essential fatty acids (HFAs), which arc necessary for main-
taining particular body functions even more so than for providing the infant with energy.
1.1 Parent essential fatty acids and their longer-chain derivatives
That certain fatty acids, besides their importance as a source of energy, also have
specific, essential biologic functions, was first revealed by the pioneering work of Burr and
Burr [5,6]. They observed retarded growth, scaly skin, impaired fertility, increased trans-
epidermal loss of water, and even death in rats maintained on a fat-free but otherwise
adequate diet for several weeks. Inclusion of small amounts of linoleic acid (18:2n-6') or
a-linolenic acid (18:3n-3) in the diet was found to alleviate these deficiency symptoms
[5,6], so they coined the term 'essential fatty acids' for these fatty acids that were obviously
not synthesized in the animal organism, but had to be derived from the diet for normal
physiological function. It was, however, not until several decades later, that EFAs were
conclusively proven to be indispensable to human infants [7-9] and adults [10-12],
Humans cannot synthesize 18:2n-6 and 18:3/i-3 <fe novo, because, unlike plants, they
lack A12- and A15-desaturases. However, the human body is capable of converting these
parent EFAs to their longer-chain and more unsaturated derivatives through alternate desatur-
ation and elongation [13,14], using the same enzymes as catalysts for the equivalent steps
in the «-7, «-9, M-6, and «-3 fatty acid pathways (figure 1.1.). The rate of synthesis of these
so-called long-chain polyunsaturated fatty acids (LCPs, having a chain length of at least 20
carbon atoms, and at least one more double bond than their parent EFA) of the n-6 and «-3
'In this thesis, the nomenclature used for fatty acids is as follows: the number of carbon atoms,
followed by a colon and the number of unsaturated, double bonds; the fatty acid family is identified
by designation of the first double bond from the methyl-n terminus of the fatty acid carbon chain.
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families is limited by the activity of A6-desaturase [15]. The substrate affinity of this
enzyme is known to be determined by the number of double bonds in the substrate and is
in the order 18:3n-3 > !8:2n-6 > l8:l«-9 (oleic acid) [16]. The activity of the desaturases is
also dependent on the concentrations of the substrate (A6-desaturase) and product (A6 and
A5-dcsaturascs) of the reaction, as well as several other nutritional and hormonal factors
[17,18|. Only recently, the final conversion step was demonstrated not use a single enzyme
('A4-dcsatura.se') as catalyst, but to occur via elongation, A6-desaturation and retrocon-
vcrsion by pcroxisomal (3-oxidalion [19]. Interconversion between the fatty acids of the
various families is not possible in mammalian tissue, because the necessary enzymes are not
available.
Although a proportion of the EFAs supplied to the body, particularly of 18:2n-6 and
l8:3n-3, is used to provide energy, many of the important biologic functions of EFAs are
related to their incorporation into phospholipids (PLs), and other structural units of biomem-
brancs. The specific presence of adequate 18:2/1-6 levels in skin sphyngolipids has been
demonstrated to be indispensable to maintaining the integrity of the epidermal water barrier
[20,211. The essentiality of 18:3n-3 seems to be mainly related to its role as a precursor of
«-3 LCPs. The major LCP of the n-3 series, docosahexaenoic acid (22:6n-3, also named
cervonic acid), together with the major LCP of the n-6 series, arachidonic acid (20:4/i-6), is
present in substantial amounts in the human brain [22-24] and retina [25]. Besides, 20:4n-6
and two additional Id ' s , dihomo-y-linolenic acid (20:3n-6) and cicosapentaenoic acid
(2O:5n-3), arc substrates for the production ol prostaglandins and other eicosanoids [20-28],
which have important bioregulatory functions [29-33].
When the amount of EFAs supplied to or present in the body is unable to cover its EFA
demands, 'surrogate' fatty acids arc synthesized instead. Because the presence of such fatty
acids in tissue lipids is a sign of an absolute or relative shortage of the parent EFAs and
their longer-chain derivatives, they arc named EFA deficiency indicators. A well-known
indicator of a general EFA deficiency is Mead acid (eicosatrienoic acid, 20:3n-9) [34,35],
since it is synthesized from 18:l/i-9 when insufficient amounts of the parent EFAs 18:2n-6
and 18:3n-3, and/or their LCPs are present to, respectively, occupy or inhibit the A6-desatur-
asc. Based on this metabolic principle, the ratio of 20:3n-9 to 20:4«-6 (triene/tetraene ratio
or EFA deficiency index) was introduced as an EFA deficiency marker [36].
Another fatty acid commonly regarded as an EFA deficiency indicator is the ultimate
desaturation and elongation product of 18:2n-6, Osbond acid (22:5n-6)*. The production of
this fatty acid is increased in case of an isolated shortage of 22:6n-3. Since the formation of
22:5M-6 also depends on the availability of its immediate precursor adrenic acid (22:4/1-6),
the ratio of 22:5n-6 to 22:4«-6, also called the cervonic acid deficiency index (CADI), is also
used as a marker of 22:6n-3 (cervonic acid) deficiency [38,39].
""The full systematic name of this fatty acid is 4,7,70, /.?. 76-docosapentaenoic acid, which cannot
be shortened to docosapentaenoic acid, because of the existence of 7./0,/.?, /6. /9-docosapcntaenoic
acid (22:5n-3). As an alternative lor ihc comprehensive designation of 22:5n-6. G. Hornstra proposed
[37] to name this fatty acid after the person who first synthesized it, J.M. Osbond [Chem Ind (Lon-
don) 1959:1288; J Chcm Soc 1961:2779 (synth)].
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Figure 1.1. TTie main pathways of fatty acid synthesis and conversion.
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1.2 Long-chain polyunsaturated fatty acids during pre- and postnatal
life
Considering the indispcnsability of EFAs to normal human body growth and function,
adequate EFA levels arc of particular importance during the limited periods of most rapid
tissue and organ growth and development, that is during the last months of fetal and the
first months of postnatal life |40). Quantities of EFAs required daily for intrauterine <fc novo
tissue synthesis have been estimated to be about 400 mg/kg body weight of «-6 EFAs and
50 mg/kg body weight of n-3 EFAs [41 ]. That the EFAs preferentially needed by the devel-
oping fetus are the longer chain derivatives, was suggested by the observation of Crawford
and co-workers (42| that levels of the parent EFAs 18:2n-6 and 18:3n-3 decreased, and
levels of their «-6 and n-3 l.CPs increased in the PLs from maternal blood to cord blood,
fetal liver and to fclal brain; a phenomenon which they termed 'biomagnification'. A
significant portion of these LCPs, especially of 22:6n-3 and 20:4/j-6, is used for incorpor-
ation in neural tissue, particularly during cell division [43]. Most of the development of the
human brain takes place in utero and during the first two years of life [44], and about 70%
of brain cells divide before birth. Indeed, 22:6«-3 and 20:4/j-6 have been shown to accumu-
late rapidly in neural tissue during the last trimester of gestation [45,46], and their accretion
has been found to continue throughout the first two years of postnatal life [47].
The exact way or ways in which the growing and developing fetus obtains the required
HFAs is not ycl known. Obviously, the fetus cannot synthesize the parent EFAs, which,
therefore, have to be derived from the maternal circulation. The LCPs, however, can poten-
tially be obtained cither directly from the maternal circulation by passage across the pla-
centa, or by conversion from 18:2/1-6 and 18:3/i-3 in placcntal or fetal tissue [48]. Yet,
since the information available on fetal fatty acid biochemistry indicates that the desaturase
activity in fetal liver microsomes is low [49], and that in human placcntal tissue is low [50]
or even not detectable [49,51], the direct LCP supply by the maternal circulation appears to
be the most likely option. Irrespective of the way in which the fetus obtains the necessary
LCPs, studies of EFA levels in umbilical cord vessel walls of full-term infants have raised
doubts as to whether the intrauterine supply of EFAs, including LCPs, adequately covers the
demands by the fetus, in particular because the umbilical artery vessel walls were found to
contain substantial amounts of the EFA deficiency indicator 2O:3/i-9 [37,51,52].
As stated at the beginning of this introduction, in about 7% of advanced pregnancies,
the physiological courses of fetal growth and development arc interrupted by (very) preterm
delivery. Consequently, preterm infants, unlike full-term infants, cannot benefit from the
maternal and placcntal HFA supply during the last trimester of pregnancy when handling the
demands of their still growing and developing brain and body. Instead, during this period of
very rapid brain growth, they are dependent on (heir own dietary supply through either
human milk, which contains small but significant amounts of 22:6/i-3, 20:4n-6 and other
l.CPs. or commercially available artificial formulas, the majority of which docs not contain
any but trace amounts of l.CPs [54,55]. An appropriate postnatal dietary LCP supply to
preterm infants is all the more important, since these infants have very limited fatty acid
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stores [41,56.57] and are bom with lower EFA levels in their plasma than infants earned to
term [58].
The first studies of the influence of either breast or bottle-feeding on the UFA status of
newborn infants were conducted in full-term infants, and in these studies higher t i l ' levels
were observed in the infants raised on their own mother's milk [59,60]. A number of
studies in pretcrm populations have since reported that conventional formulas, even when
they do contain substantial amounts of the parent KFAs 18:2/1-6 and 18:3«-3, are unable to
maintain postnatal 22:6n-3 and 20:4n-6 levels in plasma and red blood cell (RBC) lipids at
levels observed after feeding pretcrm human milk [61-63], Probably, (he desaturase capacity
of (pretcrm) newborns is too limited to guarantee and adequate supply of M-3 ami »i-6 i.c'Ps
solely through metabolic conversion of the two parent EFAs [49.57], The potential import-
ance of maintaining adequate LCP levels during development was indicated by various
animal studies, in which dietary EFA and LCP levels were found to influence visual and
cognitive functions in rats and rhesus monkeys [39,64-66], These observations prompted the
first cautious attempts to reduce the differences between the biochemical l.O" status of
human milk and formula-fed infants by adding LCPs to the diets of formula-fed infants
[63.67.68],
1.3 Outline of thesis
So far, this introduction consisted of a brief review of the information on t-l-As in
general and the role of LCPs during development in particular, that was available from the
literature at the time the studies described in this thesis were initiated. Even though the
research carried out thus far supported the relevance of an adequate LCP supply for proper
development, especially for the vulnerable prctcrm infant, a number of important questions
were still unanswered. The primary aim of this thesis was to extend the existing knowledge
on the biochemical LCP status of the preterm infant and how this status is influenced by the
(potentially limited) pre- and postnatal supplies of EFAs, the longer-chain derivatives in
particular. More specifically, a number of protocols were developed to study the following
items:
1.3.1 Supply of long-chain polyunsaturated fatty acids during intrauterine life
LoHg-c/iai'/i /w/yM«.saf «rated/a/fy ac/J j/afMS «ƒ />refe/7w /'/i/iirir.v a/ fciVf/j
The EFA profiles of umbilical cord vessel walls (reflecting the fetal EFA status) of
preterm infants are evaluated in Chapter 2 by comparing them with those of infants carried
to term. Besides, the potential relations among cord vessel wall EFA levels, gcstational age
(GA) at birth, and parameters of prenatal growth are studied. The EFA status is assessed in
umbilical cord vessel walls, since their EFA profile is considered a longer-term represen-
tation of the EFA supply to (cord vein) and return flow from (cord arteries) the fetus [53,-
69]. The PL fraction is studied especially, because PLs arc structural lipids, which arc the
richest source of polyunsaturated fatty acids (PUFAs), including EFAs in general and LCPs
in particular. In addition, changes in PUFA profile are most pronounced in PLs [18].
Chapter 1
/affy acW jfafuj af WrtA ai a re/fccf/on o/ f/it /<?fa/ «se/ifia/ /afry
As in Chapter 2, studies on the fetal EFA and LCP status are usually based on material
(umbilical plasma, RBCs and/or cord vessel walls) collected after delivery [37,53,58,69-71].
However, to what extent the EFA status at birth is an accurate reflection of the fetal EFA
status, is virtually unknown. Therefore, the PL-associated EFA profiles of plasma obtained
through fetal blood sampling, giving more direct information on the fetal EFA status, and of
plasma collected from the umbilical cord shortly after delivery at a similar GA are compared
in Chapter 3. Moreover, these plasma data are used to better understand the differences
between the cord vessel wall EFA profiles of preterm and full-term infants that are described
in Chapter 2.
£jjfMia/ /affy acid sfafu5 o/ in/ante bora a/iff r a mu//ip/> /wgna/jcy
A major cause of prctcrm delivery is multiple pregnancy [72]. If the low efa status,
reported for full-term infants born after an uneventful, singleton pregnancy [37,51,52], is
caused by a limited maternal EFA supply, the higher total fetal EFA demand associated with
a multiple pregnancy would result in an even lower biochemical EFA status of the infants
born after a multiple pregnancy. To study whether the maternal EFA supply is a limiting
factor in the neonatal EFA status indeed, the EFA profiles of umbilical artery and vein wall
PLs of 30 pairs of twins, 7 sets triplets, and one set of quintuplets arc compared with those
of 94 infants born after a singleton pregnancy in Chapter 4.
1.3.2 Postnatal long-chain polyunsaturated fatty acid status of preterm infants
/n/7«f«ce o/ƒ<??dinj? /tuman mi/A: or conwnf/wia/ arfi/icia/ /ormu/as
The first of the two main studies of the influence of the postnatal dietary LCP supply on
the postnatal LCP status of prctcrm infants is described in Chapter 6. During the first four
weeks of postnatal life, patterns of weekly changes in the LCP status of 12 human milk-fed
infants and of 27 infants raised on a conventional artificial formula, lacking LCPs, are com-
pared. Special emphasis is given to the evaluation of effects on the two major LCPs 22:6n-3
and 20:4w-6. Fatty acid values in plasma and RBC PLs are expressed in terms of both
absolute amounts (mg/1 plasma or RBC suspension) and the usual relative levels (mg/100 mg
total fatty acids), in view of the potential additional information that can be obtained from
the first.
The observations described in Chapter 6 and similar findings by others [61-63] of a signifi-
cant influence of the postnatal dietary LCP supply on the postnatal LCP status of preterm
infants, gave rise to the questions addressed in the following two chapters of this thesis:
/«/7i«virr o/ /wnafa/ /ong-r/iain /m/vunftifurafrd /afry acid 5M/>p/y
Whether postnatal LCP values in preterm infants are also significantly affected by the
LCP supply during intrautcrine life is studied in Chapter 7, again with special emphasis on
22:6n-3 and 20:4n-6. To this end. the LCP status at preterm birth (measured in the umbilical
artery wall PLs, and in umbilical plasma or RBC PLS) which results from the prenatal LCP
supply, and the postnatal diet (human-milk or conventional artificial formula), representing
the postnatal LCP supply, are related to the LCP status measured in plasma or RBC PLs
collected from the preterm infants in the period during which they were actually due to be
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bom (37-42 weeks GA). In addition, the exploration conducted in Chapter 2 of the relations
among EFA status. GA. and growth parameters at birth is extended by also studying l.CP
levels in umbilical plasma and RBC PLs.
cia//omtultu or/<>rmi«toj enric/»«i H'i//i 22:6n-J
The results of a randomized controlled intervention study of the potentially favourably
effects on the LCP status of supplying formula-fed prctcrm infants with an artificial formula
containing both 22:6/i-3 and 20:4n-6 in levels present in human milk until three months
after their initially expected date of delivery, arc described in Chapter 8 When this study
was initiated, results of other studies using LCP-supplcmcntcd formulas were avuiluhlc
{63,67,68,73], but these were of short duration and/or focused on ;i-3 LCP addition only. In
our study, blood LCP levels of 15 infants fed on the LCP-cnriched study formula were
compared with those of 16 infants receiving a conventional formula (lacking I <Ts) and with
those of a group of 12 prctcrm infants raised on human milk.
1.3.3 Methodological considerations
i/ifv «ƒ /affy acid /m>///« o/ venous am/ ra/jiY/firv /»/«.vm« </m/ r«/ />/rxx/ rr//
The influence of the postnatal dietary LCP supply on the postnatal LCP status of prcterm
infants was studied in plasma and RBC PLs of blood samples collected at regular intervals
after birth (Chapters 6 and 8). To reduce the burden placed on the participating infants, the
required blood samples were to be collected in conjunction with diagnostic punctures,
which are part of the routine clinical management at the neonatology ward. Since the blood
obtained in this manner can be of venous or capillary origin, the fatty acid profiles of these
two types of blood have to be comparable in order to obtain reliable information on the
dietary influences. Since information on this comparability appeared unavailable, the I'L-
associated fatty acid profiles of plasma and RBC PLs from blood obtained by venous and by
capillary puncture are compared in Chapter 5. In addition, the effects of storage at -20 °C
for a maximum of four weeks are evaluated, since all blood samples of a pretcrm infant
were to be analyzed simultaneously to ensure uniformity of analytic conditions. For ethical
reasons this study was not performed in young infants but in 8 healthy adult volunteers.
Finally, the major findings of the above-mentioned studies and their implications for
current views and future research are discussed in Chapter 9.
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2.1 Abstract
The essential fatty acid (EFA) composition of umbilical vessel walls is increasingly being
studied as a longer-term reflection of the fetal EFA status. We evaluated the EFA content of
umbilical artery and vein vessel walls in 43 preterm infants and compared it with that of 43
full-term cord vessels. In addition, relations among cord vessel wall fatty acid composition,
gestational age (GA) at birth, and anthropometric parameters at birth (weight, head circum-
ference, and length) were explored in the preterm infants. Generally, «-6 and «-3 EFA levels
were lower, while levels of EFA deficiency markers were higher in preterm than in term
cords, both in the walls of the draining arteries and the supplying vein. In preterm cords,
significant correlations were observed between GA at birth and levels of «-6 and n-3 EFAS
(positive) and EFA deficiency markers (negative). Birth weight showed significant (P<0.01),
positive correlations with n-6 and n-3 EFA levels in the cord artery walls of preterm infants,
all after correction for GA at birth. In conclusion, substantial differences between the EFA
profiles of preterm and full-term cord vessel walls indicate a lower biochemical EFA status
of the preterm than of the term fetus. The lower preterm EFA values might be a reflection
of a physiologically lower EFA demand for growth and development of the preterm fetus
than of the term fetus.
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2.2 Introduction
In recent years, nutritional researchers have adopted the essential fatty acid (EFA) profile
of umbilical vessel walls as a tool for studying the fetal EFA status. Considering the absence
of va.su va.yr>rMm for human umbilical vessels and the inability of human tissue to syn-
thesize EFAs de novo, EFAs present in the umbilical vessel walls must have been derived
from the blood flowing through them. Consequently, and because of the relatively slow
turnover of vessel wall phospholipids (PLs), the EFA composition of the umbilical vein wall
PLs can be regarded as a longer-term representation of the EFA supply to the fetus. Similar-
ly, the EFA profile of the umbilical artery wall PLs can be considered a longer-term reflec-
tion of the EFA content of the return flow from the fetus to the mother and, as such, an
indication of the fetal EFA status.
The first studies that evaluated the EFA content of umbilical vessel walls suggested that
the biochemical EFA status of healthy, full-term infants, born after an uncomplicated preg-
nancy might not be optimal: substantial amounts of Mead acid (2O:3n-9) were observed,
particularly in the umbilical artery [1-3]. This 20:3n-9 is considered a reliable marker of
EFA deficiency (4|, since it is synthesized when insufficient amounts of the EFAs a-linolenic
acid (18:3/1-3) and linolcic acid (18:2n-6) are present to occupy the A6-desaturasc. In
addition, levels of 18:2n-6 were found to be low in umbilical vessel wall PLs when com-
pared to adult colonic vessel wall PLs [2|. Moreover, the PLs of the draining arteries gen-
erally contained significantly less long-chain polyunsaturalcd fatty acids (LCPS, formed from
the parent EFAs 18:2n-6 (n-6 LCPs) and 18:3n-3 (n-3 LCPs) through alternate desaturation
and elongation) than the wall of the supplying vein [2,3,5]. Considering the growing evi-
dence that these LCPs arc of essential importance for a normal development of brain and
visual function [6-9], a sub-optimal EFA status at birth could have important implications for
postnatal life. Besides, cord vessel wall levels of EFAs and their deficiency indicators have
been reported to be related to parameters of antenatal growth [10-12; Chapter 7].
So far, all studies regarding the EFA composition of cord vessel walls were carried out
in full-term infants, or in infants born after at least 36 weeks of pregnancy [11]. To our
knowledge, data on cords of younger prcterm infants are not yet available. Therefore, we
studied the fatty acid compositions of preterm umbilical artery and vein walls and compared
these with the fatty acid profiles of cord vessel walls of a full-term population. In addition,
we evaluated relations among prcterm cord vessel wall fatty acid composition, gestational
ugc (GA) at birth, and anthropometric parameters at birth (weight, head circumference (HC),
and length).
2.3 Patients and methods
2.3.1 Infants
The total population studied comprised 43 preterm infants (GA: 26-36 weeks, birth wei-
ght: 650-1860 g) and 43 full-term infants (GA: 37-41 weeks, birth weight: 2630-4130 g). All
infants were born in the same period, after a singleton pregnancy. Relevant clinical charac-
teristics of both study populations arc listed in table 2.1. GA was confirmed by menstrual
history and early ultrasound dating, and by Dubowitz score [13] if the former information
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Table 2.1. Clinical characteristics of study
maternal age (years)
pnmipara (n)
geslauona) age at birth (wks days)
birth weight (g)
head circumference at birth (cm)
length at birth (cm)
pH umbilical artery blood
male : female (n)
populations (mean ± SO).
preterm infants (n>43)
28.3 * 5.6
24 (55.8%)
31.0 ±2.4
1412 ±321
27.9 ± 2.6
40.2 ± 3.1
7.22 ±0.12
2 3 : 20
full-term infants (n>43)
28.8 ± 4.9
35(814*)*
40.0 ± 1.0*
3288 ±348*
34.1 ± 1.3*
49.9 ± 1.9*
7.23 ± 0.09
26: 17
Significance level for statistical difference between preterm and term infants:
'chi-square test: P=0 01,
*two-tailed Student's t-test: P<0.0005.
was missing or doubtful. The infants all had a birth weight appropriate for gcstutionul age,
that is above the 2.3rd percentile of the Amsterdam growth charts 114], and were free from
metabolic disease and congenital malformations. Approximately 15 cm of umbilical cord
was collected from each infant immediately after delivery.
Birth weights were assessed, shortly after delivery, on a calibrated infant scale and
recorded to the nearest 5 g. HC and crown-heel length of the term newborns were measured,
with a measuring tape, shortly after delivery. For the preterm infants, this was done on the
third day of life to reduce the effects of head moulding at birth on HC and of intra-uterine
body position (eg breech position) on length. For the measurement of HC, the measuring
tape was placed over the most pronounced parts of the occiput and the forehead. Crown-
heel length was measured with the infants in supine position. Both measurements were
recorded to the nearest millimetre.
The study was approved by the medical ethics committee of the University Hospital of
Maastricht and written informed consent was obtained from one or both parents.
2.3.2 Laboratory analysis
Umbilical vessel wall samples were prepared and analyzed as described previously
[12,15; Chapters 6,7]. At the start of the analysis, approximately 40 pg of 1,2-di-
nonadecanoyl phosphatidylcholine [PC-( 19:0)2] w^s added to every sample as an internal
standard to quantify fatty acid amounts present in the PL fraction of the umbilical arteries
and vein. Absolute fatty acid amounts were expressed as mg/kg dry weight of cord vessel
wall tissue, relative fatty acid levels as % (wt/wt) of total fatty acid methylesters.
In total, 26 fatty acids were identified. Since this study focuses on the EFA status, only
the following relevant 8 fatty acids and 6 fatty acid combinations are reported: 20:3n-9,
dihomo-Mead acid (22:3n-9), 18:2«-6, dihomo-y-linolenic acid (20:3n-6), arachidonic acid
(20:4n-6), adrenic acid (22:4n-6), Osbond acid (22:5n-6), docosahexaenoic acid (22:6n-3,
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also named cervonic acid), Z SAFA (sum of all saturated fatty acids), Z MUFA (sum of all
monounsaturated fatty acids), Z PUFA (sum of all polyunsaturated fatty acids), £ n-9 PUFA
(sum of all PLTFAS of the «-9 series), Z «-6 LCP (sum of the LCPs of the n-6 series, and Z
n-3 LCP (sum of the LCPs of the «-3 series).
In addition, three indices were calculated to describe the functional EFA status. The EFA
status index, defined as the ratio of the sum of all fatty acids of the n-3 and n-6 series to
the sum of all fatty acids of the «-7 and n-9 series (Z n-3+n-6/Z n-7+/i-9) [5] was used
because a sufficient supply of n-3 and n-6 fatty acids will limit the desaturation of the non-
essential n-7 and n-9 MUFAs to their respective PUFAs. For a similar reason, the classic
tricnc/tctraenc ratio (EFA deficiency index, EFADI): 20:3n-9/20:4n-6 [16] was calculated. The
cervonic acid deficiency index (CADI), defined as the ratio of 22:5n-6 to its immediate
precursor 22:4n-6, was calculated because a shortage of 22:6n-3 (cervonic acid) is accom-
panied by an increased conversion of 22:4n-6 to 22:5n-6, leading to higher CADI values
2.3.3 Data analysis
Data arc presented as mean ± standard deviation, unless mentioned otherwise. Fatty acid
levels in the umbilical vessel walls of preterm and term infants, as well as continuous
clinical variables, were compared using the two-tailed Student's t-test. Discrete clinical
variables were compared with the chi-square test.
In the prctcrm study group, relations among fatty acid levels in the umbilical vessel
walls, GA at birth, and anthropometric parameters at birth were explored using linear
regression (Pearson correlation coefficients). Significant correlations between the EFA profile
of prctcrm infants and anthropometric parameters at birth were corrected for GA at birth by
multiple regression analysis.
In view of the relatively large number of comparisons made, differences with P-values
£0.01 were considered significant.
2.4 Results
2.4.1 Essential fatty acid profiles of preterm and full-term cord vessel walls
The total fatty acid concentration (mg/kg dry weight) in the artery wall PLs was sig-
nificantly higher in the preterm than in the full-term study group (table 2.2.). This was
mainly due to higher amounts of MUFAS in the preterm cords. Moreover, the absolute
amount of the EFA deficiency marker 2O:3n-9 was significantly higher in the preterm cord
artery walls. The concentrations of most n-6 and n-3 PUFAs were significantly lower in the
preterm artery PLs, the only exceptions being 18:2/i-6 (no significant difference) and the
22:6n-3 deficiency marker 22:5n-6, the concentration of which was higher in preterm artery
PLs.
For the non-essential fatty acid concentrations, results obtained in vein wall PLs were
comparable with those in the artery walls. For most essential PUFAs, however, the inter-
group differences did not reach statistical significance, except for 22:4n-6 (reduced in
prelerm cords), and 18:2n-6 and 22:5n-6 (both higher in preterm cords).
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Table 2 J . Absolute (mg/kg dry weight) fatty acid
preterm (n=43) and full term (n=43) infants (mean ±
fatty acid*
umbilical artery
prctenn
compositions
SD)
full-tenn
of cord vessel
umbilical vein
preterm
wall phospholipids of
full-tenn
total
ÏSAFA
IMUFA
XPUFA
2O:3ii-9
22:3n-9
I n-9 PUFA
18:2n-6
2O:3fl-6
20:4*1-6
22:4n-«
22:5n-6
I n-6
Z n-6 LCP
22:6n-3
Z n-3+n-6
I n-3+n-6 LCP
16348 * 3242
7591 ± 1504
4115 ± 1108
4641 ±933
562 ± 162
239 ± 105
801 ± 232
171 ±94
144 ±45
1836 ±446
342 ±96
602 ± 164
3151 ±715
2927 ± 647
689 ± 186
3840 ± 866
3616 ± 800
14722 ±2121*
6930 ± 1024
2768 ± 567*
5023 ± 751
450 ± 168'
224 ±85
674 ± 247
202 ±54
187 ±48**
2137 ± 39T
446 ± 110**
483 ± 103'
3519 ±614
3316 ±584''
831 ± 184'
4349 ± 744'
4147 ±715'
17878 ±3317
8438 ± 1672
3434 ± 803
6005 ± 1123
170 ±86
113 ±59
283 ±131
393 ±123
259 ± 73
2866 ± 591
615 ± 177
652 ± 220
4950 ± 1018
43% ± 884
773 ± 195
5722 ± 1140
5168 ± 1012
15330 ± 2012*
7316 ± 9I9*
2259 ± 38(y*
S7SS ± 849
66 ± 33'
55 ± 25'
121 ± 56'
306 ±79 '
270 ± 72
2871 ± 441
800 ± ISO**
420 ± 108''
4828 ± 702
4522 ± 672
805 ± 182
5633 ± 834
5328 ± 810
"SAFA= saturated fatty acids; MUFA= monounsaturated fatty acids; PUFA= polyunsaturated fatty acids; n-9
PUFA= 20:3n-9, 22:3n-9; n-6= fatty acids of the n-6 series; n-6 LCP= long-chain PUFAs of the n-6 series (18-
:3n-6, 20:3n-6, 20:4n-6, 22:4n-6, 22:5n-6); n-3+n-6= n-6+22:6n-3 and n-3+n-6 LCP= n-6 LCP+22:6n-3 (no
other fatty acids of the n-3 series were present in detectable amounts).
Significance level for difference between preterm and full-term infants (two-tailed Student's t-test):
*P<0.01, T><0.005, ^ 0 0 0 0 5
The results for the relative fatty acid levels (% (wt/wt), table 2.3.) were grossly comparable
with those for absolute amounts, although particularly for the vein wall PLs, more inter-
group differences were significant. Again, most /i-6 and n-3 PUFA levels were significantly
lower in the preterm than in the term population, the only exception being 22:5n-6, which
was significantly higher in the preterm cords.
The EFA status index (ratio of £ n-3+/t-6 to I n-7+n-9) was significantly reduced in the
preterm cord vessel wall PLs. This observation was confirmed by the EFA deficiency index
(EFADI, ratio of 20:3n-9 to 20:4n-6) and the cervonic acid deficiency index (CADI, ratio of
22:5«-6 to 22:4n-6), which both were significantly higher in preterm artery and vein walls.
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Table 2.3. relative (weight %) fatty acid composition of cord
and full-term (n=43) infants (mean ± SD).
fatty acid'
£ SAFA
£ MUFA
£ PUPA
20:3/i-9
22:3/1-9
£ n-9 PUFA
l8:2n-6
20:3/1-6
20:4n-6
22:4/i-6
22:5/1-6
In -6
£ n-6 LCP
22:6n-3
£ /I-3+/1-6
£ /I-3+H-6 LCP
RFA status
EFAOI
CADI
umbilical artery
preterm
46.6 ± 3.5
24.9 ± 3.3
28.5 ± 3.1
3.43 * 0.77
1.47 ±0.60
4.90 ± 111
1.03 ±0.45
0.89 ± 0.23
11.3 ±2.0
2.13 ±0.63
3.69 ± 0.74
19.4 ± 3.0
18.0 ± 2.8
4.24 ± 0.93
23.6 ± 3.7
22.3 ± 3.5
0.82 ± 0.21
0.32 ±0.10
1.86 ±0.62
full-term
47.1 ± 1.3
18.8 ± 2.3''
34.2 ± 2.4'
3.05 ± 1.00
1.51 ±0.49
4.56 ± 1.45
1.37 ±0.31 '
1.26 ±0.24'
14.6 ±2.r*
3.04 ± 0.63'
3.29 ± 0.57^
24 0 ± 3.0^
22.2 ± 2 . ^
5.64 ± 0.89^
29.6 ± 3.3'
27.8 ± 3.3'
1.32 ±0.35'
0.22 ±0.10'
1.12 ±0.27'
vessel wall phospholipids of preierm (n=43)
umbilical vein
pretenn
47.1 ± 1.6
19.2 ± 2.5
33.7 ± 2.7
0.96 ± 0.49
0.64 ± 0.33
1.61 ±0.74
2.20 ± 0.56
1.44 ± 0.27
16.1 ±2.3
3.46 ± 0.79
3.60 ± 0.89
27.7 ± 3.00
24.6 ± 2.6
4.33 ± 0.87
32.1 ±3.2
29.0 ± 2.9
1.60 ± 0.39
0.06 ± 0.04
1.13 ±0.49
full-term
47.8 ± 1.7
14.7 ± I.?*
37.5 ± 1.9*
0.43 ± 0.21'
0.36 ±0.16'
0.78 ± 0.36'
2.01 ± 0.53
1.74 ±0.34'
18.7 ± 1.6'
5.22 ± 0.80*
2.73 ± 0.63'
31.5 ± 1.8'
28.4 ± j y
5.23 ± 0.84'
36.7 ± 2.0*
33.7 ± 2.2'
2.40 ± 0.31'
0.02 ± 0.01'
0.54 ±0.17'
Legend as in (able 2.2. In addition:
•EFAstntus= essential fatty acid status: ( I n-3+/i-6)/(I n-7+n-9); EFADI= EFA deficiency index: 20:4/1-6/20-
:3zi-9; CADI= cervonic acid (22:6n-3) deficiency index: 22:5n-6/22:4/i-6.
2.4.2 Relation between essential fatty acid pronies of preterm cord vessel walls and
gestational age at birth
For the majority of the fatty acids or combinations of fatty acids reported, relative levels
in the artery and vein wall PLs were found to be significantly related to GA at birth. In
general, arterial and venous levels of fatty acids of the n-6 series increased with advancing
GA (P<0.0005), with the exception of 22:5n-6 levels, which were negatively correlated with
GA ut birth (P<0.0005). Venous levels of the EFA deficiency-indicating n-9 PUFAs generally
decreased with advancing GA (P<0.005). Similar relations were observed for absolute
amounts, but these reached significance for only a limited number of fatty acids.
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The three indices calculated confirmed the changes observed for the individual fatty
acids, with the EFADI (P<0.0005) and CADI (P<0.001) decreasing and the EFA status index
(P<0.0005) increasing with advancing GA, both in arterial and venous cord vessel walls.
2.4.3 Relation between essential fatty acid profiles of preterm cord vessel walls and
prenatal growth
Information on birth weight was available for all pretcrm infants Data on HC and length
were not available for eight and seven prcterm infants, respectively. Partial correlation
coefficients for significant relations between the EFA profile measured in preterm cord
vessel walls and the anthropometric parameters, all corrected for GA at birth, arc given in
table 2.4. In all cases, a significant positive relation was observed between GA at birth and
the anthropometric parameter.
Birth weight was positively correlated to arterial concentrations of both n-6 and n-3
LCPs. Length at birth was positively correlated to the arterial concentration of 22:6n-3. No
significant correlations were observed between the venous EFA content and any of the
anthropometric parameters.
2.5 Discussion
This study demonstrates that the EFA status measured in arterial and venous cord vessel
wall PLs of preterm infants is considerably different from that measured in cord vessel walls
of full-term newborns (tables 2.2. and 2.3.). The n-6 and n-3 LCP contents of prcterm cords
were significantly lower than those of term cords, while values for EFA deficiency markers,
such as 20:3«-9, 22:5n-6, EFADI (20:3«-9/20:4«-6) and CADI (22:5n-6/22:4n-6) were signifi-
cantly higher in preterm than in term cords. In both study groups, most differences between
arterial and venous fatty acid values were significantly different from zero (data not shown)
and their directions were comparable to those observed in earlier studies in full-term cord
vessel walls [2,3,5].
Based on the observations in arterial vessel wall PLs (indicating the fetal EFA status) the
biochemical EFA status of downstream preterm fetal tissue is substantially lower than that of
the term fetus. However, the EFA supply to the preterm fetus, as reflected by the relative
EFA contents of the umbilical vein, is lower as well. For a proper interpretation of these
findings, it is important to realize that, in this study, cord fatty acid profiles were found to
be related to GA at birth. These relations were explored in the preterm study group only,
because the range of GA at birth in the term population (4 weeks, compared with 10 weeks
of the preterm cords) was considered too small to detect the potential correlations with EFA
status. Data from both study groups were not combined to avoid spurious correlations. With
advancing GA, the EFA content increased, while values for EFA deficiency markers
decreased, which is in accordance with the differences observed between mean fatty acid
values in preterm and term cords. In fact, when correcting the inter-group differences for
GA at birth, many were no longer significant, which indicates that differences between the
EFA profiles of preterm and term cords can, at least partly, be explained by the relations
existing between fatty acid levels and GA at birth.
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Table 2.4
growth in
2
. Correlations (P<0.05)
pretcrm infants.
between fatty acid content of cord
Fatty acid"
vessel walls
partial r*
and parameters of prenatal
P,-value'
birth weight (n=43)
umbilical artery (mg/kg dry wt)
umbilical artery (wt %)
20:4/i-6
22:4n-6
£n-6
I «-6 LCP
22:6n-3
I n-3+/i-6
I 71-3+71-6 LCP
22:6n-3
+.334
+J79
+.358
+.362
+.470
+J97
+402
+.364
0.03'
0.01'
0.02'
0.02'
0.002'
0.01'
0.008*
0.02**
head circumference at birth (n=3S)
umbilical artery (mg/kg dry wt) 22:4/i-6 +.398 0.02'
length at birth (n=36)
umbilical artery (mg/kg dry wt)
umbilical artery (wt %)
22:6/1-3
Z 7I-3+/I-6 LCP
22:6/1-3
+.448
+.384
+.378
0.007'
0.02'
0.03^
"Sec table 2.2.
degression equation calculated:
anthropomctric paraineter=A+B,'fatty acid level in vessel wall+Bj*GA at birth.
'Significant correlations (PS0.01) are in bold face.
Significant positive correlation between anthropometric parameter and gestational age at birth:
**P,S0.00l.'PjS0.000l.
The significant, positive correlations found for arterial and venous EFA levels with GA at
birth, could be considered a reflection of the maternal response (increased supply) to the
increasing fetal demands for these fatty acids, necessary for brain and body growth, during
the last trimester of pregnancy. Increasing /i-3 EFA levels with increasing pregnancy dur-
ation are also in line with the hypothesis of Olsen and co-workers [19] that a higher
maternal dietary «-3 intake, resulting in increased circulating n-3 LCP levels, might prolong
gestation through a down-regulation of the formation of dicnoic prostaglandins involved in
the triggering of parturition; they found this view supported by the results of a recent
intervention study [20]. On the other hand, van Houwclingen and co-workers (21; Chapter
20
EFA composition of preterm cords
3) observed a significant positive correlation between plasma M-3 levels and GA in samples
obtained through fetal blood sampling during continuing pregnancies.
The decreasing values of EFA deficiency markers («-9 PUFAS, 22:5n-6, EFAW, CAM)
found with advancing GA might suggest an increasing adequacy of the EFA supply towards
term. However, interpreting the EFA compositions of umbilical cord vessel walls on the
basis of biochemical relations in adult material has been the subject of debate. For example,
Sanders and Rcddy 122] recently postulated that the presence of 2O:3n-9 in cord artery
walls may not reflect an EFA deficiency, but rather a high activity of the conversion system
(overactive A6-desaturase) in the arterial wall. A number of observations in this and other
studies, however, are not in line with this hypothesis. Firstly, the information available on
fetal fatty acid biochemistry indicates that the desaturase activity in fetal liver microsomes
is low [23], and that in (fetal) placenta! tissue is low [24] or even not detectable [23,25).
Secondly, the higher 20:3n-9 content of preterm than of full-term cord vessels would
indicate a decreasing activity of the fatty acid desaturation system during progressing
pregnancy. However, microsomal synthesis of LCPs was shown to increase with advancing
GA in piglet liver and brain [26]. Finally, in case of a highly active dcsalurusc system, the
conversion of oleic acid (18:ln-9) to 2O:3n-9 would be accompanied by the conversion of
18:2/1-6 and l8:3n-3 to their LCPs, leading to higher amounts of n-9 as well as n-6 and n-3
longer-chain derivatives. However, when relating cord levels of 20:3n-9 to those of 2():4«-6
(major n-6 L.CP), significant «rg«f/\r correlations between these two fatly acids were
observed both in our preterm (artery: r=-0.45, P=0.002; vein: r=-0.63, P<0.0005) and in our
full-term (artery: r=-0.79, P<0.0005) study populations.
The results of the present study suggest that the apparently lower EFA status of the
preterm fetus when compared to the term fetus is, at least partly, related to the earlier stage
of body and brain growth and development of the preterm infant, and the lower EFA
demands that are associated with this phase. Yet, in view of the importance of LCPs for
normal brain and visual development [6-9], the lower EFA and LCP status in preterm infants,
as observed in the present study deserves to be further explored. This is the more so since,
recently, a lower neonatal 20:4n-6 and 22:6«-3 status at preterm delivery was demonstrated
to result in a lower postnatal 20:4n-6 and 22:6«-3 status, irrespective of the type of the
postnatal diet (human milk which contains LCPs, or a conventional artificial formula which
lacks LCPs)[12; Chapter 7].
An additional objective of the present study was to explore the relations between the
overall EFA profile of preterm arterial and venous cord vessel walls and parameters of
prenatal growth. After correction for GA at birth, arterial concentrations of both n-3 and n-6
LCPs were found to be positively related to birth weight, while the arterial 22:6n-3 concen-
tration was positively related to length at birth as well. These findings are supported by a
number of positive relations between n-6 and n-3 LCPs and weight, HC, or length at birth
which tended to be significant (table 2.4.: P<0.02 or 0.03; significance level was set at
P<0.01), and illustrate the importance of LCPs for proper antenatal growth. The fatty acid
composition of the PLs of the supplying vein was unrelated to any of the parameters of
prenatal growth. This could indicate that varying amounts of the supplied EFAs are used as
'building bricks' for structural growth.
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A few other studies have addressed the potential relations between the EFA status
measured in umbilical vessel walls and parameters of prenatal growth. Felton and co-
workers [11] reported significant correlations with growth of both arterial and venous «-6
and n-3 fatty acid levels. Crawford and co-workers [10] stressed the importance of the
highly significant correlations they observed for the EFADI and the CADI measured in the
umbilical artery wall with both weight and HC at birth. However, the above-mentioned
correlations were reported without mentioning a correction for GA at birth. This correction
proved to be of substantial influence on the relations observed in our study population:
strong correlations between prenatal growth and deficiency indicators as well as venous
fatty acid levels were completely attributable to GA at birth.
In conclusion, we report substantial differences between the EFA profiles of preterm and
full-term cord vessel walls, indicating a lower biochemical EFA status in the preterm than in
the term fetus. In addition, the EFA composition of preterm cord vessel walls was found to
be related to GA at birth as well as to parameters of prenatal growth. The lower preterm
EFA values could very well be a reflection of a physiologically lower demand for EFAs,
necessary for growth and development, of the preterm fetus when compared to the term
fetus.
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3.1 Abstract
Hardly any direct information is available on the EFA status of the fetus during
intrauterine development. Therefore, we studied 86 umbilical plasma samples obtained by
transabdominal puncture during ongoing pregnancies (gestational age (GA): I8-39 weeks).
These were compared with 51 samples of umbilical cord blood that were collected immedi-
ately after birth (GA: 28-39 weeks). The total amount (mg/1) of fatty acids in fetal plasma
phospholipids (PLs) did not change during gestation. The relative level (weight %) of
linoleic acid (18:2n-6) showed a slight increase (P<0.05) during fetal maturation. Values for
arachidonic acid (20:4n-6) decreased (P<0.0001), while those for docosahexacnoic acid
(22:6n-3) increased (mg/l: P<0.005, %: P<0.0001) when pregnancy progressed. The overall
EFA status increased, but the functional 22:6/i-3 status appeared to decline with advancing
GA. The EFA profiles of fetal samples were generally comparable with postnatal results of
infants born at similar GAs. However, the 18:2n-6 status of the fetus was lower than that of
the neonate. The same was true for the overall EFA status. The results of this study indicate
that the low EFA values observed in preterm infants at birth, are a developmentally related
phenomenon.
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3.2 Introduction
Fetal development is associated with a high demand for essential fatty acids (EFAs), but
the development of each organ system follows a specific course in time and, consequently,
the fetal demand is not necessarily constant throughout pregnancy. Brain and retina are very
rich in EFAs, and a sufficient supply of these fatty acids during pregnancy and the neonatal
period is of great importance. Data in primates show that an insufficient amount of /t-3 fatty
acids at a critical stage in brain and retinal development results in a long term impairment
of brain and retinal function [1,2]. Studies in human infants have observed the same phe-
nomenon [3,4],
Hardly any direct information is available with respect to the EFA status of the fetus
during its development in utero. Some data arc available on the fatty acid composition of
fetal tissue obtained via elective abortion during the first trimester of pregnancy [5]. So far,
the fetal EFA status has mainly been assessed in materials collected after birth [6-9]. These
studies have shown that the EFA status in plasma PLs of normal neonates is different from
that of adults. This applies to linolcic acid (18:2/i-6, lower), arachidonic acid (20:4/i-6:
relative levels higher, absolute amounts lower) and docosahexaenoic acid (22:6n-3, also
called ccrvonic acid: relative levels higher) in particular [6,7]. Data on the fatty acid com-
position at birth arc also available for prcterm neonates [8,10; Chapter 2): EFA values are
lower in prcterm than in full-term infants. It is unknown, however, whether the results in
materials collected aflcr delivery are comparable to fetal plasma fatty acid compositions
during ongoing pregnancies at similar GAs.
Therefore, in this study the EFA profile of umbilical plasma samples obtained by fetal
blood sampling, was compared to the EFA profile of umbilical plasma samples obtained
immediately after birth at comparable GAs. The fatty acid composition of the plasma PL
fraction was analyzed, because PLs are the richest source of polyunsaturated fatty acids
(I'UFAs), including EFAs, and changes in the PUFA profile are most pronounced in the PLs
[ 111, making them the preferable plasma lipid parameter. To our knowledge this is the first
time that the fatty acid compositions of prenatal blood samples are reported as absolute
amounts.
3.3 Patients and methods
3.3.1 Study population
The study population consisted of pregnant women referred to the participating centres
for fetal blood sampling because of fetal karyotyping or expected pregnancy complications.
Only singleton pregnancies were included. Blood sampling of the fetal umbilical vein was
performed by transabdominal puncture under ultrasound guidance without maternal fasting
or sedation. About 1 ml of fetal blood was collected in an EDTA-containing tube.
Eighty six blood samples were obtained through fetal blood sampling during pregnancy
(range 18-39 completed weeks of gestation) among which 10 samples were taken at elective
cacsarcan sections performed at term (37-39 weeks). In 55 women we were able to collect
a maternal blood sample from an antccubital vein at the same time the fetal blood sampling
was performed.
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For comparison, 51 postnatal blood samples were taken trom the umbilical vein, 34
immediately after preterm childbirth (GAS ranging from 28 to 36 completed weeks of
gestation) and 17 immediately after term childbirth (GAs comparable to those of ihc
cacsarean sections). The study was approved by the local Medical Ethics Committees. All
participating women gave their written informed consent.
3.3.2 Fatty acid analysis
After separation from the red blood cells by ccntrifugation. the plasma samples were
kept in tubes closed under nitrogen, and stored at -80 °C until transportation to Maastricht
for analysis. The EFA status was studied by determining the absolute (mg/l) and relative (%
(wt/wt) of total fatty acids) fatty acid composition of plasma PUs as described before (7). At
the start of the analysis, approximately 40 ug of 1,2-dinonadccnnoyl phosphatidylcholinc
[PC(19:0)j] was added to every sample as an internal standard lor quantification of the abso-
lute amounts of fatty acids present.
Three indices were calculated to describe the functional EFA status. The overall F.FA
status, or EFA status index, defined as the sum of all n-6 and n-3 (essential) fatty acids
divided by the sum of all n-7 and n-9 (non essential) fatty acids, was used because a
sufficient supply of EFAs will limit the desaturation of the non EFAs (9]. The ccrvonic acid
sufficiency index (CASl=22:6n-3/Osbond acid, 22:Sn-6) was calculated, because a shortage
of 22:6n-3 is accompanied by an increased conversion of adrcnic acid (22:4n-6) to 22:5«-6,
leading to lower CASI values. Moreover, we calculated the cervonic acid deficiency index
(CADl=22:5n-6/22:4/i-6), because the amount of 22:5n-6 also depends on the amount of its
precursor 22:4n-6 [2,12].
3.3.3 Data analysis
Results of the fatty acid composition of the fetal plasma samples are presented as mean
± standard deviation, after classification into five groups on the basis of increasing GA.
Changes in the fetal fatty acid levels during gestation were evaluated using multiple
regression analysis, to correct for the possible influence of the centre at which the blood
was collected. Maternal values were related to the values of their fetus by linear regression
(Pearson correlation coefficients). Multiple regression analysis was also used to compare the
plasma samples taken before birth (fetal samples, only GA 28-39 weeks, n=36) and umbili-
cal plasma samples taken directly after birth (postnatal values, GA 28-39 weeks, n=51), with
correction for GA at the time of blood collection.
P-values <0.05 were considered significant.
3.4 Results
3.4.1 Fatty acid changes in fetal plasma samples during pregnancy
Absolute and relative fatty acid compositions of plasma PLs, isolated from fetal blood
samples taken during ongoing pregnancies are given in table 3.1. The total amount of
PL-associated fatty acids in plasma did not change during gestation. The same was observed
for the absolute amount of 18:2n-6. The relative amount of 18:2n-6 showed a slight
increase (P<0.05) during gestation. Absolute and relative amounts of 20:4n-6 and eicosa-
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Table 3.1. Fatty acid composition (mean ± SD) of fetal plasma phospholipids obtained by transabdominal
puncture during ongoing pregnancies (except for 37-39 weeks gestational age (GA): obtained during elective
caesarcan sections).
mg/1
wt %
fatty acid"
total
£SAFA
£ MUFA
2O:3n-9
18:2/1-6
20:4;i-6
22:5/1-6
I/I-6
I /I-6 LCP
2O:5/i-3
22:6n-3
I /I-3 LCP
£ SAFA
£ MUFA
20:3/1-9
18:2/1-6
20:4n-6
22:5/1-6
£n-6
£ n-6 LCP
2O:5n-3
22:6«-3
£ zi-3 LCP
EFA status
CADI
CASI
18-22 wks
(n=36)
573 ± 141
252 ±64
104 ±36
4.7 ± 2.0
35 ± 11
120 ± 27
2 0 ± I I
181 ± 38
143 ± 30
2.6 ± 1.9
21.4 ± 5.9
25.9 ± 7.3
44.1 ±2.0
17.9 ± 2.7
0.81 ±0.28
6 2 ± 1.3
21.1 ± 2 2
0.35 ± 0 18
31 8 ± 2 6
254 ±2.1
0.43 ± 0.26
3.75 ± 0.59
4.54 ± 0 65
2.09 ± 0.41
0.93 ± 0.44
12.8 ±5.5
23-27 wkt
(n=!4)
524 ± 70
237 ± 28
89 ±25
4 8 ± 1.9
32.6 ± 6.5
I1O± I I
189 ± 0 71
169 ± 19
133 ± 13
1.53 ±0.82
20.3 ± 3.6
23.2 ± 4.0
45.2 ± 1.2
16.6 ± 2.6
0.90 ± 0.32
6.20 ± 0.87
21 1 ± 13
0.36 ±0.12
32.3 ± 1.6
25.9 ± 1.5
0.30 ± 0 16
3.90 ± 0.74
4 46 ± 0 82
2.27 ± 0 43
0.83 ± 0 24
11.7*4.5
28-32 wks GA
(n=!3)
608 ± 187
281 ±86
109 ±40
6.4 ± 5.4
44 ±22
103 ± 38
3.3* 15
182 ± 71
133 ±49
1.42 ± 0.87
23 ± 11
26 ± 12
46.5 ± 2.6
18 8 ±6.1
1.10 ±083
6.6 ±2.4
16.6 ± 3.6
0.61 ± 0.33
28.8 ± 6.3
21.8 ±4.2
0 20 ±0.12
3.6 ± 1.1
4 1 ± 12
1 98 ± 0.80
111 ± 0 55
8 4 ± 5.5
33-36 wks GA
(n=13)
479 ± 236
222* 106
76 ±45
4.7 ± 2.3
39 ±23
82 ±39
3.2 * 2.4
153*75
109*52
0.94 ± 0.94
19 ± 10
22 ± 12
46.7 ± 2.5
15.8 ±2.8
111 ±0.50
7.9 ± 1.4
16.8 ±2.2
0.73 ± 0.39
31.7 ± 2.4
23.4 ±2.1
0.18 ±0.12
4.00 ± 0 50
4.47 ± 0.61
2.36 ± 0.47
1.27 ±0.51
7.3*4.1
37-39 wks GA
(n=IO)
586 ± 106
279 ± 52
83 ± 18*
5.6 ± 1.7
41 ± 12
94 ± 19^
3.9 ± i .y
175 ± 39
129 ± 26*
2.0 ± I T
34.5 ± 5.7'
39.3 ± 6.7*
47.6 ± l V
14.0* l ^
1.0* 3.0
6.8 ± 1.2*
16.0 ± i .y
0.67 ±0.19^
29.7 ± 2.9
22.5 ± 2.2'
0.34 ± 0 20*
6.0 ± l V
6.9 ± l.ö'
2.64 ± 0.42*
105 ±0.29*
9.8 ± 3 8'
*SAFA= saturated fatty acids; MUFA= monounsaturated fatty acids; n-6= fatty acids of the n-6 series: n-6 LCP= long-
chain polyunsaturated fany acids (PUFAs) of the n-6 series (18:3/1-6, 20:3n-6. 20:4n-6. 22:4/i-6. 22:5n-6); n-3 LCP=
long-chain PUFAs of the n-3 scries (20:4n-3, 2O:5n-3, 22:6n-3); EFA slalus= essential fatty acid status: (I n-3+n-
6)/(£ n-7+n-9); FJ-ADI= EFA deficiency index: 20:4n-6/20:3n-9; CADI= cervonic acid (22:6/i-3) deficiency index:
22:5n-6/22:4n-6; CASI= cervonic acid sufficiency index: 22:6n-3/22:5n-6.
Significance level for relation between fatty acid value and gestational age at blood collection, corrected for
influence of participating centre by multiple regression analysis:
*P<0 05; 'PS0.01; *P<0005; 'P<0.00l; ^PSO.0001.
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pentaenoic acid (2O:Sn-3) decreased with fetal maturation (table 3.1). Absolute and relative
amounts of 22:6n-3 increased with increasing GA (P<0.005, and P<0.0001 respectively).
The contents of 22:5n-6, which is a deficiency indicator for 22:6n-3, as well us values
for the CADI increased (P<0.000I. and P<0.05, respectively), whereas the CASI decreased
(P<0.001) during gestation. The overall EFA status in fetal plasma PLs increased with
increasing pregnancy duration (P<0.005).
3.4.2 Relation of maternal plasma fatty acid values with the values of their fetus
The average fatty acid composition of the maternal plasma samples is given in table 3.2.
Hardly any significant relations were found between the maternal fatty acids in plasma I'l.s
and GA at blood collection. For most fatty acids, relative maternal levels were significantly
and positively correlated with the corresponding fetal values. For the absolute amounts,
hardly any significant relations between maternal and fetal fatty acid values were found.
3.4.3 Comparison between fetal and postnatal plasma fatty acid values
When comparing the values of fetal plasma samples collected at (Ms of 28-39 weeks
(n=36, table 3.1.) with postnatal results of infants, bom at similar GAS (n=51, table 3.3.), no
significant differences were observed for the total amount of PL-associated fatty acids. The
same applied to most of the absolute amounts of the individual EFAs. The absolute (P<().05)
and relative (P<0.0001) 18:2n-6 levels in fetal plasma were lower than those in umbilical
plasma of postnatal samples. Relative levels of n-6 fatty acids were lower (P<0.005) in fetal
plasma and the values for the indicator of a general EFA deficiency, Mead acid (2():3n-9)
were higher in fetal than in postnatal plasma (mg/1: P<0.05, and % (wt/wt): P<0.00l). In
addition, the overall fetal EFA status was slightly lower (P<0.05) in fetal plasma than in
postnatal plasma.
3.5 Discussion
The main findings of this study arc that the EFA status of the fetus is not stable during
its development, but changes with GA in a fatty acid specific way (fig 3.1.) and that fetal
plasma EFA values are similar or slightly lower than infant plasma EFA values directly after
birth at a comparable GA.
In this study, the participating (pregnant) women were referred to the centres for fetal
blood sampling because of fetal karyotyping or expected pregnancy complications. Fortu-
nately, the majority of the fetus turned out to be normal (80%). No differences in fatty acid
profiles were observed between normal and abnormal fetus (data not shown). Therefore, the
results of the latter population were not excluded from the data set.
That the relative plasma level of n-6 long-chain PUFAs (LCPs) exceeds that of their
precursor 18:2«-6, seems to be a specific feature of the fetus [5] and the newborn [6-8]
since it has never been observed in normal adults. The relatively high n-6 LCP status in
plasma PLs is a favourable situation for the developing human being, especially during the
last trimester of pregnancy when, in addition to 22:6n-3, high quantities of the major «-6
LCP, 20:4n-6 are needed for growth and development of neural tissue [13,14).
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Table 3.2. Fatty acid composition of plasma phospholipids from mothers subjected to fetal blood sampling
(n=55) and the relation with corresponding fetal values.
fatty acid" mean ± SD
mj/1
% (wt/wt)
total
I SAFA
£ MUFA
20:3n-9
18:2/1-6
20:4n-6
22:5n-6
£n-6
I n-6 LCP
2O:5n-3
22:6n-3
£ n-3 LCP
I SAFA
£ MUFA
20:3n-9
18:2/1-6
20:4n-6
22:5n-6
£n-6
£ n-6 LCP
20:5n-3
22:6n-3
£ n-3 LCP
EFA status
CADI
CASI
1624 ± 292
720 ± 134
235 ± 58
6.8 1 2.4
313 ± 7 0
135 ± 3 1
8.2 ± 3.9
529 ± 9 6
201 ± 53
7.2 ±4 .1
71 ± 2 3
90 ± 2 8
44.4 ± 1.7
14.3 ± 2.2
0.42 ±0.14
19.3 ± 2.6
8.4 ± 1.5
0.50 ±0.19
32.7 ±2.1
12.9 ± 1.8
0.44 ± 0.23
4.4 ± 1.7
5.5 ± 1.3
2.73 ± 0.48
1.40 ±0.40
10.1 ± 5.2
0.03
0.07
0.13
0.25
0.27
0.08
0.20
0.03
0.11
0.44
0.19
0.24
0.52
0.45
0.42
0.53
0.08
0.28
0.72
018
0.40
0.28
0.32
0.41
0.72
0.51
NS
NS
NS
NS
0.04
NS
NS
NS
NS
0.0007
NS
NS
<0.0001
0.0007
0.001
<0.0001
NS
0.04
•cO.0001
NS
0.003
0.04
0.02
0.002
<0.0001
•cO.0001
'As in table 3.1.
'"Significance level for relation between maternal and fetal fatty acid values (linear regression).
The relative level of 18:2/1-6 showed a slight increase during gestation. Apparently, the
decrease in 18:2«-6, as observed in fetal tissue during the first trimester of pregnancy [5],
does not continue in plasma during the 2nd and 3rd trimester. An important specific physio-
logical function of 18:2«-6 is maintaining the water barrier of the skin [15]. We speculate
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Table 3-3 Fatty acid composition
after delivery at various gestational
(mean ± so) of umbilical cord plasma phospholipids collected shortly
«ges (GAS).
fatty acid*
28-32 wks QA
(n»23)
33-36 wks OA
(n-ll)
37-39 wks OA
(n-17)
mg/1 total
ESAFA
ZMUFA
2O:3n-9
l8:2n-6
20:4n-6
22:5n-6
En-6
E n-6 LCP
2O:5n-3
22:6n-3
En-3 LCP
E SAFA
E MUFA
20:3n-9
18:2/i-6
20:4n-6
22:5n-6
En-6
E n-6 LCP
20:5n-3
22:6n-3
E n-3 LCP
EFA status
CADI
CASI
603 ± 163
277 ±74
95 ±27
4.5 ± 2.4
53 ± 19
105 ± 3 0
3.5 ± 1.6
194 ±57
136 ± 3 9
1.7 ± 1.3
23 ± 7.3
27 ± 8.7
45.9 ± 1.7
15.8 ± 2.2
0.73 ± 0.34
8.6 ± 1.5
17.5 ± 2.0
0.58 ± 0.20
32.0 ± 2.0
23.1 ± 2.2
0.27 ±0.19
3.9 ± 1.0
4.5 ± 1.1
2.36 ± 0.44
0.95 ± 0.32
7.6 ± 3.1
538 ± 162
247 ± 80
78 ±27
3.3 ± 2.8
47 ± 18
89 ±27
3.5 ± 1.7
174 ±54
122 ± 35
1.43 ±0.83
26 ± 7.2
30 ±7.8
45.8 ± 2.2
14.7 ± 3.5
0.58 ± 0.35
8.6 ± 1.0
16.8 ±2.1
0.66 ± 0.21
32.2 ± 1.6
23.3 ± 1.4
0.26 ±0.15
5.0 ± 1.2
5.7 ± 1.2
2.74 ± 0.72
1.05 ±0.33
8.2 ± 2.4
556 ± 99
253 ±45
80 ± 19
4.2 ±2.1*
48 ± 13*
89 ± 16
4.4 ± 15
180 ±34
125 ±21
142 ±0.45
28 ± 5.3
32 ± 5.8
45.4 ± 2.1'
14.3 ± 2.2
0.74 ± 0.30'
8.6 ± I.O'
16.0 ± 1.4
0.79 ± 0.20
32.3 ± 1.2'
22.6 ± 1.2
0.25 ± 0.08
5.13 ±0.71
5.82 ± 0.78
2.73 ± 0.43*
1.13 ±0.28
7.1 ± 2.6
(wt/wt)
For legend see table 3.1.
"'Significance level for difference between fetal (see table 3.1.) and neonatal fatty acid values, corrected for
gestational age at blood collection by multiple regression analysis (only gestational age range 28-39 weeks).
that in the fetus which is surrounded with amniotic fluid, this function is likely to be of
minor importance and, therefore, the fetus might not need the normal adult level of !8:2n-6.
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Pigure 3.1. Relative levels (wt %, mean ± SD) for 18:2n-6 (-- v--), 20:4n-6 (—O—), and 22:6n-3 (-
in fetal plasma phospholipids.
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In this respect, the slightly increasing 18:2n-6 level observed with advancing gestation
could be considered a first sign of adaption to postnatal life.
As is also known from postnatal values [7,8,16; Chapter 7], 22:6n-3 values in fetal
plasma I'l.s were found to increase during pregnancy. However, this observation differs
from that by Crastes de Paulet and coworkers [17], who did not report an increase in
relative levels of 22:6/i-3 in fetal plasma total lipids during gestation. Apart from possible
differences between their and our study populations, these different results could be recon-
ciled by assuming that the levels of 22:6n-3 in the other lipid fractions decrease with
increasing GA. For the cholesterol fraction this is unlikely, since fatty acids attached to
cholesterol arc mainly derived from plasma PLs by the lecithin-cholesterol acyltransferase
(LCAT) reaction [18]. Indeed, Hoving et al [19] observed that the levels of 22:6«-3 in
umbilical plasma cholcstcrolestcrs increased during a similar period of gestation. Perhaps,
more fluctuating 22:6«-3 levels in the triglycerides and free fatty acids have obscured the
rise of 22:6n-3 in the samples studied by Crastes de Paulet and colleagues.
Although the fetal plasma 22:6n-3 values increased as pregnancy progressed, the CADI
and CASI values indicated a lowering of the functional 22:6n-3 status during fetal matura-
tion, suggesting that the increased availability of 22:6n-3 might not be sufficient to cover
the increasing fetal demand. This might be the result of a relative shortage of maternal
22:6/1-3. During normal pregnancy, the maternal 22:6/i-3 status has been shown to decrease
(7), which may result from the maternal attempt to meet the high fetal demand for 22:6n-3.
Recently, it has been demonstrated that the maternal 22:6«-3 status can be enhanced by
increasing the intake of n-3 fatty acids during pregnancy [20].
A highly significant relation was observed between the majority of the maternal and
fetal plasma fatty acid values (table 3.2.). Consequently, differences between the EFA status
of the mothers that were subjected to fetal blood sampling and of the mothers of the new-
born infants, would be a confounding factor in the comparison of fetal with neonatal EFA
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values. However, no significant differences in plasma PL fatty acid composition were
observed for both groups of mothers (data not shown).
During the third trimester of pregnancy, the EFA profile in PLs from fetal plasma,
sampled during ongoing pregnancy, was generally comparable with that of the postnatal
umbilical plasma samples of term and preterm infants. Consequently, the differences
between the fatty acid compositions of plasma PLs of term and preterm infants arc com-
parable to the differences observed for fetal samples taken at the same GAS. Thus, the lower
EFA status of the preterm infant when compared to the term infant (K. 10; Chapter 21 is
likely to be a developmental^ related phenomenon, possibly associated with (he lower HFA
requirements of the preterm fetus for brain and body growth. The higher l8:2n-6 level
observed directly after birth might, again, be a sign of adaption to postnatal life. The slight
differences in fatty acid composition of the plasma PLs observed between fetal and postnatal
samples might also be due to an influence of delivery, because, in general, comparable
differences were observed between fetal blood samples taken at cacsarcan sections and
samples taken after a vaginal birth at comparable GAS.
In conclusion, our results demonstrate that the EFA profile of the fetus is not stable
during its development, but changes with pregnancy duration in a fatty acid specific way
(fig 3.1). This implies that a proper interpretation of the fetal BFA status during its develop-
ment needs consideration of GA. Moreover, the unborn fetus has an KI-'A profile, which is
generally similar to that of newborn infants when measured directly after birth at compar-
able GAS. This indicates that the relatively low EFA values at birth of preterm infants arc of
developmental origin. Besides, the plasma EFA profile measured after delivery appears to be
a reasonably adequate reflection of the fetal plasma EFA profile.
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4.1 Abstract
The essential fatty acid (EFA) status of full-term infants born after an uneventful, single-
ton pregnancy has been reported to be marginal. If this low EFA status is caused by a
limiting maternal EFA supply, the higher total fetal EFA demand associated with a multiple
pregnancy would result in an even lower EFA status of the infants born after a multiple
pregnancy. Therefore, we compared the EFA status at birth of 30 pairs of twins, 7 sets of
triplets, and one set of quintuplets with that of 94 infants (51 preterm, 43 full-term) born
after a singleton pregnancy. Phospholipid (PL)-associated EFA profiles of the umbilical
vessel walls, considered a longer-term reflection of the fetal EFA status, were studied. After
correction for gestational age (GA) at birth, levels of n-6 and M-3 EFAS were generally lower,
while levels of EFA-deficiency indicating /i-9 polyunsaturated fatty acids (PUFAs) were sig-
nificantly higher both in the draining umbilical arteries and the supplying veins of infants
bom after a multiple pregnancy. EFA profiles of twins and triplets were similar, but the
average EFA status of the set of quintuplets was lower than that of twins and triplets. In
conclusion, the observation that the EFA status of infants born after a multiple pregnancy is
lower than that of infants born after a singleton pregnancy supports the view that the
maternal EFA supply to the fetus is limiting. Considering the importance of EFAS, the
longer-chain derivatives in particular, for proper growth and development, this finding
warrants further studies of the adequacy of the maternal EFA intake during pregnancy.
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4.2 Introduction
The EFAs of the n-3 and n-6 series are known to be indispensable to normal human cell
function (for reviews, see: [1,2]). As such, EFAs, and particularly their long-chain polyun-
saturatcd derivatives (LCPs: fatty acids with a chain length > 20 C, derived from the parent
EFAs a-linolcnic acid (18:3n-3) and linoleic acid (18:2w-6) through alternate desaturation
and elongation), are also of considerable importance in fetal and infant development. LCPs,
especially docosahexaenoic acid (cervonic acid, 22:6n-3) and arachidonic acid (20:4n-6), are
present in large quantities in nervous tissue [3-6] and a growing number of studies in
human infants indicate their necessity for normal brain and visual development and function
[7- II]. In addition, the LCP status has been reported to be related to parameters of prenatal
growth [12-17; Chapter 2].
Human tissue cannot synthesize the parent EFAs, so these have to be taken up by the
diet. Obviously, the human fetus must derive the necessary EFAs from the maternal cir-
culation through placcntal transfer. The maternal EFA supply to the fetus will be dependent
on the dietary EFA intake of the mother, the degree of metabolic conversion of dietary EFAs
in her body, the amounts and types of EFAs present in her stores, and her ability to mobilize
these stored F.FAs. The biochemical EFA status at birth of healthy full-term infants, born
after an uncomplicated singleton pregnancy has been suggested to be marginal [18-20], in
particular because substantial quantities of Mead acid (20:3n-9) were found in their um-
bilical artery vessel walls. This fatty acid is considered a reliable indicator of EFA deficien-
cy [21|, since it is formed from oleic acid (18:1/1-9) when insufficient amounts of the
parent EFAs 18:3«-3 and 18:2n-6 and/or their LCPs are present to, respectively, occupy and
inhibit the A6-dcsaturase. This low EFA status of the full-term newborn could be the result
of a limiting maternal liFA supply to the growing and developing fetus. If such is the case,
the higher total fetal EFA demand associated with a multiple pregnancy, may, at one point
or another, lead to an even lower fetal EFA status during a multiple pregnancy than during
a singleton pregnancy.
Therefore, we decided to assess the EFA status at birth of infants born after a multiple
pregnancy by comparing it with that of infants born after a singleton pregnancy. To this
end, EFA levels in the PL fraction of umbilical cord artery and vein vessel walls were
studied, because their EFA profiles are considered a longer-term representation of the EFA
supply to (vein) [19] and return flow from (arteries) the fetus [19,22].
4.3 Patients and methods
4.3.1 Infants
The population of newborn infants born after a multiple pregnancy comprised 30 pairs
of twins, 7 sets of triplets, as well as one set of quintuplets. The quintuplets, all triplets and
24 pairs of twins were born preterm (GA: 23-36 wks, birth weight: 570-2650 g). while the
remaining 6 pairs of twins were carried to term (GA: 37-41 wks. birth weight: 1850-3210
g). 51 Pretcrm infants (GA: 26-36 wks, birth weight: 650-1860 g) and 43 full-term infants
(GA: 37-41 wks. birth weight: 2630-4130 g), born in the same period, but after a singleton
pregnancy, served as controls. GA was confirmed by menstrual history and early ultrasound
36
Infant EFA status after multiple pregnancy
Table 4.1. Clinici] characteristics of study populations (mean ± SD).
maternal age (y)
primipara (n)
geslational age (weeks.days)
birth weight (g)
SGA (P<2.3f (n)
singletons
(n=94)
29 ± 5.2
65(69.1 %)
35.3 * 4.5
2268 ±997
8 (8.5 %)
twins
(n«3O»2)
29 ± 5 2
20 (66.6 %)
32.0 ± 4.4
1545 ± 687
7(11.6%)
triplets
(n«7*3)
29 ± 2.6
2 (28.6 %)
31.0 ±3.2
I486 ±521
0 (00%)
quintuplets
(n-l»5)
31
0
29.4
1256 ± 143
0 (0.0 %)
"SGA= small for gestational age (birth weight below 2 3rd percenlile (P) of the Amsterdam growth charts
1361).
dating, and by Dubowitz score [23] if the former information was missing or doubtful.
Relevant clinical characteristics of the study populations are given in table 4.1.
Of each infant, approximately 15 cm of umbilical cord was collected immediately after
delivery. The study was approved by the medical ethics committees of the participating
hospitals and written informed consent was obtained from one or both parents.
4.3.2 Laboratory analysis
Umbilical cord samples were prepared and analyzed as described previously [16; Chap-
ter 7]. At the start of the analysis, approximately 40 ug of 1,2-dinonadccanoyl phosphati-
dylcholine [PC( 19:0)2) was added to every sample for the quantification of absolute fatty
acid amounts present in the PL fraction of cord artery and vein walls (mg/kg dry weight of
cord vessel wall tissue). Relative fatty acid levels were expressed as weight % of total fatty
acid methylesters.
In total, 26 fatty acids were identified and present in detectable amounts. Since the
present study focuses on the EFA status, only the following relevant 8 fatty acids and 6 fatty
acid combinations are reported: 20:3w-9, dihomo-Mead acid (22:3n-9), 18:2«-6, dihomo-y-
linolenic acid (20:3n-6), 20:4n-6, adrenic acid (22:4n-6), Osbond acid (22:5/i-6), 22:6n-3, I
SAFA (sum of all saturated fatty acids), I MUFA (sum of all monounsaturated fatty acids), £
PUFA, I n-9 PUFA (sum of all PUFAs of the n-9 series), Z «-6 LCP (sum of the LCPs of the
w-6 series, and Z «-3 LCP (sum of the LCPs of the n-3 series).
In addition, three indices were calculated to describe the functional EFA status. The EFA
status, defined as the ratio of the sum of all fatty acids of the n-3 and «-6 series to the sum
of all fatty acids of the n-7 and «-9 series (Z n-3+n-6/Z n-7+n-9, [24]) was used because a
sufficient supply of «-3 and n-6 fatty acids will limit the desaturation of the non-essential n-
7 and n-9 monoenes to their respective PUFAs. For a similar reason, the classic triene/tctra-
ene ratio (EFA deficiency index, EFADl): 20:3/i-9/20:4n-6, [25]) was calculated. The cervonic
acid deficiency index (CADI), defined as the ratio of 22:5n-6 to 22:4n-6, was calculated
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because a shortage of 22:6«-3 is accompanied by an increased conversion of 22:4n-6 to
22:5«-6, the 'surrogate' fatty acid for 22:6n-3, leading to higher CADI values [26,27].
4.3.3 Data analysis
Data are presented as mean and standard deviation unless mentioned otherwise. Data of
the one set of quintuplets were not included in the statistical analyses.
Since the EFA status measured in cord vessel walls is known to be related to GA at birth
[15-17,28; Chapter 2), fatty acid levels in the umbilical artery and vein vessel walls of
infants born after a multiple pregnancy and after a singleton pregnancy were compared
using multiple regression analysis to correct for GA at birth. Dummy variables were used to
indicate whether infants were born after a multiple or a singleton pregnancy and whether
they were one of twins or of triplets. For sets of twins and triplets, the average level of a
given fatty acid for each pair or trio of infants was calculated and used in these statistical
analyses. For three pairs of twins, umbilical cord material was available from only one
infant, the fatty acid levels of which were used as averages for the pair. For one set of
triplets, the umbilical vein sample of one of the infants was lost during fatty acid analysis,
and the average fatty acid levels were based on those of the two remaining samples.
P-valucs <0.05 were considered to reflect a significant difference.
4.4 Results
4.4.1 Umbilical artery walls
Since the total concentration (mg/kg dry weight) of PL-associated fatty acids was similar
for all study populations, only relative fatty acid levels (weight %) were compared (table
4.2.). The majority of the fatty acid levels and all indices reported were significantly related
to GA at birth.
Cord artery vessel walls of infants born after a multiple (twin or triplet) pregnancy
contained significantly lower levels of I8:2n-6 and of its main LCP 20:4n-6, as well as of
the major I.CT of the n-3 scries, 22:6«-3 (its parent EFA 18:3/i-3 was not present in detec-
table amounts) than infants born after a singleton pregnancy. Levels of the EFA deficiency
indicator 20:3H-9 and its elongation product 22:3n-9, as well as the total amount of MUFAS
were significantly higher in twins and triplets. The EFA status index was significantly lower,
while the EFADI was significantly higher in cord artery walls of infants born after a multiple
pregnancy than in those of infants born after a singleton pregnancy. The values for the
indicators of a specific 22:6n-3 deficiency, the CADI and the fatty acid 22:5H-6, were similar
in all study populations.
The fatty acid profiles of twins and triplets were not significantly different. In the set of
quintuplets, the average levels of 18:2w-6, 20:4n-6, and 22:6/i-3 were 35%, 27%, and 40%
lower, respectively, than those in the twins and triplets. Levels of the PUFAs of the n-9
scries were clearly higher (up to 86%) in the quintuplets than in the twins and triplets.
These differences between the cord artery fatty acid profiles of the set of quintuplets and of
the other infants born after a multiple pregnancy were reflected by the EFA status index
(48% lower in quintuplets) and the EFADI (77% higher in quintuplets), but not by the CADI.
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Table 4-2. Relative (weight %)* fatty acid composition of cord artery vessel wall phospholtpids of study
populations (mean ± SD, except for set of quintuplets: average value of the five infants).
Fatty acid* singletons
(n=94)
pain of twins
(n=30)
sets of triplets
(n=7)
set of quintuplets
ZSAFA
£ MUFA
£ PUFA
20:3n-9
22:3n-9
£ n-9 PUFA
18:2n-6
20:3/1-6
20:4/1-6
22:4II -6
22:5n-6
£n-6
£ n - 6 LCP
22:6/1-3
£ / I - 3 + / I - 6
£ n-3+n-6 LCP
EFA status
EFADI
CADI
total"
46.8 ± 2.6
21.7 ±4.1»
31.5 ± 3 V
3.21 ± 0.88*
i .44 ± o.sr
4.7 ± 1.3'
1.22 ± 0.41'
1.08 ±0.29
13.1 ± 2.6'
2.60 ± 0.76
3.51 ±0.69
21.9*3.7 '
20.3 ± 3.5'
4.95 ± 1.14'
26.8 ± 4 V
25.3 ± 4 . 3 '
1.08 ± O ^
0.26 ± 0 . 1 1 "
1.48 ± 0.59
15579 ± 2 7 5 5
46.1 ± 1.9
25.9 ± 4.3
28.0 ± 4 0
3.77 ± 0.98
1.66 ± 0 56
5.4 ± 1.3
0.84 ± 0.27
0.89 ± 0.27
10.9 ± 2.7
2.11 ±0.65
3.45 ± 0.60
18.6 ± 4.0
17.4 ± 3.7
4.02 ± 0.%
22.6 ± 4.8
21.4 ± 4 . 5
0.78 ± 0.33
0.38 ±0.15
1.78 ±0.53
16634 ± 1767
45.16
26.9
28.0
4.17
199
6.16
0.83
0.94
10.5
197
3.64
18.3
17.1
3.57
21.9
20.6
0.67
0.41
1.90
18366
±0.33
± 1.6
± 1.6
±0.34
±0.17
±0.47
±0.22
±0.27
± I I
±0 28
±049
± 1.6
± 1.4
±0.57
± 1.9
± 1.8
±0.10
±0.07
±0.41
± 1320
44.8
30.7
24.6
5.44
3.21
8.7
0.S4
0.S9
7.9
1.51
2.74
13.6
12.8
2.36
15.9
15.1
0.40
0.69
1.86
16170
"total amount of phospholipid-associated fatty acids expressed as mg/kg dry weight.
^ SAFA= sum of all saturated fatly acids; I MUFA= sum of all monounsaturated fatty acids; £ PUFA= sum of all
polyunsaturated fatty acids; X n-9 PUFA= sum of all PUFAs of the n-9 series (2O:3n-9, 22:3n-9); I n-6= sum of all fatty
acids of the n-6 series; I n-6 LCP= sum of all long-chain PUFAS (PUFAS with a chain length 2 20 C. derived from parent
essential fatty acids through alternate desaturation and elongation) of the n-6 series (20:3n-6. 20:4n-6, 22:4n-6. 22:5/i-6);
I n-3+n-6= I n-6 + 22:6n-3 (no other fatty acids of the n-3 series were present in detectable amounts); I n-3+n-6
LCP= I n-6 LCP + 22:6n-3. EFA status= essential fatty acid status: (E n-3+n-6)/(I n-7+n-9); EFADI= essential fatty acid
deficiency index: 20:4n-6/20:3n-9; CADI= cervonic acid (22:6/1-3) deficiency index: 22:5n-6/22:4n-6.
Significance level for difference between infants born after singleton and after multiple (twin, triplet) pregnancy (multiple
regression analysis with correction for gestational age (GA) at birth):
"•p<0.05. '*P<0.02, 'P<0.01, 'P<0.005. *P<0.001, *PS0.0001.
Except for Z SAFA and 22:3n-9. fatty acid levels and indices reported were significantly related to GA at birth: P-
<0.0001, except for 22:5n-6: P<0.02, I n-9 PUFA: P<0.01, and 2O:3n-9: P<0.001.
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4.4.2 Umbilical vein walls
As with the cord artery vessel walls, the total fatty acid concentrations of the three
groups were not significantly different, so only relative fatty acid levels were compared
(table 4.3.). All but one of the fatty acid levels and indices reported were significantly
related to GA at birth.
Table 4.3. Relative
populations (mean ±
Fatty acid*
£ SAFA
£MUFA
£ PIJFA
20.3/1-9
22:3/i-9
£ /i-9 PUPA
18:2/1-6
20:3/1-6
20:4/i-6
22:4n-6
22:5/i-6
£zi-6
£ zi-6 irp
22:6/i-3
£ /I-3+/1-6
£ ZI-3+/1-6 LCP
EFA status
BFAO1
CADI
total"
(weight %f fatty
SD, except for set
singletons
(n=94)
47.4 ± 1.7'
16.9 ± 2.9*
35.7 ± 3.0
0.67 ± 0.45*
0.48 ± 0.30»
1.16 ±0.70*
2. l9±0.6y
1.59 ±0.35
17.6 ±2.4
4.3 ± 1.2
3.09 ± 0.90"
29.8 ±3.1
26.6 ± 2.9
4.76 ± 0.95
34.6 ± 3.5
31.4 ±3.5
2.02 ± 0.5y
0.04 ± 0.03*
0.82 ± 0.46'
16654 ± 2910
acid composition of cord vein vessel wall phospholipids of study
of quintuplets: average value of the five infants).
pairs of twins
(n=30)
46.3 ± 2.1
20.2 ± 3.4
33.9 ± 3.6
1.32 ±0.79
0.82 ± 0.45
2.2 ± 1.2
1.82 ±0.44
1.48 ±0.35
15.8 ± 2.8
3.6 ± 1.2
3.75 ± 0.87
27.4 ± 4.3
24.6 ± 3.7
4.38 ± 0.64
31.8 ±4.6
29.0 ±4.1
1.53 ±0.51
0.10 ±0.07
1.23 ±0.65
17569 ± 2048
sets of triplets
(n=7)
45.6 ± 1.5
21.0 ± 1.7
33.4 ± 1.8
1.25 ±0.58
0.92 ± 0.26
2.18 ±0.81
1.89 ±0.42
1.59 ±0.41
15.5 ± 1.2
3.43 ± 0.74
3.99 ± 0.91
27.4 ± 2.0
24.5 ± 1.5
3.78 ± 0.58
31.2 ±2.2
28.3 ± 1.8
1.38 ±0.23
0.09 ± 0.05
1.26 ±0.53
18504 ± 1964
set of quintuplets
(n=l)
44.5
25.6
29.9
3.06
1.91
4.97
1.15
1.35
12.4
2.23
4.18
21.9
20.2
3.12
25.0
23.3
0.82
025
1.94
19146
Legend as in table 4.2.
Except for 18:2/i-6. fatty acid levels and indices reported were significantly related to GA at birth: P-
<0.000l, except for £ SAFA: P<0.02.
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The umbilical vein walls of infants bom after a multiple pregnancy contained signifi-
cantly less 18:2/1-6 and significantly more n-9 Pl'FAs and more Mt'FAs than infants born
after a singleton pregnancy. The EFA status index was lower and the I-FAM higher in twins
and triplets. While levels of 22:6/i-3 were similar in all study populations, values for its
specific deficiency indicators. 22:5n-6 and the CADI, were significantly higher in the um-
bilical vein walls of infants born after a multiple pregnancy.
Fatty acid profiles in venous cord vessel walls of twins and triplets were comparable In
the one set of quintuplets, levels for 18:2/t-6, 20:4n-6 and 22:6/1-3 were between 20 and
30% lower than the mean levels for these fatty acids in twins and triplets. Venous n-9 Pl'FA
levels of the quintuplet were more than twice as high as those in the other infants born after
a multiple pregnancy. The differences mentioned were reflected in all three functional
indices calculated.
4.5 Discussion
The results of this study show that the EFA status, measured in cord vessel wall Pt.s, of
infants born after a multiple pregnancy is different from that of infants born after a single-
ton pregnancy (tables 4.2. and 4.3). After correction for GA at birth, «-6 and n-3 EFA levels
were generally lower, while values for EFA deficiency indicating fatty acids and EPA defic-
iency indicating fatty acid indices were higher in twins and triplets lhan in infants born after
a singleton pregnancy. Most differences between arterial and venous fatty acid values in
each study population were significantly different from zero (data not shown) and their
directions were comparable to those observed in earlier studies [17,19,20,24; Chapter 2).
Results in the cord artery wall PLs (the EFA profile of which is considered a longer-term
representation of the EFA return flow from fetus to mother, and as such of the fetal EFA
status) indicate that the general EFA status of downstream fetal tissue during a multiple
pregnancy is considerably lower than that during a singleton pregnancy. To our knowledge,
only one recent other study reporting EFA data of infants born after a multiple pregnancy is
available for comparison: Hoving and co-workers [29] measured umbilical plasma choles-
terol ester and triglyceride fatty acid levels (molar %) in one prelerm and two term twins.
Although these data were not analyzed statistically, average EFA and LCP levels of each pair
appeared to be in the lower range of those of 38 infants born at various GAS after a single-
ton pregnancy, which were studied simultaneously.
The differences observed between the EFA profiles of infants born after a singleton and
after a multiple pregnancy support the hypothesis that the maternal EFA supply to the fetus
is limiting. This hypothesis is also confirmed by the results in the cord vein walls (the EFA
profile of which is regarded a longer-term reflection of the EFA supply from mother to
fetus). The daily amounts of n-6 and /J-3 EFAs used for intrauterinc dc novo synthesis of
tissues have been estimated to be about 400 and 50 mg/kg of body weight, respectively
[30]. Based on calculations by Crawford and co-workers [31], women with a singleton
pregnancy would have to increase their daily dietary EFA intake by about 1.5 energy % to
adequately cover these demands of the fetus, as well as those of the accreting placcntal and
maternal tissues. This amount is roughly similar to that recommended to pregnant women
by the Food and Nutrition Council [32] in the Netherlands. No specific guidelines, however,
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have been formulated for women having a multiple pregnancy. Moreover, results of a
recent longitudinal study [33] of the maternal EFA status during and after an uneventful,
singleton pregnancy indicated that the pregnant women had drawn on their EFA stores to
supply their fetuses with the necessary quantities of EFAs, 22:6n-3 in particular.
When assuming that the lower EFA status of infants born after a multiple pregnancy
results from the fact that the limited maternal EFA supply has to be shared by more than
one fetus, EFA levels in sets of triplets would be expected to be lower than those in the
pairs of twins. Yet, in the present study, umbilical artery and vein wall fatty acid profiles of
these two subpopulations were comparable. The average EFA status of the one set of quin-
tuplets studied, however, was substantially lower than that of the other infants born after a
multiple pregnancy. Because the differences between the EFA profiles of the set of quin-
tuplets and those of the twins and triplets could not be verified statistically, they could not
be corrected for an effect of GA. Nevertheless, considering their magnitude, a complete
dependency of these differences on this confounder seems highly unlikely.
Crawford and co-workers |12] and Hoving and co-workers [29] observed higher EFA
levels in the heaviest infants of the one pair of twins (umbilical artery vessel walls) and the
three pairs of twins (umbilical plasma) they, respectively, studied. In the present study of a
considerably larger group of infants born after a multiple pregnancy, no significant differen-
ces were observed between (he HFA and LCP levels of the lightest and heaviest infants of a
set of twins or triplets, except for 22:6«-3 in the umbilical vein wall, which was signi-
ficantly lower in the lightest infants (P=0.04).
Multiple pregnancy is one of the major causes of preterm delivery [34]. PL-associated
EFA and LCP levels in umbilical plasma [35] and umbilical vessel walls [17; Chapter 2] of
prctcrm infants born after a singleton pregnancy have been found to be lower than those of
infants carried to term. This lower LCP status may be related to the lower physiological
demand for these fatty acids of the prctcrm fetus, considering the earlier stage of its brain
and body growth. However, the added effect of a lower EFA and LCP status as a result of
multiple pregnancy (all differences between infants born after multiple and singleton preg-
nancy were corrected for GA at birth), may be a reason for concern with respect to the
adequacy of the EFA and LCP status of preterm twins and triplets. Particularly since, in
preterm infants, a lower LCP status at birth has been shown to result in a lower postnatal
LCP status, irrespective of the type of postnatal diet the infants received [16; Chapter 7].
Considering the importance of LCPs for normal brain and visual development [7-11], the
results of the present study warrant further consideration and evaluation of the need for
supplying women who carry more than one infant with additional n-3 and «-6 parent EFAS
and/or LCPs during their pregnancy.
In conclusion, the biochemical EFA status, measured in umbilical cord vessel walls of
infants born after a multiple pregnancy is lower than that of a comparable group of infants
born after a singleton pregnancy, indicating that the pregnant women have difficulty coping
with the EFA demands of the multiple developing and growing fetuses. In view of the
importance of EFAs, particularly the longer-chain derivatives for proper growth and develop-
ment, this observation warrants further studies of the adequacy of the maternal EFA intake
during a multiple pregnancy.
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5.1 Abstract
In eight healthy volunteers, fatty acid concentrations in plasma and red blood cell (RBC)
phospholipids (PLs) isolated from venous and from capillary blood were compared. To
evaluate the effect of storage, lipids were extracted on the day of blood collection and after
one and four weeks of storage at -20°C. Plasma fatty acid profiles from venous and capil-
lary blood were comparable and not affected by up to four weeks of storage. RBC fatty acid
concentrations from venous and capillary blood were comparable after up to one week of
storage before lipid extraction. However after four weeks of storage, the total amount of PL-
associated fatty acids in capillary RBCs was decreased to half the initial value. This decline
was mainly caused by a decrease of almost 90% in the concentration of polyunsaturated
fatty acids (PUFAs) and was not observed in venous RBCs. Consequently, highly significant
differences developed between the fatty acid profiles of venous and capillary RBCs. Loss of
RBC membrane structural integrity may have added to the higher susceptibility to lipid loss
of RBCs collected by capillary puncture. In conclusion, plasma PL-associated fatty acid pro-
files of venous and of capillary blood are comparable and unaffected by storage at -20°C
until lipid extraction for at least four weeks. The fatty acid compositions of, particularly
capillary, RBC suspensions stored for more than one week are affected by lipid loss and,
therefore, unreliable.
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5.2 Introduction
When the effects of the dietary essential fatty acid (EFA) intake on the human EFA status
are studied, blood samples are usually collected through venous puncture. In our recent
study of dietary influences on the EFA status of preterm infants in plasma and RBC PL [1;
Chapter 6), the necessary blood samples were collected in connection with diagnostic
punctures, which arc part of the routine clinical monitoring at the neonatal care unit. In a
large portion of these punctures, the blood is of capillary origin, usually collected by heel-
prick. Since weekly blood samples were to be collected from the participating infants for at
least four weeks after birth, it was more than probable that a set of samples collected over
time would contain both venous and capillary blood.
Consequently, to obtain reliable information on dietary influences, the fatty acid profiles
of venous and capillary plasma and RBC PLs should be comparable. To our knowledge, no
detailed information on this particular subject is available in the literature. The few studies
relating to the comparability of venous and capillary plasma for more general analyses of
the major lipid classes have yielded ambiguous results [2,3]. Therefore, the primary aim of
the present study was to compare PL-associated fatty acid profiles of plasma and RBCs,
collected through cither venous or capillary puncture. Moreover, since all blood samples of
a given study subject were to be analyzed simultaneously to ensure uniformity of analytic
conditions, the different storing times of the various blood samples should not influence the
results. Tncrelore, we also evaluated the effects ot storage at -20 "C tor a period up to four
weeks on both venous and capillary plasma and RBC PLs.
5.3 Subjects and methods
5.3.1 Experimental design
For ethical reasons, we decided not to perform this study in young infants. In stead,
eight healthy adults (3 males, 5 females), who were all employees or students at our depart-
ment, volunteered to participate in this study. Informed consent was obtained from all
participants. Every subject donated two blood samples: five ml of venous blood were drawn
from an antecubital vein, and approximately two ml of capillary blood were collected by
finger-prick. The blood samples were collected in EDTA-containing tubes to prevent coagul-
ation. The plasma was separated from the RBCs by centrifugation. RBCs were washed twice
with EDTA-containing saline (NajEDTA, 2 H,O 28.64 g, NaCl 7.00 g, HjO 1000.0 ml). Each
plasma or RBC sample was divided into three duplicate samples. To evaluate a possible
effect of storage on the fatty acid content of the blood samples, extractions of the lipids of
the three sets of venous and capillary blood samples were done at the day of collection, or
one or four weeks thereafter. The tubes containing plasma or RBC suspension were closed
under a stream of nitrogen to prevent oxidation and stored at -20 °C until analysis.
5.3.2 Fatty acid analysis
To ensure uniformity of analytic conditions, the venous and capillary blood samples
were analyzed simultaneously.
At the start of the analysis, approximately 40.0 ug 1,2-dinonadecanoyl phosphatidylcho-
line (PC-ll9:0],) were added to every sample as internal standard. Total lipid extracts of 100
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pi of plasma or RBC suspension were prepared according to the method of Bligh and Dyer
[4]. The phospholipid (PL) fractions of plasma and RBCs were isolated by solid phase
extraction on an aminopropyl-silica column |5). The PLs were saponified and the fatty acids
converted to the corresponding methyl esters by reaction with 14% boron tri fluoride in
methanol at 100 °C for one hour [6). To all organic solvents, butylated hydroxytoluenc (50
mg/L) was added as an anti-oxidant. The fatty acid composition of the PLs was determined
by gas liquid chromatography as described before (1), only modified by the use of a CP-Sil
88 column (Chrompack*, Middelburg, The Netherlands). Fatty acid amounts present in the
PL fraction were quantified based on the amount of 19:0 internal standard fatty acid methyl
ester recovered and expressed as mg/1 plasma or RBC suspension.
In total, 35 fatty acids were identified. In this paper, only the following relevant 8 fatty
acids and 5 fatty acid combinations arc reported: linolcic acid (l8:2n-6), dihomo-7-linolcnic
acid (20:3/i-6), arachidonic acid (20:4/i-6). adrenic acid (22:4/i-6), Osbond acid (22:5/1-6),
eicosapentaenoic acid (2O:5n-3), docosahexaenoic acid (22:6/i-3). £ SAFA (sum of all
saturated fatty acids), £ MUFA (sum of all monounsaturatcd fatty acids), £ PUFA, £ /1-6 LCP
(sum of the long chain polyunsaturatcd fatty acids (LCPs) formed from the parent EFA
18:2/J-6 through alternate desaturation and elongation), and £ n-3 LCP (sum of the LCPs
formed from the parent EFA a-linolenic acid (18:3/i-3) through alternate desaturation and
elongation). In addition, two indices were calculated: the unsaturation index |UI, sum of
(.nurriDer 01 üoüoie bonus * %'level óllatty aciü)J'[7J. am» the EhA status (2. n-b+n-J/L /1-
7+n-9) [8].
5.3.3 Data analysis
Fatty acid concentrations are presented as medians and interquartile ranges. Fatty acid
concentrations of venous and capillary plasma and RBC PLs were compared for each of the
three intervals between blood sampling and lipid extraction (zero days, one week and four
weeks). In addition, both for venous and capillary plasma and RBC samples, fatty acid con
centrations in samples of which lipids were extracted one or four weeks after blood collec-
tion were compared with fatty acid concentrations in samples extracted on the day of blood
sampling. Because of the number of subjects studied, differences between venous and
capillary blood samples were evaluated by calculating the non-parametric 95% confidence
intervals of the ratio of the capillary to the venous concentration of a given fatty acid [9].
Similarly, differences between stored samples and samples that were analyzed on the day of
blood collection were evaluated by calculating the non-parametric 95% confidence intervals
of the ratio of the concentration of a given fatty acid after one or four weeks of storage to
its concentration after immediate lipid extraction. The average value of each set of duplicate
samples was used in these calculations. All 95% confidence intervals were calculated based
on the two-tailed Wilcoxon signed ranks test and after a log transformation of the ratios to
obtain a symmetrical distribution. The intervals thus obtained were then transformed back
by taking the exponents of the range limits.
To present the results of the statistical analyses, fatty acid data of venous RBCs stored
for one or four weeks are also presented as the percentage level of their concentration at
day 0. Furthermore, fatty acid data of capillary RBCs at day 0, week 1 and 4 are expressed
as the percentage level of their venous RBC concentrations at those times, while those at
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weck 1 and 4 are also expressed as percentage level of the capillary RBC concentration at
day 0. For these percentage levels, the above-mentioned 95% confidence intervals are
given, preceded by the Hodges-Lehmann estimate [10], which is a non-parametric estimate
of the actual ratio of the various samples. This Hodges-Lehmann estimate is comparable t
o, but more accurate than the median.
If the ratio of one (relative level=100%) was not within the 95% confidence interval o
btained, samples were considered to be significantly different.
5.4 Results
In general, the fatty acid profiles of venous and capillary plasma PLs were comparable
and unaffected by one or four weeks of storage at -20 °C before lipid extraction (table
5.1.). Sometimes, the lower limit of the 95% confidence interval was just above the 100%
level.
The fatty acid profiles of venous and capillary RBC PLs did not differ when lipids were
extracted on the day of blood collection or one week thereafter (see table 5.2. for fatty acid
concentrations and table 5.3. for accompanying confidence intervals). For venous RBCs, on
c or four weeks of storage before lipid extraction, generally, did not result in significantly
different fatly acid concentrations, when compared to those of samples that were extracted
on the day of collection. The only exceptions were the concentration of 22:6n-3 and the v
alues for the (wo indices calculated, which were significantly decreased after four weeks o
f storage, with the 100% level lying just above the upper limit of the 95% confidence
interval.
Fatty acid profiles of capillary RBC PL samples were similar when stored for zero days
or one week until lipid extraction. However, after four weeks of storage, substantial differ-
ences from the initial values were observed. The total amount of PL-associated fatty acids
decreased to almost half the initial value and was significantly lower than that in venous
RBCs stored for four weeks. This decline mainly resulted from a decline of nearly 90% in
the concentration of polyunsaturated fatty acids (Z PUFA). Compared to their values after
immediate lipid extraction, I MUFA and 2 SAFA concentrations in capillary RBC samples
stored for four weeks were 40% and 20% lower, respectively. As a result, capillary RBC
concentrations of Z PUFA and, to a lesser extent, Z MUFA and Z SAFA were lower than their
venous concentrations.
Within the group of PUFAS, the largest decrease was observed in the LCPs, particularly
those ol' the «-6 scries. After four weeks of storage, the concentration of Z «-6 LCP, on
average, was decreased to merely 4% of its initial concentration, while that of the parent
EFA 18:2n-6 decreased to 17% of its value after immediate lipid extraction. The concen-
tration of Z n-3 LCPs declined to 10% of its initial value; the parent EFA 18:3n-3 was not
present in detectable amounts. Consequently, after four weeks of storage, all capillary LCP
concentrations were significantly lower than the venous concentrations with the upper limit
of the 95% confidence interval well below the 100% level.
Values for both the unsaturation index and the EFA status were also significantly
decreased in capillary RBC PLS after four weeks of storage, again reflecting the loss of
mainly highly unsaturatcd fatty acids.
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Table 5.1. Absolute fatty acid composition of venous and capillary plasma phospholipid». with Upid extraction done on the day of collection (day
0), or I week, or 4 weeks thereafter [median (interquartile range)].
fatty acid"
mg/1
total
£ SAFA
Z MUFA
L PUFA
18:2>i-6
20:3n-6
20:4n-6
22:4n-6
22:5n-6
£n-6 LCP
20:5n-3
22:5n-3
22:6n-3
I n-3 LCP
Ul
EFA status
venous (n=8)
1209(453)
583(199)
138 (45)
473(162)
290(84)
27.5 (5.2)
101 (20)
2.6(1.7)
2.1 (1.2)
135 (23)
6.0 (5.9)
5.8 (2.8)
32.9 (9.3)
45(13)
124.9(5.1)
2.93 (0.71)
day 0
capillary (n=8)
1250(398)*
604(171)*
149 (49)*
481(167)
293 (83)
28.9 (6.5)
103 (24)
2.7 (2.0)
2.2(1.0)
138(24)
6.5 (6.1)
5.8 (3.0)
35 (12)
48(12)
123.6 (8.7)
2.92 (0.44)
venous(n=8)
1260 (212)
595(111)
150 (42)
503 (87)
289 (49)
30.4 (7.6)
110(35)
3.1 (1.9)
2.6(1.1)
146 (36)
7.5 (7.4)
5.7(4.1)
35 (15)
49(16)
124.6 (7.8)
3.06 (0.58)
week 1
capillary (n=7)
1260(141)
588 (84)
157 (34)
494(80)
272 (66)
33(11)
103 (34)
3.1 (2.4)
2.8(13)
144 (43.7)
7-5(7.1)
5.3 (4.7)
31 (18)
46(17)
124(14)
2.94 (0.50)
venous (n=8)
1254 (232)
611 (105)
153 (38)
520(155)
306(84)'
29(11)
115(36)
3.2(1.8/
2.4(1.4)
143 (39)
7.6 (7 J ) '
6.0 (4.0)
39(12)
51 (16)
129(13)
3 04 (0.68)
week 4
capillary (n=8)
1267 (272)
602(114)
156 (35)
524(146/
313(81/
29.4 (9.6)
116 (36)
3.2 ( U /
2.3 (1.2)
141 (43)
7.4 (6.9/
6.1 (3.5)
39(11/
52(16/
129(14)
2.91 (0.75)
"SAFA= saturated fatty acids; MUFA= monounsaturated fatty acids; PUFA= polyunsatumed fatty acids; n-6 LCP= tag-chain niFA* (LCP>) of the «-6
series (20:3n-6. 20:4n-6. 22:4n-6. 22:5n-6); n-3 LCP= LCPs of the n-3 series (20:5n-3. 22:6n-3); Ul= Unsaturabon Index; sum of (number of double
bonds • % level of fatty acid); EFA status= essential fatty acid sums: ( I n-6+n-3)/(I «-7+«-9).
Statistical differences:
*ratio of capillary to venous concentration: 100% level just below lower limit of non-parametric 95% confidence interval;
''ratio of concentration at week 4 to that at day 0: 100% level just below lower limit of non-parametric 95% confidence interval.
TaMe 5.2. Absolute fatty acid composition of venous and capillaiy red blood cell phospholipids, with lipid extraction done on the day of collectioa
(day 0), or 1 week, or 4 weeks thereafter [median (interquartile range)].
n
fatty acid"
mg/1
total
ISAFA
IMUFA
I PUFA
18:2/1-6
20:3/1-6
20:4/i-6
22:4/1-6
22:5/J-6
1/1-6 LCP
20:5/i-3
22:5/i-3
22:6/i-3
Z n-3 LCP
Ul
EFA status
venous (n=8)
882 (346)
407(140)
166 (74)
297(133)
119(39)
11.2(4.6)
91 (46)
21 (17)
2.6(1.9)
125 (73)
4.1 (2.7)
13.2 (4.4)
27(14)
46(18)
131 (12)
1.70(0.17)
day 0
capillary (n=8)
841 (282)
396(121)
162 (59)
271 (101)
117(20)
10.6 (4.5)
83 (36)
20(15)
2.3 (1.7)
113(58)
4.1 (2.5)
12.1 (3.1)
27 (12)
44(17)
131 (10)
1.72(0.15)
venous (n=8)
914(1%)
422 (78)
177 (42)
301 (60)
116(25)
12.7 (4.2)
103 (28)
24.8 (8.6)
3.2 (1.8)
148 (36)
7.5 (7.4)
13.1 (5.3)
35 (15)
46(19)
129.0 (8.8)
1.73 (0.24)
week 1
capillary' (n=6)
893(164)
421 (78)
172 (42)
293(51)
123 (27)
12.3 (3.8)
99(17)
25.3 (9.5)
3.2 (2.4)
135 (25)
7.5(7.1)
13.4 (5.5)
31(18)
45(19)
132(13)
1.74(0.11)
venous (n=8)
811(241)
393(111)
176 (59)
261 (77)
112(44)
9.4 (4.4)
78(21)
20.9 (7.8)
2.5(1.5)
109 (33)
3.4 (3.4)
13.3 (4.5)
18(14)
35(12)
118(20)
1.49(0.55)
week 4
capillary (n=8)
462(137)
330 (82)
103 (29)
33 (26)
18(12)
0.99(1.06)
2.5 (7.6)
1.7(1.3)
ND
6.1 (7.9)
ND
2.10(0.91)
2.5(1.8)
4.4 (4.0)
50(13)
0.35 (0.12)
"as in table 5.1., in addition: ND= none detected (<0.1% (wt/wt) of total fatty acid methyl esters). For statistical differences: see table 5.3.
Table 5.3. Comparison of fatty acid compositions of venous (v) and capillary (C) red blood cell (RBC) photpholipids. with lipid extraction done on
the day of collection (day 0), or 1 week (wk 1), or 4 weeks (wk 4) thereafter [venous RBC» day 0: median (interquartile range), others: HodfM-
Lehmann estimate (95% confidence interval)"].
fatty acid*
total
£ SAFA
ï MUFA
I PUf A
I8:2n6
2O:3it-6
20:4n-6
22:4n-6
22:5-6
I-6LCF
20: Ju-.'
22:5«-3
22«~3
I-3LCT
EFA SUIUS
v day 0 (mf/L)
<n=8>
882 (346)
407(140)
166 (74)
297(133)
119 (39)
11.2 (4 6)
91 (46)
21 (17)
16(19)
125 (72)
4.1 (2.7)
13(4 4)
27(14)
46(18)
131 (12)
1.70(0.17)
c day 0/v day 0 *
100» (n=8)
97 2(90 5 106 5)
98 1 (91 3-1064)
969(90 8-108 6)
94 8(89 3-105 6)
96 5 (89.7-106 5)
96 1 (89.0-109 7)
96 4(88 2-107 6)
94 6(87 2-105 2)
95 5(89 4-107 0)
96 0(88 4-107 7)
99 6(94 6-107 6)
94 2(830-104 4)
95 5(916-104 4)
95 6(904.1035)
992 (97 9-1010)
99 7(97 6-118 8)
v wk l/v day 0 •
100» (n=8)
1069(84 8-123 9)
107 1 (87 8-1209)
1087 (849-1265)
1067(81 1-128.7)
104.5(84 4-122.6)
1052 (829-1223)
1074(79 81345)
1089(80 4-137 7)
10*4(82 0-1310)
107 5(8 0-133.6)
108.3(81 7-1313)
105 7 (79 7-1330)
103 2(79 1136 6)
104 7(79 6-132 0)
99 8 (95 4-105 4)
99 1 (93 4-105 3)
C wk IK day 0 •
100% (n=6)
107.6(93.6-124 4)
1066(95 4-121.3)
1044 (95 5-1202)
111.0(89.8-130.8)
106.6(910-1210)
107 9(86.5-1218)
112.4(91.2-139.7)
118 2(89.9-143 5)
114.5(85 4-144.6)
113.1 (91.0-138 1)
107.2 (M.3-130 6)
113.3(87.1-144 9)
1139(858 1398)
113.0(16 4-1408)
1039(969-105 9)
105.3 (93 9-1099)
C wt 1/V wk 1 •
100* (»6>
93 1 (130-1016)
93.7 (M 4-101 1)
93-5(*3*»9)
916(16 1-102.1)
92.9(15 7-1019)
91.2(14 6-102 2)
93 2(16 7 103 9)
93 7(116-1013)
94.31*2 9-1022)
914 QB 9-103 2)
90.7 (M 3-1009)
93.1 (M0-100 7)
94.4 (14 0-1017)
93.9K26-I02A
1002 (97 9-MB. 7)
1001 (965-1064)
V wt 4/V fey 0 •
100» (»-*>
905(7021176)
965(12 3-1249)
934(739-1233)
117(33 4-1111)
132 (47 1-121 J)
•09(34 3-1074)
113(19 4-114 4)
171(29 6-129 5)
«6(130-127 7)
t i l (219-1133)
U 2 (9 2-1230)
•93 0*3-130*)
SM( I7*9*J>
69 5(24 9-1042)
91J (57449 J)
•94 (41.1-9*4)
"Non-parametric Hodges-Lehmann estimates and 95% confidence intervals, calculated based on the two-tailed
a log transformation of the ratios to obtain a symmetrical distribution.
95% Confidence intervals indicating significant differences (100% level outside limits) are printed in bold face
*As in table 5.1.
C*4**,0.
100» <«-«)
534(4X3-64.4)
794(6*3-99.1)
S94 (494-764)
1L3 (9.4-164)
17.1 (I24-M.9)
6.9 (14-111)
I.4I6.M4)
6.7(44-9.9)
4J (14-9.1)
3.7 (14-9.5)
12(14-16-1)
17J (9.1-22.7)
«4(SJ-ISJ)
MJ (7 7-164)
3S4C»9-.IJ)
194 (16.7-234)
Wilcoxon signed
Cwt 4/V wt4*
*S4 (43.1-74.1)
7*4 (644-97 J)
61.9 (47.1424)
ISJ (E4-33.T)
I9J (114-J64)
«J (11-3*4)
14 (6 J-16.7)
7.7 (34-UJ)
S4O4-134)
6.7 (1.7-214)
«(14-1*4)
l7*«4-6t7)
1*4(64-517)
W.7<a4-IM.
414U34-«*4)
25J IUJ-44J)
ranks test and after
1acid
 profilles
.
2,
uid
 c
apillary
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5.5 Discussion
The results of this study show that, after four weeks of storage at -20°C before lipid
extraction, fatty acid profiles in RBC PLs isolated from venous and from capillary blood are
no longer comparable. This is the result of substantial losses of fatty acids, and of PUFAs in
particular, mainly in capillary RBCs. The fatty acid profiles of venous and capillary plasma
PLs are unaffected by four weeks of storage and remain to be essentially similar.
The good comparability of the fatty acid compositions of venous and capillary plasma
PLs enables an accurate evaluation of dietary influences in longitudinal sample sets consist-
ing of both venous and capillary plasma, as was the case in our dietary study in preterm
infants [ 11. Particularly in this type of study, which is increasingly being done, the above-
mentioned observation can contribute to a reduction of the burden that extra blood punc-
tures impose on the participating infants.
A few studies have evaluated changes in the PL-associated fatty acid profile of venous
plasma samples that were stored for longer periods (up to one year) under conditions
similar to ours [11,12]. Hirsch and co-workers [11] identified the limited number of 6 fatty
acids, of which !8:2n-6 and 20:4n-6 were the only PUFAs, and found a significantly
decreased percentage level of 20:4n-6. De Jong [12] and co-workers reported a few signifi-
cant decreases of individual fatty acid levels, that were independent of the degree of unsat-
uration.
Loss of PL-associated PUFAs from RBCs as a consequence of storage at temperatures
below 0 °C has also been reported by others [13-15]. Autoxidation of PUFAs is the obvious
major cause for the changes observed in the fatty acid content of stored RBC samples. Iron,
which is largely present in haemoglobin, is a catalyst in the process of lipid peroxidation,
both in the initiation and propagation stages [16-20]. Indeed, in contrast to his observations
in intact RBCs, Ways [ I4| reported that the PL content of haemoglobin free RBC ghosts was
not affected by storage under the same conditions.
However in the present study, the pronounced decrease of the PUFAs in the capillary
samples was accompanied by reduced concentrations of SAFAs and MUFAs, which are
unlikely to be caused by autoxidation. Breakdown of PLs by phospholipases as an explana-
tion for these SAFA and MUFA losses seems improbable, because this requires the presence
of calcium, which will have been removed by the substantial amounts of EDTA that were
present both in the tubes in which the blood samples were collected and in the solution with
which the RBCs were washed. A reduced recovery, particularly during the extraction step of
fatty acid analysis [21], of PLs containing a SAFA or MUFA chain next to an oxidized PUFA
chain, which is more polar than an unaffected PUFA chain, seems a more possible cause.
Anyway, the observation of decreased SAFA and MUFA concentrations stresses the additional
information that can be obtained from evaluating absolute fatty acid data. In figure 5.1.,
effects of storage on the absolute and relative (% (wt/wt) of total fatty acids) SAFA, MUFA
and PUFA values in venous and capillary RBC PLs are visualized. After four weeks of
storage, relative levels of Z SAFA and Z MUFA were increased in stead of decreased, which
would suggest a shift in the fatty acid content of the RBCs, rather than a loss of all types of
fatty acids, which is what really happened.
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Figure 5.1. Absolute (u/yxr,) and relative (/onrr) fatty acid composition of capillary and venous red blcxnl
cell suspensions, stored at -20°C for zero days, one week or four weeks before lipid extraction. £ SAI-A =
sum of all saturated fatty acids; £ MUFA = sum of all monounsaturated fatty acids; £ PUFA = sum of all
polyunsaturated fatty acids.
The most striking finding of the present study is not that of multiple significant fatty
acid losses, but the fact that these losses were mainly observed in the capillary RBC
samples. When performing a capillary puncture, the blood is driven into a tube with con-
siderable manual pressure, leading to more damage to the RBC membrane than when per-
forming a venous puncture. In fact, all of the capillary and none of the venous samples
collected in our study showed signs of haemolysis as a result of this loss of RBC membrane
structural integrity, which may enhance RBC susceptibility for lipid pcroxidation in a num-
ber of ways. Firstly, the tissue damage can result in the release of otherwise sequestered
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iron, which thus becomes available for the radical reactions involved in autoxidation [20].
Secondly, the structural insulation that proteins give to autoxidisable lipids [22] as well as
the protective structural organization of the lipids themselves [23] are disturbed. In any
event, also in the present study, venous RBC PLs were not completely unaffected by four
weeks of storage: the 22:6«-3 concentration and the unsaturation index and EFA status index
were even significantly reduced. Moreover, the 95% confidence intervals of all PUFAS were
wide, with a low lower limit.
Attempts ought to be made to prevent the observed loss of RBC fatty acids. Storage of
RBC suspensions at temperatures below -20°C, e.g. at -50°C or even -80°C, will perhaps
delay, but not prevent lipid loss (A.C. v. Houwelingen, unpublished data). Based on the
concept of iron-induced oxidation as the major cause of lipid loss from stored RBCs, one
option is to remove haemoglobin from the RBC lipids by preparing red cell ghosts [14] or
lipid extracts from the RBCs within one week after blood sampling. Dodge and Philips [13]
observed no changes in RBC extracts stored in the presence of butylated hydroxytoluene, an
anti-oxidant which we add to all the organic solvents used in the fatty acid analysis. How-
ever, if one wishes all steps of the analyses to be simultaneous for a series of consecutive
RBC samples, storage of RBC suspensions is unavoidable. In this case, autoxidation may be
prevented by handling and storing the RBC samples in the presence of a chelating agent,
preferably desl'crrioxaminc [24], which binds iron and thus prevents it from promoting lipid
pcioxiu'uiion. i'Jc.srcriioxuiiimc nus ócen uuinonsuaieu' lo eiTecuvefy prevent or at least
reduce lipid peroxidation in various in v/rro and /« v/vo studies [24-27]. However, further
studies arc needed to determine its effectiveness in preventing lipid loss from RBC samples
stored for longer periods at temperatures below 0 °C, as will be the case in many dietary
studies.
In conclusion, the results of this study show that plasma PL-associated fatty acid profiles
of venous and of capillary blood arc comparable and unaffected by storage at -20°C until
lipid extraction for up to four weeks. When stored for more than one week until lipid
extraction, the tatty acid content of RBC suspensions, particularly when of capillary origin,
will be affected by lipid loss, with the largest decreases observed in the highly unsaturated
fatty acids. This makes these RBC samples unsuitable for a proper evaluation of dietary
effects.
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6.1 Abstract
The long-chain polyene, or long-chain polyunsaturated fatty acid (LCP) status of 39
preterm infants (birthweight < 1800 g) was evaluated. Twenty-seven infants were fed on an
artificial formula, 12 received their own mother's breast milk. Fatty acid compositions of
both plasma and red blood cell (RBC) phospholipids (PLs) were determined in umbilical
venous blood and in weekly postnatal blood samples until the 28th day of life. Individual
fatty acid levels were expressed as absolute quantities (mg fatty acid/1 plasma or RBC
suspension) and as relative (weight %) values. The changes with time in the absolute values
for 22:6n-3 and 20:4«-6 in plasma were strikingly different from those of the relative values
for these fatty acids. In plasma PLs the inter-group differences in the absolute postnatal
values for 22:6/i-3 (P<0.0005) and 20:4n-6 (P<0.05) and the relative values for 22:6n-3
(P<0.02) were significant, with lower fatty acid values in the formula fed infants. In RBC
PLs, no significant inter-group differences in the postnatal 22:6n-3 and 20:4n-6 values were
found. Based on the assumption that it is desirable for formula-fed infants to achieve
postnatal plasma LCP values at least comparable with those found in infants fed on human
milk, the findings of the present study indicate that both n-3 and «-6 LCPs should be added
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to prcterm infant formulas. Moreover, the additional importance of absolute fatty acid levels
was demonstrated, although analytical procedures need to be standardized to enable effec-
tive comparison of results from different research groups.
6.2 Introduction
The demand of the fetal and neonatal brain for docosahexaenoic acid (cervonic acid,
22:6n-3) and arachidonic acid (20:4n-6) shows a substantial increase during the last trimes-
ter of pregnancy and the first months of postnatal life [1,2]. Therefore, an adequate supply
of these LCPs (essential fatty acids (EFAS) with a chain length of 20 carbon atoms or more),
which arc two of the most abundant structural fatty acids in the brain [3,4] as well as in the
retina [5|, is required both prc- and postnatally.
Conventional artificial formulas, unlike human milk, do not contain any but trace
amounts of 22:6n-3, 20:4n-6 and other LCPs [6-8]. Substantial amounts of the parent EFAS
linolcic acid (18:2/1-6) and a-linolenic acid (18:3n-3) are present in artificial formulas [6-8].
However, the desaturase capacity of newborns is probably too limited to guarantee an
adequate supply of n-3 and H-6 I.CPS solely through metabolic conversion of these two fatty
acids [9,10]. Since neonatal LCP stores, particularly those of prcterm newborns, are very
limited as well [2,11], the use of conventional formulas could result in a considerable
deterioration of the LCP status after birth, csjieciallv in children who arc born ,nre.tr.rm The
occurrence of such a deterioration has indeed been reported in a number of studies [12-15].
Further investigations have demonstrated that adding n-3 or n-3 and «-6 LCPs to the artifi-
cial formulas results in a substantial reduction of this deterioration [14,15-17].
The conclusions of the majority of these studies were based on relative fatty acid values
(that is either weight or molar percent of total fatty acids) for plasma [14] or RBC lipid
fractions [12,13,16]. The impression obtained from relative values, however, can be strik-
ingly different from that obtained from absolute amounts. For example, while relative
values for 2():4n-6 and 22:6/i-3 are higher in cord plasma PLs than in maternal plasma,
absolute quantities (mg/1 plasma) arc significantly lower. This is due to a considerably
lower PL concentration in cord blood [ 18]. In addition, when comparing preterm infants fed
on an artificial formula with prelerm infants receiving fat-free parenteral nutrition, a larger
increase between birth and the 3rd day of life in the ratio of 20:3n-9 to 20:4n-6 (commonly
used as biochemical evidence of EFA deficiency) was observed in the latter group. This was
not associated with lower «/wo/ure amounts of n-3 and n-6 LCPs in this group [19]. Thus,
absolute fatty acid values may very well provide additional information on the LCP status of
preterm infants, as influenced by their nutritional EFA intake.
To evaluate this assumption, the postnatal pattern of the LCP status, with special em-
phasis on 22:6«-3 and 20:4/i-6. of preterm infants fed on conventional artificial formulas
was compared with that of preterm infants receiving their own mother's breast milk. The
LCP patterns of both plasma and RBC PLs were studied. PLs are structural lipids, which are
the richest source of polyunsaturalcd fatty acids (PUFAs). including LCPs. In addition,
changes in PDFA profile are most pronounced in PLs [20]. The fatty acid values were
expressed as absolute quantities (mg/1 plasma or RBC suspension) and as relative values (%
(wl/wt) of total fatty acids).
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63 Subjects and methods
6-3.1 Experimental design
Su/yVctt
Thirty-nine infants, born before the 37th week of gestation and free from metabolic
disease and major congenital malformations, participated in this study. Gcstutional age was
confirmed by menstrual history and early ultrasound dating, and by Dubowit/ score |21 | if
the former information was missing or doubtful. The infants had to have a birthweight of
1800 g or less, because larger infants were likely to be discharged before the intended
duration of the study (4 weeks). Immediately after delivery (day 0), approximately 3 ml
umbilical venous blood was collected. Thereafter, the EFA status of the infants was monito-
red until they were discharged or transferred to a non-participating hospital. For this pur-
pose, a weekly sample of approximately 0.5 ml of capillary or venous blood was collected
in conjunction with a diagnostic puncture. These diagnostic punctures were part of the
routine clinical monitoring of all prctcrm infants at the neonatology ward and were done
mainly to evaluate the electrolyte status, blood glucose, triglyccridc and ammo acid levels
and the red and white blood cell count. Because frequent oral feeds arc given (every 2-3
hours) to preterm infants, blood samples could not be collected after fasting, but were taken
between 1 and 1.5 hour after a feed. The study was approved by the Medical lithics Com-
mittee of the participating hospitals and written informed consent was obtained from one or
both parents.
The children were admitted to the neonatal care unit, where they were cared for in an
incubator until being transferred to a crib at a weight of 2000 g. If the infants were in
satisfactory clinical condition they were discharged at a weight of 2400 g. Clinical care was
provided by the attending neonatologists and resident physicians, according to current
standards; this included respiratory support through continuous positive airway pressure or
intubation and mechanical ventilation, if necessary. Careful records of these and other
clinical details were made. Weight was recorded daily.
Some infants received intravenous RBC and plasma infusions at different times during
the treatment. Since these preparations contain significant amounts of 22:6/i-3 and 20:4«-6,
the time of infusion and the amount administered were recorded carefully. Furthermore,
neonatal blood samples were always collected 24 hours or more after an infusion.
The most important clinical and nutritional characteristics of the study groups are shown
in table 6.1. No significant differences were found for any of these features.
Until the infants were on full enteral feeding they received parenteral nutrition, contain-
ing the appropriate amounts of carbohydrates (210 kJ/kg/d), amino acids (50 kJ/kg/d),
vitamins, and minerals. In addition, up to 95 kJ/kg/d of intravenous lipids (Intralipid* .10%
and 20%, Vitalipid*) were given as a source of fat. Since these preparations proved to
contain up to 0.2 and 0.3 %(wt/wt) of 22:6«-3 and 20:4n-6 respectively (M.M.H.P. Fore-
man-v Drongelen, unpublished results), the amounts given were registered.
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Table 6.1. Clinical and nutritional characteristics of human milk (HM) and artificial formula (AF) study
groups".
HM group (n=12) AF group (n=27)
maternal age (y) 29.0 (28.0-32.0) 28.0 (24.5-30.5)
primipara* 7(58.3%) 14(51.9%)
gestational age (wceks.days) 31.2 (29.5-34.1) 30.5 (29.0-34.3)
birth weight (g) 1415(1065-1615) 1400(1120-1720)
weight gain day 0-28 (g/kg/day) 10.1 (7.4-12.9) 12.1 (9.3-14.7)
SOA' (P<2.3)* 3(25.0%) 5(18.5%)
IV' lipids (kJ/kg/day) 23.8 (15.4-52.2) 16.2 (6.7-31.6)
IV plasma (ml)'' 10.4(12.4) 21.8(32.3)
IV RBCs' (ml)'' 14.5 (20.7) 27.8 (35.0)
enteral intake (kJ/kg/day) 298 (222416) 261 (240-368)
age at first enleral intake (days) 4.0 (3.0-6.5) 6.0 (3.0-8.0)
age at full tnteral intake (days) 14.5 (11.0-19.5) 13.0 (9.0-22.0)
vent, support (days)'' 3.0 (5.2) 5.0 (10.4)
vent, support > 24 h*' 6 (50 0%) 11 (44.8%)
BPl)'" 0 (0.0%) 2 (7.4%)
sepsis'' 4(33.3%) 4(14.8%)
0(0.0%) 4(14.8%)
"Median (interquartile range) except for ''number of subjects and ''mean ± SD.
*SOA= small for gcstational age (birth weight below the 2.3rd percentile of the Amsterdam growth charts
[44]). IV= intravenous, RBCs= red blood cells,
BPD= bronchopulmonnry dysplasia, IVH= intraventricular haemorrhage.
'ventilatory support included mechanical ventilation and continuous positive airway pressure.
When the infants were able to tolerate enteral feedings, they were given (initially
expressed) preterm human milk obtained from their own mothers, in case they decided to
breastfeed. These infants (n=12) formed the human milk group. Incidentally, 5 g preterm
formula powder (preterm formula A. table 6.2.) per 100 ml of preterm human milk was
added to increase an infant's energy intake, in case there was no satisfactory growth on
breast milk alone. When the mother was unable to express enough milk, an appropriate
formula was supplied to cover the nutritional demand of her child. If the intake of artificial
formula exceeded 25 percent (vol/vol) of the total enteral intake, the infant was excluded
from the human milk group. If the mother did not wish to provide breast milk, the infant
was introduced to enteral feeding with a special preterm infant formula (A or B, table 6.2.)
used on the ward. At a weight of 2100-2200 g the preterm infant formula was replaced by
a regular infant formula (C or D, table 6.2.). All formulas given were commercially avail-
able. These infants (n=27), who did not receive any human milk, formed the artificial
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Table 6.2. Fatty acid composition
and term artificial formulas (AFs).
Fatty acid*'
*(wt/wt)
preterm
(own
HM
1)
LCP status of
analyses) of total lipids
preterm <
A
human milk and formula-fed
of preterm human milk* (HM) and
AF
B
term AF
C D
infants
pretefm
ZSAFA
IMUFA
I n-9 PUFA
18:2/1-6
20:4*1-6
I n-6 LCP
18:3*1-3
22:6fi-3
Z #1-3 LCP
44.3(415-49.9)
36.9(32.4-39.1)
ND
12.2(10.8-15.2)
0.58 (0.48-0.70)
1.86(1.57-2.12)
1.01 (0.90-1.25)
0.36 (0.30-0.44)
0.79(0.71-0.86)
53.6
29.2
ND
15.6
ND
ND
1.47
ND
ND
54.4
26.5
0.10
18.1
ND
0.13
0.62
ND
0.16
54.7
33.5
ND
10.8
ND
ND
0.77
ND
ND
45.6
37.7
ND
16.3
ND
ND
0.34
ND
ND
•Median (interquartile range) of average content during the study period (day 0 to day 28).
'SAFA= saturated fatty acids. Ml<FA= monounsaiurated fatty acids, PUHA= polyun&aturated fatty acids, n-6
LCP= sum of n-6 long-chain polycnes (20:2/i-6. 2O:3n-6. 20:4n-6. 22:2/i-6. 22:4n-6. 22:5n-6 and 24:2n-6), n-
3 LCP= sum of n-3 long-chain polyenes (20:4n-3. 2O:3/i-3. 20:5n-3. 22:3n-3, 22:5n-3 and 22:6n-3).
'ND= none detected (less than 0.1 % (wt/wt) of total fatty acid methyl esters).
formula group. The discrepancy between the number of subjects in the human milk group
(n=12) and the formula group (n=27) reflects the general distribution of the type of oral
nutrition given within the preterm population at the Neonatology Departments of the partici-
pating hospitals.
Enteral feeds were administered through a nasal tube, until the infant was able to drink
from a bottle or his or her mother's breast. The majority of the infants received their first
enteral intake during the first week of life and they were on full enteral feeding of 420-500
kJ/kg/d at, on average, the 14th day of life (table 6.1.).
To obtain accurate information on the dietary EFA intake of the participating infants, a I
ml sample for fatty acid analysis was taken from every bottle of expressed milk after
homogenization. Furthermore, the volumes consumed from every bottle of expressed breast
milk and the volumes and types of formula given were recorded carefully by the nursing
personnel.
6.3.2 Laboratory analysis
These were collected in tubes containing EDTA to prevent coagulation. The plasma.was
separated from the RBCs by centrifugation. RBCs were washed twice with EDTA-containing
saline (Na^EDTA, 2 HjO 28.64 g, NaCl 7.00 g, HjO 1000.0 ml). The tubes containing
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plasma or RBC suspension were closed under a stream of nitrogen to prevent oxidation and
stored at -80 °C until analysis.
Mi/A: jamp/f.v
Individual human milk samples were collected in fat-free glass tubes, containing 2 pi of
the antioxidant butylhydroxytoluene (500 mg/l methanol), after which they were stored at
-80 °C.
Based on the volumes consumed from the corresponding bottles of expressed milk, the
appropriate amounts of the individual samples were pooled into one representative weekly
sample, which was used for fatty acid analysis. This pooling was carried out according to
the guidelines of the International Dairy Federation [22] for the preparation of a test
sample. The weekly samples were stored at -80 °C until fatty acid analysis.
f'a/fy ac»V/
To ensure uniformity of analytical conditions, all blood samples of a given study subject
were analyzed simultaneously as soon as the subject had completed the study. The same
applied (o the weekly human milk samples.
At the start of the analysis, 31.0 ug 1,2-dinonadecanoyl phosphatidylcholine (PC[19:0]2)
was added to every sample as internal standard. Total lipid extracts of plasma and RBC were
prepared using a modified Folch extraction; 50-100 pi samples of plasma or RBC suspension
were added to 3 ml mcthanol-chloroform (1:2, vol:vol)[23,24]. The PL fraction was isolated
by solid phase extraction on an aminopropyl-silica column [25]. The PLs were saponified
and the fatty acids converted to the corresponding methyl esters by reaction with 14%
boron tnfluoride in methanol at 100 °C for one hour [26].
For trans-cstcrification of fatty acids in human milk and artificial formula, 100 pi
samples of milk were added to 2 ml of mcthanol-hydrochloric acid (5:1, vol:vol) and heated
at 90 °C for 4 hours. After cooling, the samples were extracted with 1 ml iso-octane [27].
The samples were analyzed using capillary gas-liquid chromatography with flame ionisation
detection, on a 50 m x 0.25 mm CP-Sil 5 CB, film thickness 0.12 jim (Chrompack, Middel-
burg, The Netherlands) column, using N, as the carrier gas. The analyses were performed
using temperature programming which had been optimized with a reference mixture con-
taining most of the fatty acid methyl esters (FAMES) of interest. The standard mixture was
also used to identify the FAMES corresponding to the various peaks. Fatty acid amounts
present in the PL fraction (for plasma and RBC samples) or in the total lipid fraction (for
milk samples) were quantified based on the amount of 19:0 internal standard FAME
recovered.
The day-to-day rcproducibility of the analytical method, as indicated by the coefficient
of variation of the amounts (mmol/1) measured for the main fatty acids of interest, varied
between 2.1% and 3.7% in 17 plasma PL samples and between 3.7% and 6.3% in 9 RBC PL
samples [28].
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Data analysis
Study-size calculations were based on the results of Kolet/.ko and co-workers |14) using
the exact calculations provided by Systat's Design program |29). With two groups of 10
infants an inter-group difference of 0.5% for 22:6n-3 or 1.0% for 20:4n-6 in plasma PLs
would be detected with 90% power.
For practical reasons, not all blood samples were taken on exactly the days intended.
Since we wanted to analyze values at one-week intervals, the fatty acid values were esti-
mated at days 7, 14, 21 and 28 by linear interpolation between the days where blood had
been sampled. The time intervals between the collection of individual nconatul blood
samples varied from 5 to 15 days, and, on average, less than one of the ideally-required
five punctures was missing. Unless mentioned otherwise, all values arc presented as
medians and the upper and lower limits of the interquartile range.
Since group membership (human milk or artificial formula) was not obtained by
randomization but by maternal choice, analyses were done essentially on postnatal chunges,
to correct for possible inter-group differences for values at day 0. The interpretation of the
results was similar when adjustment for values at day 0 was made using regression analysis.
The two LCPs of primary interest, 22:6n-3 and 20:4/i-6 were analyzed most extensively.
Since after the interpolation procedure there were remaining missing observations, a repeat-
ed measures analysis of variance model was used which uses all available data |3()J. This
technique is available in the BMDP package [31]. It should be noted that in conventional
repeated measures analysis all patients with incomplete data have to be omitted from the
analysis. When pooled over the sampling days the normality condition was reasonably satis-
fied, except for the absolute fatty acid amounts in plasma, where a log transformation was
needed. Outcomes of this analysis are obtained as Wald tests for each considered factor:
time, group and time by group. The first term (time) tests whether there are differences
between days for both groups together, the second term (group) tests the mean difference
between both groups. These two tests are not of primary interest. The last term (time by
group) tests whether the time effect is different for the two groups. This is an overall test,
however, not specifically testing inter-group differences for postnatal changes with respect
to day 0. Therefore, we present the results of the Wald tests based on the same repeated
measures model, which test whether sampling day changes (postnatal changes or differences
with respect to day 0) are different for both groups. For these analyses, P-values smaller
than 0.05 were considered to reflect a significant difference.
For the other fatty acids less sophisticated, more descriptive analyses arc presented.
Two-tailed Mann-Whitney tests were used to compare values at day 0 and changes between
day 28 and day 0 for the two study groups. Additionally, the Wilcoxon signed ranks test
was used to evaluate differences between day 28 and day 0 within groups. For these sup-
portive analyses, P<0.01 was considered significant.
The volumes of plasma, RBCs and intravenous lipids administered in both groups and
continuous clinical variables were compared using the two-tailed Mann-Whitney test. Dis-
crete clinical variables were compared using the chi-square test.
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Figure 6.1. Docosahexaenoic (22:6n-3) and arachidonic (20:4n-6) acids values in plasma phospholipids
(IMS). Median and interquartile range expressed as mg/1 (/^ /f) and as % (wi/wt) of total fatty acid methyl-
esters fn'jf/i/J. Number of infants in human milk (HM) and artificial formula (AF) (n^/n^) at day 0: 12/22;
day 7: 12/26; day 14: 12/26. day 21: 11/25; day 28: 9/20.
Statistical differences between MM group and AH group (repeated measures analysis):
*P<0.05, "P<0.02, "*P<O.0l. P<0.0005.
6.4 Results
6.4.1 Human milk and formulas
The results of the fatty acid analyses of the various formulas and the preterm human
milk (average content during the study period) are shown in table 6.2. Note that no 22:6n-3,
20:4n-6 and only trace amounts of other LCPs (preterm formula B) were present in the
artificial formulas. Relative levels of 22:6n-3, 20:4n-6 and the sums of n-3 and n-6 LCPs
measured in human milk were comparable to those reported in other studies relating to the
fatty acid composition of preterm breast milk [7,12].
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6.4.2 Plasma phospholipids
Umbilical blood sample were not available from eight infants in the artificial formula
group and one child in the human milk group. For three children in the artificial formula
and the one child in the human milk group, a neonatal sample, taken within 24 h after birth
and before any administration of plasma or red blood cells, served as a replacement. Des-
pite restrictions placed on birthweight (<I8OO g), three infants in the human milk group and
eight infants in the artificial formula group were discharged from the neonatal care unit
before the 4th week of study. One child in (he human milk group and two in the artificial
formula group were discharged home in good clinical condition after three weeks. The other
infants were transferred to the neonatal care unit of a non-participating hospital.
The patterns of postnatal changes in absolute values for both 22:6/1-3 and 204/ift (mg/1
plasma) differed markedly from those for relative fatty acid values (% (wl/wt) of total fatty
acids; figure 6.1.). The absolute values for 22:6n-3 and 20:4n-6 increased during the first
week of life in both study groups. This increase was followed by a gradual decrease during
the next three weeks of life. For both 22:6/i-3 and 20:4n-6, the absolute postnatal values for
the human milk group were significantly different from those for the formula led infants
(repeated-measures analysis; at day 21: P<0.01 for 22:6/?-3. at day 28: P<O.(XX)S for 22:6n-
3 and P<0.05 for 20:4n-6).
Relative levels declined steadily and significantly from (he first to the 28th day of life.
For 22:6n-3, this decline was 60.2 percent in the artificial formula group, which was more
than double that in the human milk group (23.5%), reflecting the significant difference
between changes in the relative postnatal 22:6n-3 values of the two study groups (repeated-
measures analysis; at day 28: P<0.02). The relative level of 20:4n-6 showed a decline of
53.7% in the artificial formula group and of 42.9% in the human milk group. The relative
postnatal 20:4n-6 values were not significantly different in both study groups.
Differences between the absolute and relative changes from birth to the 28th day of life
were also present for the n-3 LCPs (see table 6.3. and 6.4. for absolute and relative amounts
respectively). The absolute amount for the sum of the n-3 LCPs (Z n-3 LCP) increased from
day 0 to day 28 in the human milk group, whereas it declined in the artificial formula
group. The change in Z n-3 LCP (day 28 minus day 0) was significantly different for both
groups (P<0.01). The relative level of Z n-3 LCP declined significantly in both study
populations. The decrease in the artificial formula group was significantly larger than that in
the human milk group (P<0.001).
Differences between the postnatal changes of absolute and relative values of Z n-6 LCP
were similar to those for Z n-3 LCP. Changes in Z n-6 LCP in the artificial formula group
were, however, not significantly different from those in the infants fed on human milk.
6.4.3 Red blood cell phospholipids
The volumes of two RBC samples in the artificial formula group, one at day 14 and one
at day 28, were too small to guarantee an adequate fatty acid analysis; these samples were
discarded.
The absolute and relative postnatal values for 22:6n-3 and 20:4n-6 showed more or less
similar patterns (figure 6.2.). Although the postnatal decrease in the formula-fed group was
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Table 6.3. Fatty
Fatty acid*'
rag/1
UHal FA
ISAFA
IMUFA
I «-9 PUFA
18:2/1-6
20:4/i-6
£ n-6 LCP
!8:3n-3
22:6/i-3
£ n-3 LCP
acid composition
HM (n=12)
567 (479-798)
260 (222-368)
86(58-136)
3.6 (2.3-7.6)
45 (38-60)
103 (80-151)
133(115-195)
ND
25.0(19.5-38.6)
28.6(22.1-43.6)
of plasma phospholipids
Day 0
AF(n=22)
592 (474-760)
274 (223-357)
90(71-109)
4.0 (2.8-7.5)
51 (36-68)
94(83-121)
135(112-166)
ND
25.1 (20.0-29.4)
28.3(21.8-34.8)
(absolute values)'.
Day
HM (n=9)
1199(1065-1523)
534 (472-674)
157(130-246)
3.2 (2.6-5.7)
262 (222-324)»
114(99-126)
162 (145-191)
ND (ND-1.46)
39.7 (26.6-44.7)
55.6 (37.5-58.4)
28
AF (n=20)
1166(973-1231)'
519(436-557)*
182(153-197)*
7.0 (4.9-9.5y
256 (229-276)*
82(67-104)"J
135(115-156)
ND(ND-1.48y
17.4(14.1-25.8)*
22.1 (19.5-33.2/
"'As in table 6.2.
Statistical difference between human milk group and artificial formula group (two-tailed Mann-Whitney U
test of changes in values (day 28-day 0), except for 22:6n-3 and 20:4/t-6: repeated-measures analysis):
**P<0.05.1P<0.01. *P<0.0005.
Statistical difference between day 28 and day 0 (Wilcoxon rank sum W test):
>P<0.0l,*P<0.00l
approximately twice the decrease in the human milk group, the postnatal patterns of
changes in both absolute and relative values for 22:6/i-3 and 20:4n-6 in the human milk
group were not significantly different from those in the artificial formula group.
No significant differences were found between the absolute fatty acid amounts in the
RBC Pl.s of both study groups (table 6.5.).Relative values for 22:6n-3 were significantly
lower in the artificial formula group (figure 6.2., table 6.6.: P<0.05) at birth.
6.5 Discussion
The present study shows that postnatal changes in the LCP status in plasma PLs of
prctcrm infants, as influenced by the fatty acid composition of their nutritional intake, is
different depending on whether it is expressed in terms of absolute fatty acid amounts
(mg/l) or as relative levels (% (wt/wt) of total fatty acids). The absolute values showed an
initial increase during the first week of life, followed by a general decline during the follo-
wing weeks (figure 6.1). Due to an even larger increase of the total amount of PL-associ-
ated fatty acids (figure 6.3. and table 6.3., values at day 0 were less than half those at day
7 and day 28), the initial increase observed for absolute quantities of 22:6/1-3 and 20:4n-6
did not become apparent when the fatty acid values were expressed as relative values. In
RBC PLs, the total amount of fatty acids present did not change markedly (figure 6.3. and
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Tmblc 6.4. Fatty
Fatty acid*'
%(wt/wt)
ISAFA
I MUFA
I «-9 PlIFA
18:2*-6
20:4n-6
ï n-6 LCP
l8:3n-3
22:6n-3
I n-3 irp
CADI
acid composition
HM (n=12)
46.4(45.5-47.1)
13.7 (11.8-16.8)
0.59(0.42-1.04)
7.78 (7.38-9 30)
16.9 (15.4-18 9)
23.6(21.9-25.7)
ND
4.50(3.41-5.31)
5.07(3.83-6.18)
1.16(0.77-1.35)
of plasma phospholipids
DayO
AF(n=22)
47.4 (45.9-48.0)
15 0(13 6-16.5)
0.75(0.55-107)
8.27 (7.32-9 74)
16.5(15.1-18.1)
22.4(21.6-23.8)
ND
3.89 (3.45-4 60)
4 49 (3 94-5.53)
1.07(0.89-1.20)
(relative values)*.
Day
HM (n«9)
43.8 (43.O-45.5V
13.3(12.1-16.3)
0.25 (0.23-0.45)
21 2 (l9.5-22.5y
9.66 (7.99-10.23V
13.7(12.6- I4.8y
ND (ND-0 12)
3.44 (2.23-3.82/
4.56 (3 08-4 75V
0.82(0.69-1.02)
28
AF (n>20)
44.8 (43.7-4S.8V
16.0 (14.2-17.7)
0.61 (0.49-0.81)
22.2(21.6-24.4)*
7.62 (5.76-8.88)*»
12.1 (10.4-13.6)*
Nt)(ND-O.I3)
1.55(1.24-2.22)'»
2.14 (1.59-2.81)»*
1.26 (0.94-1.69)
"•As in table 6.2.. in addition: CADI= cervonic acid (22:6n-3) deficiency index: 22:5ntV22:4n-6
Statistical difference between human milk group and artificial formula group (two lailcd Mann Whitney U
test for changes in values (day 28-day 0), except for 22:6/i-3: repeated-measures analysis):
^O.OS, T><0.02. *P<0.001.
Statistical difference between day 28 and day 0 (Wilcoxon rank sum W test):
'P<0.01,*P<0.001.
table 6.5.). As a result, the postnatal changes in absolute and relative values for 22:6n-3 and
20:4n-6 were more or less similar (figure 6.2.).
A possible explanation for the observed increase of the total plasma PL-associated fatty
acids may be the change in nutrient supply, which accompanies the transition from fetal life
to life outside the uterus. /n «tera, glucose is the major nutrient, while after birth, fal
becomes the main source of energy [32]. An increase in the absolute amounts of n-3 and /»-
6 LCPs of plasma PLs within the first days of life was also observed in a group of 10
preterm newborn infants (gcstational age < 34 wks), who received only fat-free parcntcral
nutrition [19]. From this finding the author concluded that, in the absence of an exogenous
lipid source, tissue stores of LCPs are released in response to birth. In our study, infants that
were unable to tolerate enteral feedings received Intralipid* as an intravenous source of fat
as early as the second day of life. This may also explain part of the initial increase in
absolute LCPS.
Recently, further studies relating to absolute fatty acid concentrations in plasma PLs,
have been published [15,17,33]. The absolute 22:6n-3 and 20:4/i-6 levels of our study
populations were similar to those reported by Clandinin and co-workers [15] in a study of
34 preterm infants, receiving either their own mother's expressed milk, a conventional
formula or a formula containing n-3 and n-6 LCPs. In this study, the increase in plasma PL-
associated fatty acids, as observed in our study, is not found, possibly because the first
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o Human milk
• Formula
0 7 14 21 28
postnatal age (days)
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postnatal age (days)
Figure 6.2. Docosahcxacnoic (22:6n-3) and arachidonic (20:4/i-6) acid values in red blood cell (RBC)
phosphohpids (I'l.s). Median and interquartile range expressed as mg/1 (/<ƒ/) and as % (wt/wt) of total fatty
acid methyl esters (ri#/?i). Number of infants in human milk (MM) and artificial formula (AF) (n„„/n^) at
day O: 12/22; day 7: 12/26; day 14: 12/25: day 21: 11/25; day 28: 9/19.
Statistical differences between M M group and AF group (Mann-Whitney U test):
*P<0.05.
blood sample was taken in the first week of life, most probably after this increase had
occurred.
Carlson and co-workers [17,33] published absolute fatty acid concentrations in plasma
phosphatidylethanolaminc (PE) and/or phosphatidylcholinc (PC), which together accounted
for >95.0% of total plasma phosphohpids [17]. The concentrations (mg/1) of 22:6n-3 and
20:4n-6 in plasma PLs of 79 pretcrm infants receiving cither a conventional formula or a
formula containing n-3 LCPs. were considerably lower (up to twofold for 22:6n-3 in PC and
PE added together) than those reported in our study. This discrepancy may result at least
partly from methodological differences. We added the internal standard at the start of the
fatty acid analysis, that is before the extraction of total lipids. In this way fatty acid losses
during all steps of the analysis were accounted for. Carlson and colleagues, however, added
the internul standard (17:0) before the transestenfication step. Consequently, fatty acid
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Table &5. Fatty
Fatty acid*'
mg/l
tout FA
ZSAFA
I Ml'FA
I n-9 PUFA
18:2n-6
20:4n-6
In-6LCP
!8:3n-3
22:6n-3
In -3 LCP
acid composition of red blood cell ptospholipids (absolute values)*.
HM(n=l2)
1061 (8711232)
514 (435-580)
201 (150-237)
10.4 (8.4-15.9)
49.3 (36.6-54.6)
165(111-191)
239(180-272)
ND
40.2 (30.7-55.0)
45.5 (35.6-62.5)
DayO
AF (n=22)
938(727-1114)
496 (420-556)
187(169-226)
11.9(7.4-15.1)
43.5 (26.8-53.4)
128 (44-166)
194 (73-238)
ND
30.9 (5.4-44.8)
36.8 (6.4-54.2)
Day
HM (n=9)
1084(909-1303)
562 (448-617)
212(180-248)
5.9 (5 0-7.2)
131 (81-149y
116(56-150)
174(82-223)
1.00 (ND-I 28)
30.8(11.4-45 6)
43.7(14.6-61.4)
28
AF (n«19)
876(692-1132)
429 (388 530)
179(162-217)
6.5(41 lo.iy
96(7713iy
60 (24-112V
IOO(44l73y
193 (NO 2.51)
9.7 (1.5-21.9)*
14.1 (2.4-36.7)
" A s in table 6.2.
Sutisdcal difference between day 28 and day 0 (Wilcoxon rank sum W test):
'P<0.01.*P<0.001.
losses during lipid extraction and separation of the PLs, were not reflected in the amount of
17:0 FAME detected by gaschromatography. This could result in artcfactually lower absolute
values for the fatty acids present in the samples. Indeed, the total fatty acid amount present
in plasma PC as reported by Carlson [33J is approximately half the total fatty acid amount
present in plasma total PLs in our study. Yet, PC represents approximately 70% of total
plasma PLs [34].
Relative levels of w-3 and n-6 fatty acids in plasma PLs of cord blood, as reported by
Foote and co-workers [19] were similar to those measured in our present study. In contrast,
the absolute (mg/l) levels of n-3 and w-6 fatty acids reported were more than ten times
lower than those in our study. Detailed information on the timing of the internal standard
addition, however, was not given. An overestimation of actual fatty acid amounts on our
side seems highly unlikely. Using solid phase extraction on an aminopropyl-silica column,
we are able to separate PLs to near homogeneity (<1.0% contamination of PLs with
triglycerides and cholesteryl esters, which is in agreement with the value of 1.15% contami-
nation reported by Kaluzny and co-workers [25]). Besides, heptadecanoic acid (17:l«-7) is
added to every sample as a standard procedure to check carry over of free fatty acids
during the PL isolation procedure.
To our knowledge, no studies relating to absolute fatty acid amounts in RBC PLs of pre-
term infants have been published so far.
In our study we observed significant differences between both the absolute and relative
postnatal LCP values in the plasma PLs of preterm infants fed their own mother's breast
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Table 6.6. Fatty
Fatty acid*'
% (wt/wt)
I SAFA
Z MUPA
r n-9 PTJFA
18:2/1-6
20:4n-6
I /t-6 LCP
18:3rt-3
22:6/i-3
I n-3 LCP
CADI
acid composition of
HM (n=12)
47.8 (47.2-50.7)
19.4(16.3-20.5)
1.02(0.78-1.33)
4.60 (3.93-5.39)
15.1 (12.3-15.9)
21.4(19.9-23.2)
ND
3.94 (2.88-4.81)
4.47 (3.34-5.60)
0.26 (0.24-0.29)
red blood cell phospholipids (relative values)".
Day 0
AF (11=22)
50.3(48.1-60.1)
20.9(17.7-23.8)
1.20(0.95-1.49)
4.11 (3.56-4.82)
13.2 (6.0-14.9)
18.3(9.4-21.6)
ND
2.91 (0.69-3.69)''
3.28 (0.88-4.42)
0.25 (0.22-0.29)
Day
HM (n=9)
46.2 (45.4-52.1)
19.4 (17.5-22.0)
0.55 (0.5 l-0.63y
111 (9.5-12.0)'
11.0(7.0-11.9)'
16.5 (10.6-17.4)
ND (ND-0.10)
2.56(1.53-3.46)'
3.89 (2.23-4.56)
0.19(0.14-0.21)
28
AF(n=19)
50.7 (46.8-58.0)
21.0(19.8-24.5)
0.72 (0.62-0.88y
10.8(9.6-11.9)*
6.1 (3.0-9.9)*
10.8 (5.3-14.9V
ND (ND-0.12)
1.16 (0.22-2.46)*
1.55(0.34-2.96)
0.20(0.14-0.26)
" "As in table 6.4.
Statistical difference between human milk group and artiflcial formula group (two-tailed Mann-Whitney U
test): ''P<005.
Statistical difference between day 28 and day 0 (Wilcoxon rank sum W test):
'P«).0.VP<0.01.*P<0.00l
milk and those of formula-fed prctcrms, with lower LCP levels in the latter group (figure
6.1., tables 6.3. and 6.4.). Similar differences were not observed for RBC PLs (figure 6.2.,
tables 6.5. and 6.6). This confirms the findings of recent studies [15,17], which, over a
period of 4 weeks, could not or hardly demonstrate a significant dietary influence on
percentage values of 22:6H-3 and 20:4n-6 in RBC PLS, but did so in plasma PLs and choles-
tcryl esters. RBC PLS are known to have a slower turnover rate than plasma PLs, which could
result in less-apparent nutritional effects over a relatively short period of time.
The nutritional effect was greater for 22:6w-3 than for 20:4n-6. Effects on 22:6n-3 status
were supported by the changes in the sum of the n-3 LCPs. Moreover, the inter-group
difference in change of the Cervonic Acid Deficiency Index (CADI) between birth and the
28th day of life tended to be significant (P<0.05, significance level for supportive analyses:
P<0.01). Because a reduction in the amount of 22:6n-3 is usually compensated for by an
increased synthesis of 22:5n-6 from 22:4n-6, the ratio between these latter two fatty acids,
CADI, is considered a functional parameter of the 22:6n-3 status (35,36]. Incidental RBC
infusions may have influenced the dietary effect on the LCP status. In our study, the average
amounts of plasma and RBCs received by the artificial formula group were approximately
twice the amounts received by the human milk group (table 6.1.). Although this difference
was not statistically significant, it may, nonetheless, have reduced the difference between
the 20:4«-6 (and also the 22:6/i-3) status of both study populations. Recently, very-low-
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ton
400
0 7 14 21 28
postnatal age (days)
400
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Figure 6 J . Total phospholipid (Pt> associated fatty acids in plasma (/</f) and red blood cells (RBCS, rr>M)
Median and interquartile range expressed as mg/1.
Number of infants in human milk (HM) and artificial formula (Al) (n,,„/n„), in plasma at day 0: 12/22. day
7: 12)26; day 14: 12/26; day 21: 11/25; day 28: 9/20. in RBCs at day O: 12/22; day 7: 12/26. day 14: 12/25;
day 21: 11/25; day 28: 9/19.
birth-weight infants (<1500 g), receiving more than six blood transfusions during their
neonatal course, were shown to maintain higher relative plasma levels of 2():4«-6 [37|,
which supports the assumption that intravenous RBC and plasma infusions may be an
important non-dietary source of LCPs. Moreover, substantial amounts of 18:2w-6, which can
be converted to 20:4n-6, were present in the formulas. Nevertheless, the absolute 2():4n-6
status also showed a significantly larger decrease in the formula fed infants than in (he
infants fed human milk.
Al l these results, and those of others [14,15-17], indicate that the conventional artificial
formulas are unable to maintain the postnatal LCP status of prctcrm infants at levels that can
be obtained when feeding with prctcrm human milk. Therefore, to establish comparable
22:6«-3 and 20:4«-6 blood levels in formula and human milk-fed pretcrm infants, both /i-3
and n-6 LCPs should be added to preterm formula [38,39]. Whether human milk is able to
maintain an optimal LCP status in preterm infants remains to be decided. In the present
study, in both plasma and RBC PLs, relative 22:6n-3 and 20:4n-6 levels decreased signifi-
cantly after birth, also in the infants raised on human milk. This resulted in values well
below those measured in cord blood of infants born after normal full-term pregnancy [40].
Recently, a number of publications have reported on the influence of the n-3 and n-6
LCP dietary intake of preterm infants on several functional and anthropomctric parameters.
The amount of «-3 LCPs present in the entcral diet was demonstrated to have a significant
effect on the function of the retina of very-low-birth-weight newborn infants [41]. Infants
having no 22:6n-3 in their formula had higher threshold and lower amplitude responses on
rod electroretinogram than those receiving «-3 LCP-supplemcnted formula or human milk.
However, the intake of n-3 LCP containing formula was found to be associated with poorer
growth in preterm infants [42]. Furthermore, the 20:4n-6 status in plasma PC was reported
to be positively correlated with postnatal growth in preterm infants through 12 months cor-
rected postnatal age [43]. Since n-3 LCP supplementation decreases the concentration of
71
Chapter 6
plasma 20:4/j-6, these findings again support the necessity to add both n-3 and n-6 LCPs in
balanced ratios to prcterm formula.
In conclusion, the results of the present study emphasize the additional value of the
assessment of absolute fatty acid concentrations, when studying the dietary effects on the
EFA status of preterm infants. Analytic procedures, however, need to be standardized to
enable a more effective comparison of results from different research groups. Furthermore,
the results obtained warrant further studies of the effects on the postnatal LCP status of
adding both «-3 and n-6 LCPs to preterm artificial formulas in amounts comparable with
those present in human milk.
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7.1 Abstract
To determine the influence of the prenatal long-chain polyunsaturated fatty acid (I.CP)
supply on prenatal growth and on postnatal LCP levels, we studied a group of 52 preterm
infants, in which we assessed the relations between the LCP status at birth (reflecting the
prenatal LCP supply), gestational age (GA) and prenatal growth, and the relation between the
LCP status at birth and at term postconceptional age (37-42 weeks GA). After correction for
GA at birth, significant relations (P<0.05) were observed between anthropometric measure-
ments at birth (weight, head circumference (HC) and length) and LCP levels in the umbilical
artery wall, the LCP content of which reflects the long-term fetal LCP status. Independent of
the neonatal diet (human milk or formula), LCP levels in red blood cell (RBC) phospholipids
(PL) 'at term' were positively related to levels in the umbilical artery wall (docosahcxacnoic
acid (22:6n-3): P<0.0003, arachidonic acid (20:4n-6): P=0.02). Postnatal diet significantly
influenced LCP levels in plasma PLs at term (22:6n-3: P<0.004, 20:4n-6: P=0.02); formula
fed infants had lower values. We conclude that the LCP status at birth of preterm infants is
related to prenatal growth. Moreover, next to the postnatal enteral diet, the LCP status at
birth significantly affects LCP levels at term postconceptional age. This finding may warrant
further studies of the effects of essential fatty acid (EFA)-enrichcd maternal dieLs during
pregnancy on the neonatal LCP status at birth.
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Figure 7.1.: Main pathways of n-6 and n-3 fatty acid conversion (EFAs=cssential fatty acids, PG=
ptxistaglandins (and other eicosanoids), LCPs=longchain polyunsaturated fatly acids).
7.2 Introduction
The LCPs (chain length of 20 carbon atoms or more and at least one double bond more
than the parent EFAs. linoleic acid (18:2n-6) or a-linolenic acid (18:3n-3), see figure 7.1.).
arc of major importance in fetal and infant development. The LCPs docosahexaenoic acid
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(22:6/i-3) and arachidonic acid (20:4n-6) are the predominant polyunsaturated fatty acids in
the structural lipids of the human brain [1-3) and retina (4). In addition, considerable
amounts of 20:4/i-6 are found in membrane PLs throughout the body. Furthermore. 20:4n-6.
dihomo-gamma-linolenic acid (2O:3«-6) and eicosapentacnoic acid (2O:5H-3) are precursors
of prostaglandins and other eicosanoids (figure 7.1.), which have important biorcgulatory
functions.
Dietary studies have demonstrated that prctcrm infants receiving a conventional artificial
formula as their main source of dietary lipids. have a poorer LCP status than infants fed
their own mother's milk (5-9; Chapter 6). This discrepancy has been attributed to the
presence of small but significant amounts of 22:6«-3, 2O:4w-6 and other t.cts in human
milk, and their absence in the majority of the commercially available artificial formulas [ 10-
12]. These formulas usually contain substantial amounts of the parent EFAs IS:2/i-6 and
18:3/i-3, which can be converted to w-6 and n-3 LCPs in the human body (figure 7.1.).
However, the desaturase capacity of premature newborn infants is probably too limited to
guarantee an adequate supply of LCPs solely through metabolic conversion of these two
fatty acids (13,14]. Adding LCPs to artificial formulas proved to reduce differences between
the LCP status of formula and breast-fed prclerm infants [7,8,15-17|. The LCP status has also
been related to anthropomctric measurements, both at birth |I8,19| and thereafter [20].
Leaf and colleagues [21[ recently observed a positive correlation between plasma l.CP
levels at birth (reflecting the prenatal LCP supply) and those at term postconccptional age
(40 wks GA). This relation was independent of the type of postnatal diet, indicating that the
intra-uterine experience of the fetus may set the pattern for postnatal l.CP levels [22],
However, the study was confined to plasma PLs and lacked information on the RBC fraction
of the blood, the LCP content of which may be a more accurate reflection of LCP levels in
the brain [23].
The aim of our study was to explore the nature of the relation between the LCP status at
birth and that in the 'term period' (37-42 wks GA) in a group of preterm infants. To this
end, the LCP levels in PLs extracted from plasma, RBCs, as well as from the umbilical artery
walls were studied; the latter is considered to reflect the long-term fetal LCP status [24,25].
In addition, the potential relations among the LCP status at birth, GA at birth, and weight, HC
and length at birth were studied.
7.3 Patients and methods
7.3.1 Infants
The population studied comprised 52 preterm infants (GA 26 - 36 wks, birth weight 650-
1860 g). The infants had no metabolic disease or congenital malformations. A 3 ml sample
of venous cord blood and approximately 15 cm of umbilical cord were collected immedi-
ately after delivery to provide information on the LCP status at birth. This material was
collected as part of a dietary study in preterm infants [9; Chapter 6], which was approved
by the medical ethics committee of the University Hospital of Maastricht; written informed
consent was obtained from one or both parents.
All infants were admitted to the neonatal care unit, where their birth weights were
assessed on a calibrated infant scale and recorded to the nearest 5 g. HC and crown-heel
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length were measured, to the nearest millimetre, with a tape on the third day of life. Crown-
heel length was measured with the infants in supine position.
Subsequently, between one and a half and two hours after a feed, 0.5 ml neonatal blood
samples were taken by venous puncture or heel-prick in conjunction with a diagnostic
puncture, and collected in EDTA-containing tubes. For 28 infants, a blood sample collected
at 37-42 wks GA was available. The fatty acid data of these latter infants were used to
assess the influence of the LCP status at birth on postnatal LCP levels.
The study populations are described in table 7.1. Of the infants followed until the term
period, 10 received their own mother's milk and 18 a commercially available artificial
formula as their main source of dietary lipids. The preterm human milk contained on
average 0.34% (wt/wt) of 22:6n-3 and 0.58% (wt/wt) of 20:4n-6. No detectable amounts of
22:6«-3, 20:4n-6 and other LCPs were present in the artificial formulas; their 18:2/i-6 and
18:3n-3 contents ranged from 10.8 to 18.1% (wt/wt) and from 0.34 to 1.47% (wt/wt),
respectively [9; Chapter 6). In the group of infants fed human milk, only two infants
received less than 90% (vol/vol) human milk during the study period; their human milk
intakes were 50.2 and 68.4% (vol/vol). Infants raised on artificial formulas consumed no
human milk.
Until the infants were on full enteral feeding, they received parenteral nutrition accord-
ing to current standards. Up to 95 kJ/kg/d of intravenous lipids (Intralipid® 10% and 20%,
and Vitalipid*. containing up to 0.2 and 0.3% (wt/wt) of 22:6n-3 and 20:4«-6 respectively
[9; Chapter 6|) were given as a source of fat. The majority of the infants received their first
cntcrul intake during the first week of life and they were on full enteral feeding of 420-500
kJ/kg/d at, on average, the 14th day of life. Some infants also received intravenous RBC and
plasma infusions as part of the treatment.
7.3.2 Laboratory analysis
Plasma and RBC samples were prepared as described previously [9; Chapter 6]. Umbili-
cal cord samples were rinsed with saline (NaCl, 0.9% wt/vol) and from segments of about
5 cm length, the arterial vessel walls were isolated from the surrounding tissue. The vessel
walls were frozen in liquid nitrogen and pulverized in an aluminum mortar with a stainless
steel pestle, which were cooled in liquid nitrogen. The pulverized samples were freeze dried
for 16 hours, followed by immediate fatty acid analysis.
At the start of this analysis, 1,2-dinonadecanoyl phosphatidylcholine (PC[19:0]2) was
added to every sample as an internal standard. Samples were analyzed as described previ-
ously [9; Chapter 6|, only modified by the use of the method of Bligh and Dyer [26] for
the extraction of total lipids from 10-30 mg freeze dried vessel wall tissue and by the use
of a CP-Sil 88 column (Chrompack*. Middelburg, The Netherlands) for the separation and
quantification of the fatty acid methyl esters in the vessel wall samples.
Fatty acid amounts present in the PL fraction were quantified based on the amount of
19:0 internal standard fatty acid methyl ester recovered. Absolute fatty acid levels were
expressed as mg/1 plasma or RBC suspension or as mg/kg dry weight of cord vessel wall
tissue. Relative fatty acid levels were expressed as % (wt/wt) of total fatty acid methyl
esters.
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Table 7.1. Characteristics of study population'.
infants involved in correlations infants followed until
at birth (n=44) term period* (n»28)
maternal age (y)
gestational age (weeks)
birth weight (g)
head circumference (cm)
length (cm)
SGA* ( P ^ J f
pH umbilical artery blood
follow-up after birth (weeks)
age at first enteral intake (days)
age at full enteral intake (days)
intravenous lipids (kj/kg/day/
intravenous plasma (ml)''
intravenous red blood cells ( m l /
human milk:formula^
28.6 ±
30.6 ±
1355 ±
27.6 ±
40.5 ±
0
7.18 ±
4.9
2.6
344
2.8
3.4
0.12
29.1 ±4 .7
32.3 ± 2.9
1380 ± 3 3 0
28 I ± 3 0
40.6 ± 3.7
8(29%)
7.16 ±0.12
6.4 ± 2.6
6 ± 3
14 t 8
22.7 ± 18.9
17.4 ±27.6
28.4 ± 44.3
10:18
"mean ± SD, except for: 'number of subjects
*lcrm period: 37-42 weeks of gestational age,
'value represents average amount received per day during entire follow-up period.
''te  SGA= small for gestational age (birth weight pea-entile < 2.3).
7.3.3 Data analysis
P-values <0.05 were considered significant. Relations between «-3 and n-6 LCP levels at
birth, GA at birth, and anthropometric measurements at birth were explored using linear
regression (Pearson correlation coefficients). Significant correlations between the LCP status
and anthropometric measures were corrected for GA at birth, using multiple regression
analysis.
The influence of the LCP status at birth on postnatal LCP levels was evaluated for the
two LCPs of primary interest, 22:6n-3 and 20:4n-6, by means of multiple regression analy-
sis. The regression equation formulated was:
LCPs in blood at term = A + B, * (LCPs in cord blood)
+ Bj * (LCPs in umbilical artery wall)
+ B, * diet
+ B4 * follow-up
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The dependent variable was the 22:6n-3 or 20:4n-6 status in the term period. As indica-
tors of the 22:6«-3 or 20:4n-6 status at birth, the levels of these fatty acids in the PL frac-
tion of venous cord blood (plasma or RBCs) and the umbilical artery walls were entered as
potential explanatory variables. The potential relation between LCP status at birth and
postnatal LCP levels was corrected for the type of postnatal enteral diet, which was entered
as a dummy variable with zero for human milk and one for artificial formula. Moreover,
the period (days) between birth and the blood sampling in the term period (follow-up) was
entered as a continuous variable. Separate equations were calculated for 22:6n-3 and 20:4n-
6, for the plasma and the RBC component of the blood, and for the absolute and relative
fatty acid data. Using an F-test, the overall relation between the LCP status at term and fcof/i
indicators of the LCP status at birth was tested, correcting for diet and follow-up. To guard
against spurious correlations, we present separa/e P-values for the two LCP-indicators only
when the F-tcst was significant.
7.4 Results
7.4.1 Relation between LCP status at birth and gestational age at birth
In table 7.2., mean values for the fatty acids studied (% (wt/wt) and total amounts of PL-
associated fatty acids) arc listed. Eight infants had a birth weight below the 2.3rd percentile
of the Amsterdam growth charts [27]. These small-for-GA infants were not included in the
analyses of the relations between LCP status, GA and anthropometric measurements at birth.
From six infants of (he remaining 44 infants, no umbilical cord sample was available. From
the cords of five other infants, no acceptable blood sample could be obtained.
In cord plasma PLs, significant positive relations were found between GA at birth and the
relative levels of 22:6«-3, the sum of all «-3 LCPs, and the sum of all LCPs (P<0.01). In the
arterial cord vessel walls, significant positive correlations were observed between GA at
birth and relative levels of 20:4n-6, the sum of all «-6 LCPs, the sum of all LCPs (P<0.001
for all), and 22:6n-3 (P<0.05). No significant relations were found between GA and plasma
or cord artery wall levels of 20:3«-6 or 2O:5n-3, nor between GA and absolute LCP levels in
plasma or umbilical artery walls, nor between GA and LCP levels in RBC PLs.
7.4.2 Relation between I.CP status at birth and prenatal growth
No significant correlations were observed for any of the anthropometric parameters with
the LCP status measured in cord plasma or RBC PLS. The relations of LCP levels in the
umbilical artery wall with birth weight arc based on 38 infants, with HC on 31 infants, and
with length on 29 infants, due to missing values for the latter two growth measures. All
significant correlations between anthropometric measurements and LCP levels in umbilical
artery wall PLs could at least partly be attributed to the significant positive correlation
between the anthropometric measurement and GA at birth (P<0.0005).
After correction for GA at birth, only absolute and relative 22:6n-3 levels remained
significantly related to birth weight (P=0.03 for both). Absolute levels of 20:4n-6, the sum
of all H-6 LCPs (P=0.05 for both), the sum of all LCPs (P=0.03) and 22:6n-3 (P=0.01), and
the relative level of 22:6n-3 (P=0.05) remained significantly related to HC at birth. The
absolute level of 22:6n-3 remained significantly related to length at birth (P=0.02). Cord
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Table 7.2. Fatty acid composition ( * (wt/wt)*. mean ± SD) of phospholipids of umbilical anery vessel walls
and of plasma and red Mood cells (RBCs) at birth and at term postconceptional age (37-42 weeks gestaiional
«y>
fatty acid umbilical artery plasma. ^ plasma» ^ RBCs„ ^ RBCs
(n=38) (n=39) (n-27) (n-39) (n-28)
20:3»-6
20:4n-6
I11-6LCP*
2ft5«-r
22:6n-3
I »-3 LCP*'
I n-3+n-6 LCP*
tour*
0 8 9 *
I I I ±
17.8 ±
4.20 ±
22.0*
15533
0.26
2.2
3.3
0.97
3.9
±4479
3.99
17 0
22.1
0.27
384
4.42
26.5
660
*
*
*
*
*
*
*
*
088
2.0
18
0.16
088
099
23
150
2.81 *
7.7 ± 1
11.4*
0.17 i
1.85*
2.39*
13.8*
1060*
070
.7
2.0
O i l
0.79
103
2.9
175
168
11.7
162
0.12
2.71
3.19
19.4
1027
*
*
*
*
*
*
*
*
054
4 4
60
010
1.39
165
7.5
267
1.22*047
7 3 * 2.9
106*4.2
0 10*009
1.28*0.77
1 85 * 1 05
12.5*5.1
925 * 263
Total amount of phospholipid (PL)-associaled fatty acids expressed as mg/kg dry weigh! fur umbilical
artery vessel walls and as mg/1 for plasma and for RW suspension Fatty acid concentrations con be
calculated from the relative fatty acid levels and the total amounls of PI associaled fatty acids.
*n-6 LCP= n-6 long-chain polyunsaturated fatty acids (20:3/1-6. 20:4/i-6, 22:4n-6 and 22:5n-6), /i-3 LCP= n-3
long-chain polyunsaturated fatty acids (20:4n-3, 2O:5n-3, 22:5n-3 and 22:6n-3).
"»o n-3 fatty acids other than docosahexacnoic acid (22:6/i-3) were detectable in the vessel walls of the
umbilical artery.
artery wall levels of 2O:3n-6 were not significantly related to any of the prenatal growth
parameters.
7.4.3 Relation between LCP status at birth and at term
From three of the 28 infants followed until the term period, no cord blood sample was
available and from 2 infants, the umbilical vessel wall sample was missing. As a result, 23
complete sets of data were available for the regression analyses concerning RBCs (Table
7.3.). From one infant, the plasma sample collected at term was lost during fatty acid
analysis, so for the regression analyses of the plasma data, 22 complete sets were used.
The postnatal diet was the only explanatory variable for absolute (P=0.004) and relative
(P=0.0004) plasma levels of 22:6«-3 and relative plasma levels of 20:4n-6 (P=0.02) at term
postconceptional age, with lower postnatal levels in the infants raised on formula than in
those fed their own mother's milk. The absolute 20:4n-6 level in plasma PLs at birth was
the only explanatory variable (positive correlation, P=0.02) for the absolute 20:4n-6 level at
term (figure 7.2.A.).
Absolute (P=0.0003) and relative (P<0.0001) 22:6«-3 levels and the absolute 20:4«-6
level (P=0.02) in the umbilical artery wall were positively related to the corresponding LCP
levels in RBC PLs at term (figure 7.2.B.). No significant explanatory variables were found
for the relative level of 20:4/i-6 in RBCs in the term period.
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Table 7.3. Explanatory variables for the 22:6/i-3 and 20:4/i-6 status in the term period (37-42 wks
gcstational age), resulting from regression analysis" performed in 22 subjects for plasma and in 23 subjects
for red blood cells.
Dependent variable
plasma
phospholipids
red blood cell
phospholipids
(in term period)
22:6/i-3, mg/1
22:6*-3, % (wt/wt)
20:4/i-6, mg/l
20:4/i-6. % (wt/wt)
22:6n-3. mg/1
22:6/i-3, % (wt/wt)
20:4n-6, mg/1
20:4/i-6. % (wt/wt)
0.18
0.23
0.04
0.57
0.0005
<0.000l
0.05
0.21
explanatory variable
enteral diet*
enteral diet*
20:4n-6 in umb. plasma
enteral diet''
22:6/i-3 in umb. art. wall
22:6n-3 in umb. art. wall
20:4/i-6 in umb. art. wall
-
P "
0.004
0.0004
0.02
0.02
0.0003
<0.0001
0.02
-
"Dependent variables: 22:6/i-3 or 20:4/i-6 level in the term period; explanatory variables: 22:6/i-3 or 20:4/i-6
levels ut birth in umbilical (umb.) cord blood and in the umbilical artery (art.) wall, type of postnatal diet
(human milk or formula) and length of period between birth and term (days). Pp.,„,: significance level for
the relation between postnatal long-chain polyunsaturated fatty acid (l.CP) level and fc»f/i indicators of the
UT status at birth (irp levels in cord blood and in the umbilical artery vessel wall), corrected for enteral
diet and length of follow-up period. P T „ „ : significance level for the separate explanatory variable, which
results from calculating the entire regression equation.
^Higher fatty acid values in the human milk fed infants (n=IO) than in the formula fed infants (n=12).
7.5 Discussion
One of the objectives of this study was to enhance the present knowledge of the rela-
tions between the l.CP status at birth, GA at birth, and anthropometric measurements. GA was
positively correlated with relative w-3 LCP amounts in cord plasma PLs and with relative /i-6
and n-3 LCP amounts in the umbilical artery walls. We consider the higher
«-6 and «-3 levels observed with advancing GA an indication of an adequate response to the
increasing demand for M-6 and M-3 LCPS, necessary for fetal brain and body growth, in the
third trimester of pregnancy.
Increasing plasma n-3 levels with increasing gestational age have also been observed by
others [19,28,29; Chapter 3]. Plasma n-6 levels have been reported to increase [28] or to
decrease [29; Chapter 3] with advancing GA, or, as in this study, no significant relation was
observed [18,19). Fatty acid levels in plasma PLs are known to be affected by relatively
short-term (dietary) influences. Therefore, we also studied umbilical artery walls, because
their LCP composition can be looked upon as a long-term reflection of the fetal LCP status
[24,251. They are regarded as such because human umbilical vessels have no vaja vasorum,
and human tissue cannot synthesize cfas, so their walls have no other way to obtain EFAs
than from the blood flowing through them. As a consequence, the LCP composition of the
umbilical artery walls represents the EFA and LCP content of the return flow from the fetus
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Figure 7.2.: A. Influence of the arachidonic acid (20:4n-6) status at birth, measured in umbilical plasma
phospholipids (PLs), on the absolute 20:4n-6 status in plasma Pl.s in the term period (at term date; 37-42
wks gestational age). B. Influence of the docosahexaenoic acid (22:6n-3) status at birth, measured in the
walls of umbilical arteries, on the absolute 22:6/i-3 status in red blood cell (RBC) Pl.s in the term period.
The scatterplots contain all available information, also that of the infants of whom incomplete data sets were
obtained. Pearson correlation coefficients and significance levels result from linear regression between the
two variables given.
to its mother and, thereby, indicates the lowest estimate of the fetal LCP status.
After correction for GA at birth, anthropometric measurements at birth were significantly
related to LCP levels in the umbilical artery wall only. Because LCP levels in cord plasma
and RBC PLs are considered to be relatively short-term indicators of the fetal LCP status,
their correlation with measures of a long-term process like fetal growth, can be expected to
be less distinct. 22:6n-3 levels in the arterial cord vessel walls were significantly related to
weight, HC, as well as length at birth, and absolute n-6 LCP levels correlated with HC.
Others have observed a positive relation of n-3 as well as n-6 LCPs with birth weight and
HC, both in premature [19] and term [24,30] newborn infants. Koletzko and Braun [18]
reported a positive relation between birth weight and relative levels of 20:4n-6 and the sum
of all n-6 LCPs in plasma triglycerides of newborn prcterm infants. No such relation was
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observed for «-3 LCPs, so they concluded that LCPs of the n-6 series specifically seem to be
associated with tissue growth in ufero. However, the correlations observed in the above-
mentioned studies were not always corrected for GA. In our population, significant correla-
tions for percentage levels of 20:4«-6 and the sum of all «-6 LCPs with birth weight and
with HC were completely attributable to GA at birth.
In the current study, we observed a striking relation between prenatal growth and 22:6n-
3 status; this fatty acid was significantly related to all three anthropometric measures, inde-
pendent of the GA at which the infant was born. 22:6n-3 has a highly specific distribution in
the human body, being present in high concentrations in brain, retina, spermatozoa and
mitochondria [31]. Perhaps an explanation for the consistent relation between 22:6«-3 status
and prenatal growth may be sought in the high 22:6n-3 concentration in mitochondrial
membrane pis and its potential influence on mitochondrial metabolic functions [32].
We also demonstrated thai the LCP status at term is determined, not only by the
postnatal diet, but also by the LCP status at birth. The observed relations did not change
when the data of infants who were SGA at birth were not included in the statistical analysis.
The 22:6n-3 and 20:4/1-6 levels in the walls of the umbilical arteries of preterm infants
were positively related to the 22:6n-3 and 20:4«-6 content of RBC PLs collected at the time
when these infants were expected to be born. Recent studies in preterm populations, have
demonstrated the importance of both the n-6 and the «-3 LCP status for several functional
[33-36| and anthropometric measures [20,37]. These studies pointed out the importance of
an adequate LCP content of the early cntcral diet of premature infants. However, our obser-
vation that higher LCP levels at birth result in higher postnatal levels stresses the signifi-
cance of an appropriate prenatal LCP supply, because this is a major determinant of the LCP
status at birth. The only potential way to achieve a change in this prenatal LCP supply is
through an adaptation of the fatty acid content of the maternal diet during pregnancy, e.g.,
through an enhanced maternal EFA intake. The results of an earlier study support the feasi-
bility of such an intervention [38].
Besides the observed relation between the LCP status at birth and LCP levels at term
postconceptional age, the type of postnatal diet was demonstrated to be the major determi-
nant of postnatal LCP levels in plasma PLs, indicating that conventional artificial formulas
(containing no «-6 and n-3 LCPs) are unable to maintain the postnatal LCP status of preterm
infants at levels that can be obtained when feeding with preterm human milk. Our observa-
tion that the type of oral nutrition received by an infant influences the postnatal LCP status
when measured in plasma PLs, but not when measured in RBC PLS, is in agreement with the
findings of recent studies |8,16].
We conclude (figure 7.3.) that in preterm infants, there are significant relations between
the LCP status at birth, GA at birth and indicators of prenatal growth. Moreover, both the
postnatal dietary LCP supply and the prenatal LCP supply, which is reflected in the LCP
status at birth, were found to affect postnatal LCP levels of preterm infants. Considering the
importance of LCPs for normal brain and retinal function, the latter observation may warrant
further studies of the effects of EFA-cnriched maternal diets during pregnancy on the neona-
tal LCP status at birth.
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Figure 7.3: Relations between prenatal long-chain polyunsaturatcd fatty acid (U'P) supply and prenatal
growth and between pre- and postnatal LCP supplies on the one hand, and postnatal UP values on the other
hand (EFA=essential fatty acid. GA=gestational age. nc=head circumference). Bold type arrows and boxes
indicate relations observed in the current study.
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8.1 Abstract
In view of the importance of long-chain polyunsaturated fatty acids LCPs for growth and
development of fetal and infant neural tissue, the influence of the dietary n-3 and «-6 LCP
intake on the LCP status of 43 preterm infants (birth weight < 1800 g) was studied. Thirty-
one formula-fed infants were randomly assigned to receive a conventional formula, lacking
LCPs, (n=16), or an 22:6n-3 (0.3 wt %) and 20:4/i-6 (0.6 wt %) enriched formula (n=15); 12
infants received their own mother's breast milk. Fatty acid compositions of plasma and red
blood cell (RBC) phospholipids (PLs) were determined in umbilical venous blood, in weekly
postnatal samples until the 35th day of life and, for the formula-fed infants, at three months
of corrected age. Both in plasma (P<0.001) and RBC (P<0.0l) PLs, the changes with time
until day 35 for 22:6n-3 and 20:4n-6 in the two groups of formula-fed infants were signifi-
cantly different, with higher values, comparable to those of human milk-fed infants, in the
LCP-enriched formula group. At three months of corrected age, differences between the two
formula-fed groups were even more pronounced. In conclusion, adding 22:6/i-3 and 20:4/i-6
to artificial formulas in balanced ratios, i.e. in amounts similar to those found in preterm
human milk, raises both the 22:6n-3 and 20:4«-6 status of formula-fed preterm infants to
values found for human milk-fed preterm infants. Additional studies are necessary to
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evaluate the potentially favourable effects of this combined addition on the neurodevelop-
mental outcome of preterm infants.
8.2 Introduction
The LCPs', docosahexaenoic acid (cervonic acid, 22:6/i-3) and arachidonic acid (20:4M-
6) in particular, are the predominant structural fatty acids in the human brain [1-3] and
retina (4|. These LCPs accumulate rapidly in fetal and infant neural tissue during the periods
of most rapid growth and development, that is during the last months of gestation and the
first months of postnatal life (5-9].
Unlike term infants, prctcrm infants cannot benefit from the maternal and placental LCP
supply during the last trimester of pregnancy to cover the demands associated with this LCP
accretion. Instead, they arc dependent on their own dietary supply through either human
milk, which contains small but significant amounts of 22:6M-3, 20:4«-6 and other LCPs, or
through commercially available artificial formulas, the majority of which does not contain
any but trace amounts of i.CPs [ 10-12]. A substantial number of studies in preterm popula-
tions have since demonstrated that these conventional formulas, even when they do contain
substantial amounts of the parent essential fatty acids (EFAs) linoleic acid (18:2w-6) and (X-
linolenic acid (18:3/i-3), are unable to maintain postnatal 22:6«-3 and 20:4M-6 levels in
plasma and RBC lipids at levels observed after feeding human milk [13-17; Chapter 6J.
Probably, the desaturase capacity of preterm newborns is too limited to adequately cover
the demands for /i-3 and M-6 I.CPS solely through metabolic conversion of the two parent
fatty acids [ 18,19]. In addition, prctcrni newborn infants have very limited fatty acid stores
118.2O|.
These observations have prompted an increasing number attempts, with varying degrees
of success to reduce the differences between the biochemical LCP status of human milk-fed
and formula-fed infants by adding LCPs to the diets of the latter [15,16,21-25]. However,
increasing only (he dietary «-3 LCP intake, through the addition of marine oils, resulted not
only in the desired enhancement of 22:6M-3 levels, but also in decreased 20:4M-6 levels
[23,24|, and has been reported to be associated with diminished first-year growth rates
[26,27]. Effects on LCP status of formulas containing both «-3 and n-6 LCPs have also been
reported 115,16,25], but the duration of supplementation in these studies was confined to a
few weeks.
Therefore, we studied the effects of long-term feeding of artificial formulas, containing
both 22:6n-3 and 20:4w-6 in amounts present in human milk, in formula-fed preterm infants
which were randomly assigned to receive cither conventional artificial formulas or the LCP-
enriched formulas. The LCP patterns of both plasma and RBC PLS were studied until three
months after the initially expected date of delivery. The PL-fraction was studied because PLs
are structural lipids, which are the richest source of polyunsaturatcd fatty acids (PUFAs),
including LCPs, and because changes in PUFA profile are most pronounced in PLs [28].
'Polyunsaiuraied tally acids with a chain length of 20 carbon atoms or more, and derived from
the parent essential fatty acids linoleic acid (18:2/t-6) and a-linolenic acid (18:3n-3) through alternate
desaturation and elongation.
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Values for 22:6/i-3 and 20:4n-6 during the first 5 weeks of life of infants fed on the supple-
mented formulas were compared with those of a group of preterm infants raised on their
own mother's breast milk.
83 Subjects and methods
83.1 Experimental design
The total study population comprised 43 infants (birth weight 900-1795 g). who were
born before the 37th week of gestation, had a birth weight appropriate for gcstational age
(above the 2.3rd pcrccntile of the Amsterdam growth charts (29|), and were free from
metabolic disease and major congenital malformations Gestational age was confirmed by
menstrual history and early ultrasound dating, and by Dubowitz score [30| if (he former
information was missing or doubtful. Only infants with a birth weight of 1800 g or less
were included, because larger infants were likely to be discharged home before the intended
minimum duration of the study (4 weeks). Immediately after delivery (day 0), approximate-
ly 3 ml of umbilical venous blood was collected. Thereafter, the essential fatly acid status
of the infants was monitored until discharge home or transfer to a non-participating hospi-
tal. For this purpose, a weekly sample of approximately 0.5 ml of capillary or venous blood
was collected in conjunction with a diagnostic puncture, which was pan of the routine
clinical monitoring at the neonatology ward. Because of the frequent oral feeds that arc
given to preterm infants (every 2-3 hours), blood samples could not be collected after
fasting, but were taken between one and one and a half hour after a feed. For the formula-
fed infants, follow-up was extended after discharge to three months after the initially
expected date of delivery (three months of corrected age), when a final blood sample was
collected.
All infants were admitted to the neonatal care unit, where clinical care was provided by
the attending neonatologists and resident physicians, according to current standards. Some
infants received intravenous RBC and plasma infusions at different times during the treat-
ment. Since these preparations contain significant amounts of 22:6/i-3 and 20:4/j-6, the time
of infusion and the amount administered were registered carefully. Furthermore, neonatal
blood samples were always collected 24 hours or more after an infusion. The infants were
discharged home when their weight reached 2400 g.
The study was approved by the medical ethics committees of the participating hospitals,
and written informed consent was obtained from one or both parents.
Infants were eligible for entering the study when they were able to tolerate enteral
feedings and did no longer require respiratory support (continuous positive airway pressure
or intubation and mechanical ventilation). If the mother did not wish to provide breast milk,
her infant was introduced to enteral feeding with a premature infant formula. These infants
were randomly assigned to receive either a commercially available, conventional artificial
formula, containing no LCPs (table 8.1., preterm C-AF), or an LCP-enrichcd version of this
formula, containing 22:6/i-3 and 20:4n-6 in balanced ratios (1:2) and in amounts approxi-
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Table 8.1. Fatty acid composition, % (wt/wt), of total lipids of preterm human
conventional (C-AF) and LCP-cnriched (LCP-AF) artificial formulas used'.
Fatty acid*'
% (wt/wt)
ISAFA
ZMUFA
£ PUFA
18:2n-6
20:3n-6
20:4n-6
£ n-6 LCP
18:3n-3
20:5n-3
22:6/i-3
£ n-3 LCP
preterm
C-AF
39.5
44.3
15.5
14.3
ND
ND
ND
1.2
ND
ND
ND
formula
LCP-AF
38.5
44.6
16.4
14.3
0.06
0.61
0.67
1.1
ND
0.30
0.30
term
C-AF
41.1
44.3
14.2
12.8
ND
ND
ND
1.4
ND
ND
ND
formula
LCP-AF
40.4
44.9
14.1
12.0
0.05
0.54
0.59
1.2
ND
0.30
0.30
milk (HM) and of the
preterm HM
(n=6)
48.1 (43.4-50.3)
32.4(30.9-36.1)
18.7(14.6-21.7)
14.7(11.3-18.1)
0.55 (0.49-0.63)
0.52 (0.43-0.64)
1.26 (1.04-1.48)
0.90 (0.77-1.02)
0.04 (0.04-0.06)
0.26 (0.22-0.42)
0.57 (0.48-0.80)
•For artificial formulas, data are based on chemical analyses performed at the Nutricia Chemical and
Physical Research Laboratory Zoetermeer, the Netherlands; for human milk, results are based on own
anulyscs as described before (I7| (median (interquartile range) of average content during the study period
|day ()-35|).
SAIA= saturated fully acids, MUIA= sum of monounsaturated fatty acids, PUFA= polyunsaturated fatty acids,
n-6 U'P= n-6 long-chain PUFAs (20:3/I-6 , 20:4n-6, 22:4n-6, and 22:5n-6), n-3 LCP= n-3 long-chain PUFAs
(2O:4n-3. 2O:5n-3. 22:5n-3 and 22:6n-3).
'NI)= none detected (less than 0.1% (wt/wt) of total fatty acid melhylesters).
mating those in human milk (table 8.1., preterm LCP-AF). The sources of the LCPs were
highly purified, so-called 'single-cell oils', which are produced by single-celled organisms,
such as micro-alga and fungi. The LCPs were added to the formula during commercial
processing. Appropriate precautions against oxidation were taken during processing and
storage, including the addition of 3 mg a-tocopherol per 100 ml of LCP-enriched formula.
Doubly-blinded randomization was performed using a computerized randomization
program, and resulted in 16 infants being fed on the conventional formula and 15 infants
receiving the LCP-enriched formula. At a weight of 2000 g, the conventional premature
infant formula was replaced by a commercially available, conventional regular infant
formula, again containing no LCPs (table 8.1., term C-AF), while the LCP-enriched preterm
formula was replaced by an LCP-enriched, but otherwise identical term formula (table 8.1.,
term LCP-AF). After the participating infants were discharged from the hospital, their parents
were provided amply and free of charge with these term formulas for use at home. The
formulas were supplied as ready-to-use bottles of 60 ml (preterm formulas) or 100 and 200
ml (term formulas). To ensure an optimal patient compliance during hospitalization, the
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volumes of formula given and the numbers of the bottles used were recorded carefully by
the nursing personnel. At home, the parents were instructed to nil in a daily questionnaire
on the volumes of study formula, as well as any additional foods, consumed by their
infants. In addition, the parents were counselled regularly.
For comparison with the LCP-enriched formula fed infants, a further 12 infants, given
(initially expressed) preterm human milk obtained from their own mothers (sec table 8.1.
for average fatty acid composition), were studied. In five of these 12 infants, a so-called
Breast Milk Fortifier was added to the milk expressed by their mothers. This fat-free
fortifier was introduced on the neonatology ward halfway through our study anil served to
bring the intake of protein, vitamins, and minerals of human milk-fed preterm infants in
line with their needs for these nutrients. It enhanced the energy intake content of the human
milk with 44 kJ/100 ml. When the mother was unable to express enough milk, an approp-
riate formula (table 8.1., preterm C-AF) was supplied to cover the nutritional demand of her
child. If the intake of artificial formula exceeded 25 percent (vol/vol) of the total cnteral
intake, the infant was no longer included in the human milk group.
Enteral feedings were administered through a nasal tube, until the infant was able to
drink from a bottle or his or her mother's breast. Until the infants were on full cnteral
feeding, they received parenteral nutrition, containing (he appropriate amounts of carbohy-
drates (210 kJ/kg/d), amino acids (50 kJ/kg/d), vitamins, and minerals. In addition, up to 95
kJ/kg/d of intravenous lipids (Intralipid* 10% and 20%, Vitalipid*) were given as a source
of fat. Since these preparations proved to contain up to 0.2 and 0.3 percent (wt/wt) of
22:6n-3 and 20:4n-6 respectively (M.M.H.P. Foreman-v Drongelen, unpublished data), the
amounts given were registered.
ana/>>5/5
Blood samples were collected in EDTA-containing tubes to prevent coagulation. Plasma
and RBC samples were prepared and the fatty acid composition of their PLs analyzed as
described previously [17; Chapter 6], with the modifications that the extraction of total
lipids from RBCs was done within one week after blood sampling, and according to the
method of Bligh and Dyer [31]. At the start of the analysis, approximately 31.0 ug of 1,2-
dinonadecanoyl phosphatidylcholine [PC-( 19:0)2] ^ ^ added to every sample as an internal
standard to quantify fatty acid amounts present in the PL fraction of the plasma and RBCs.
Absolute fatty acid amounts are expressed as mg/1 plasma or RBC suspension, relative fatty
acid levels as % (wt/wt) of total fatty acid methyl esters.
In total, 39 fatty acids were identified on the basis of a standard reference mixture
containing most of the fatty acid methyl esters of interest. Since this study focuses on the
22:6n-3 and 20:4n-6 status, only the following additional relevant fatty acids and fatty acid
combinations are reported: 18:2n-6, dihomo-y-linolenic acid (20:3n-6), 18:3«-3, eicosap-
entaenoic acid (20:5«-3), L SAFA (sum of all saturated fatty acids), I MUFA (sum of all
monounsaturated fatty acids), £ PUFA (sum of all polyunsaturated fatty acids), £ n-9 KUFA
(sum of all PUFAs of the n-9 series), I n-6 LCP (sum of the LCPs of the n-6 series), and L
n-3 LCP (sum of the LCPs of the n-3 series).
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In addition, two indices were calculated to describe the functional 22:6n-3 status. The
cervonic acid deficiency index (CADI), defined as the ratio of 22:5n-6 to its immediate
precursor 22:4w-6, was used because a shortage of 22:6n-3 (cervonic acid) is accompanied
by an increased conversion of 22:4«-6 to 22:5n-6, resulting in higher CADI values [32,33].
The cervonic acid sufficiency index (CASI), defined as the ratio of 22:6n-3 to 22:5n-6, was
calculated based on the same metabolic principle, leading to a decreased CASI value in case
of an 22:6n-3 shortage [24].
Dato
Study size calculations were based on the results of one of our previous studies [17;
Chapter 6] using the exact calculations provided by Systat's Design program [34]. Assum-
ing an a of 0.05 two-sided, a sample size of 15 infants per formula group was calculated to
be ample for demonstrating a significant inter-group difference in 22:6n-3 status (4 infants
per group resulted in a power of 0.96), while for 20:4«-6 a power of 0.77 would be
obtained.
Since, during the clinical follow-up, not all blood samples could be collected at exactly
the intended days, fatly acid values were estimated at days 7, 14, 21, 28 and 35 by linear
interpolation between the actual days on which blood had been sampled. Blood samples
were usually collected within two days of these reference days, and for the majority of
infants, none or only one of the ideally required six samples was missing. Unless mentioned
otherwise, all data arc presented as median and the upper and lower limits of the
interquartile range.
The iwo LCPs of primary interest, 22:6n-3 and 20:4n-6 were analyzed most extensively.
Values measured at birth and weekly up to 5 weeks postnatal age were evaluated in a
repeated-measures analysis-of-variance model [35,36], with gestational age and its square as
covariables. The model gives estimated mean LCP levels at the mean gestational age of 220
days for each group, at each of the observation times, with correction for missing data. In
the same model, we tested the difference between the conventional and the LCP-enriched
formula groups at 4 weeks and at 5 weeks of postnatal age. Within the repeated-measures
analysis, 22:6n-3 and 20:4«-6 values of the infants raised on LCP-enriched formulas were
also compared to ihose of the human milk fed group. Since the postnatal LCP status has
been shown to be related to the LCP status at birth [37], and assignment to the human milk
or the LCP-enriched artificial formula groups was not obtained by randomization but
resulted from maternal choice, we compared the changes from the initial values at 4 and 5
weeks in the LCP-enriched formula and human milk groups using 95% confidence intervals.
Confidence intervals were used here instead of tests since demonstration of an unequal LCP
status was not a study objective. The confidence intervals reveal how close the LCP-enriched
formula group gets to its 'natural target": the human milk group. Model assumptions were
checked visually in scatterplots, and apparent outliers were examined for their impact on the
qualitative results. Values for 22:6/i-3 and 20:4/i-6 at three months of corrected postnatal
age were analyzed using the two-tailed Mann-Whitney test. For all these primary analyses,
P-valucs smaller than 0.05 were considered to reflect a significant difference.
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For the other fatty acids, two-tailed Mann-Whitney tests were used lo compare values of
the two formula-fed study groups at day 0, at day 35, and at 3 months of corrected age. For
this relatively large number of supportive analyses, differences with a significance level of
PiO.01 were regarded as significant
The volumes of plasma, RBCs and intravenous lipids administered in the three groups
and continuous clinical variables were compared using the two-tailed Mann-Whitney test.
Discrete clinical variables were compared using the chi-square test. Bonfcrroni correction
with a factor three for the number of groups compared was used, when applicable.
8.4 Results
8.4.1 Study populations
The most important clinical and nutritional characteristics of the study groups are shown
in table 8.2. No relevant differences between the two formula-fed study groups were present
for any of these features. The majority of the infants received their first cntcral intake well
within the first week of life and they were on full cntcral feeding of 420-500 kJ/kg/d at, on
average, the 12th day of life. Both during the clinical and the out-patient follow-up periods,
the two groups of formula-fed infants achieved similar and adequate weight gains on
comparable enlcral energy intakes, which were almost exclusively originating from the
study formulas. Energy sources other than formula milk were introduced at the same pace
in both groups during the third month of corrected age. They consisted of fruits, which are
known to contain any but trace amounts of fat [38], and were consumed in limited amounts
in addition to the regular formula feeds.
As a result of the entrance-restriction placed on birth weight (<1800 g), the majority of
the participating infants completed the initially intended minimum follow-up of 28 postnatal
days before discharge home. The one exception were the human milk fed infants, nearly
half of whom were transferred to a non-participating hospital or received less than 75 %
(vol/vol) of human milk by the 4th week of life. However, because for a sufficient number
of infants information on blood LCP status was even available until the 35th day of life, the
statistical evaluation of the clinical period could reliably be extended to this postnatal age.
Nearly all formula-fed infants continued to participate in the study after discharge home;
one infant in each group was discharged before the required term study formulas were
available, one infant fed on the conventional formulas turned out to have been fed on a
non-study term formula from the second month of corrected age onward.
8.4.2 Plasma phospholipids
From one infant in the conventional artificial formula group, 3 infants in the LCP-
enriched formula group, and one child in the human milk group, no umbilical blood sample
was available.
Different patterns of postnatal changes of 22:6n-3 and 20:4n-6 were obtained when the
fatty acid values were expressed as mg/1 plasma or as percentage (wt/wt) of total fatty acid
methyl esters (figure 8.1). In the conventional formula fed group, concentrations (mg/1) of
these major LCPs progressively decreased from 7 (22:6n-3) or 0 (20:4n-6) days of postnatal
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Table 8.2. Clinical and nutritional
maternal age (y)
primipara''
gestalional age (weeks.days)
pH of arterial cord blood
birth weight (g)
weight gain day 0-35 (g/kg/day)
Iv* lipids (kJ/kg/day)
IV plasma (ml)''
IV RBtY (ml)''
total entcral intake day 0-35
(kJ/kg/day)
intake of experimental formula
day 0-35 (kJ/kg/duy)
intake of experimental formula
day 0-35 (% (vol/vol) of total
enteral intake)
age at first enteral intake (days)
ugc at first intake of experimen-
tal formula (days)
age at full enteral intake (days)
vent, support (days)'
vent, support > 24 h*-'
BPD*'
sepsis''
IVH*<
weight gain 0-3 months of
corrected age (g/kg/day)
intake of experimental formula
0-3 months of corrected age
(kJ/kg/day)
characteristics of study
conventional formula
(n=16)
29.5 (28.0-32.0)
8 (50.0%)
31.5(28.6-34.0)
7.22 (7.17-7.36)
1545(1233-1700)
17.1 (15.0-20.8)
11.3(4.1-22.3)
4.9 (8.0)
9.7 (16.5)
377 (345-*88)
364 (324-459)
98.8 (93.9-99.8)
1.0(0.0-3.0)
4.5 (4.0-6.8)
10.0(6.3-16.5)
0.5 (0.0-4.0)
5(31.3%)
1 (6.3%)
2(12.5%)
0 (0.0%)
9.7(8.4-11.7)
495 (473-542)
groups".
LCP-enriched formula
(n=!5)
26.0 (23.0-32.0)
8 (53.3%)
30.5 (28.4-32.4)
7.18(7.16-7.26)
1532(1050-1740)
14.4(12.3-17.8)
13.8(6.9-18.9)
9.7(10.1)
8.6(13.2)
362(321-415)
357(31MO4)
97.5 (95.8-99.7)
2.0 (0.8-4.3)
7.0 (4.0-9.0)
12.0(8.0-17.0)
5 0 (0.0-8.0)
10 (66.7%)
1 (6.7%)
3 (20.0%)
0 (0.0%)
10.7(9.3-11.2)
479 (447-486)
human milk
(n=12)
27.5 (22.0-28.0)
9 (75.0%)
29.3 (28.2-33.6)
7.25 (7.23-7.27)
1225(988-1490)
11.6 (8.3-14.9)*
18.9 (10.8-29.4)
9.2(13.1)
22.6 (26.3)
321 (267-353)
-
5.0 (3.0-7.0/
-
13.5(10.3-18.3)
3.0(0.3-13.3)
8 (66.7%)
0 (0.0%)
4 (33.3%)
3 (25.0%)
-
"Median (interquartile range) except for number of subjects and mean ± standard deviation.
*ÏV=intrnvenous, RBCs=red blood cells, BPD=bronchopulmonary dysplasia. iVH=intraventricular haemorrhage,
'venlilatory support included mechanical ventilation and continuous positive airway pressure.
Statistically significant differences were found only between conventional formula group and human milk
group (two-tailed Mann-Whitney U lest with Bonferroni correction factor 3 for number of groups compared
when applicable): 'P<0.02. *P<0.005
LCP-enriched formulas and prcterm LCP status
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Figure 8.1.: 22:6/i-3 and 20:4n-6 values in plasma phospholipids (PL). Median and interquartile range
expressed as mg/l (fe/W and as % (wt/wt) of total fatty acid methyl esters (rig/if,). Number of infants,
respectively, in conventional (—•—) and long-chain polyunsaturated fatty acid (LCP)-enriched (—O—)
artificial formula groups and in human milk group (--V--J at day 0: 15/12/9; day 7: 16/13/12; day 14:
16/14/12; day 21: 14/14/9; day 28: 12/13/7; day 35: 9/12/7; 3 months corrected age (3mc): 14/14.
Statistical difference between conventional and LCP-enriched artificial formula groups (repeated measure*
analysis, except for 3 months of corrected age: Mann Whitney U test):
*P<0.01, "P<0.001. "*P<0.0001.
Difference between LCP-enriched artificial formula group and human milk group (changes from the values
at day 0):
*0 outside 95% confidence interval.
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age onwards. In the group of infants fed on an LCP-enriched formula, these LCPs again
increased after the 14th day of life. This resulted in significantly higher postnatal concentra-
tions in the latter study group (22:6n-3: day 28: P<0.01, day 35: P<0.001; 20:4n-6: day 28:
P<0.001, day 35: P<0.0001). At 3 months of corrected age average absolute 22:6«-3 and
20:4n-6 amounts, respectively, were more than 3 and 2 times higher in the LCP-enriched
formula group than in the conventional formula group (P<0.0001 for both). Relative 22:6n-
3 and 20:4n-6 levels decreased to almost half the values at birth during the first week of
life in both study groups. They continued to decrease in the conventional formula group,
while they stabilized in the infants fed on an LCP-enriched formula, again resulting in
significantly higher levels in the latter population (22:6n-3: day 28: P<0.001 and 35: P<
0.0001, 20:4«-6: days 28 and 35: P<0.0001). At 3 months of corrected age the magnitudes
of inter-group differences for relative 22:6n-3 and 20:4n-6 levels were similar to those for
absolute amounts and also highly significant (P<0.0001 for both). At 28 to 35 days of
postnatal age, the 22:6/i-3 and 20:4«-6 status of infants fed on an LCP-enriched formula was
at least comparable to that of prctcrm infants fed on their own mother's human milk (see
table 8.3. for accompanying 95% confidence intervals).
Table 8.3. 95% Confidence intervals for differences between U'P-enriched artificial formula (LCP-AF) group
and human milk (HM) group:
plasma phospholipids
mg/1
% (wt/wt)
red blood cell phospholipids
mg/1
% (wt/wt)
fatty acid
22:6/i-3
20:4n-6
22:6/i-3
20:4/i-6
22:6n-3
20:4«-6
22:6/.-3
20:4/i-6
day 28-f\c,.« - day 28-O„„
[-8.1 . 3.7]
[-2.9 . 34.3]
[-1.0,0.8]
[-2.8 , 0.8]
[-9.59 . 4.8]
[-30.5.31.6]
[-0.54 . 0.04]
[-11 . 1.2]
day 3:
[-3.9 ,
[3.5 .
[-0.6,
[-2.12
[-18.2
[-67.5
[-0.51
[-0.91
5-0LCPAP " day 35-OHM
,6.9]
41.8]
, 1.1]
, 136]
. 1 1 ]
,6.1]
,0.19]
, 1 3 ]
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Significant inter-group differences were also observed for the other fatty acids reported
(see tables 8.4. and 8.5. for absolute and relative amounts, respectively). The absolute
amount of the sums of the n-6 LCPs (Z n-6 LCP) and of the n-3 LCPs ( I n-3 LCP) remained
similar between day 0 and day 35 in the conventional formula group, whereas their concen-
trations increased in the LCP-enriched formula group, resulting in significantly higher
concentrations in the latter (Z n-6 LCP: P<0.001. Z n-3 LCP: PSO.0001). The relative levels
of Z n-6 LCP and Z n-3 LCP declined in both formula-fed study populations, but this led to
significantly lower levels in the conventional formula group (PiO.001 for both). At three
months of corrected postnatal age, inter-group differences were even more pronounced, both
for absolute and relative Z n-6 LCP and Z n-3 LCP values (P< 0.0001 for all). The relative
levels of 20:3n-6 and 2O:5n-3, next to 20:4n-6 precursors of prostaglundins and other
cicosanoids, were significantly lower in the infants fed formulas enriched with 22:6n-3 and
20:4n-6 until three months of corrected age (day 35: 2O:3«-6: P<0.0l; 3 months: 20:3n-6:
P10.0001, 2O:5n-3: P<0.0l). The percentage levels of the parent EFAs. l8:2n-6 and l8:3n-3,
were also significantly lower in the LCP-cnrichcd formula-fed infants (day 35: l8:2n-6:
P<0.0l; 3 months: l8:2n-6: P<0.0001. 18:3n-3: P<0.001).
The inter-group differences found for the 22:6n-3 status were also reflected by the two
indices representing the functional 22:6n-3 status. Both at 35 days postnatal age and al three
months corrected age, CADI values were significantly lower (P<0.001 and P<().(XK)1) and
CASI values significantly higher (P<0.0001) in the group raised on LCP-enriched formulas.
8.4.3 Red blood cell phospholipids
Two RBC samples, both in the study group fed on the conventional formula, one at day
28 and one at day 35, were lost during fatty acid analysis.
Both absolute amounts and relative levels of 22:6w-3 and 20:4n-6 in RBC Pl.s decreased
after birth (figure 8.2.). The postnatal patterns of change for absolute amounts of 22:6n-3
and 20:4n-6 in the group fed on a conventional formula during the first 5 weeks of life
were not significantly different from those in the LCP-enriched formula group. However, al
three months of corrected age, the 22:6n-3 concentration was significantly higher (P<().00l)
in the RBC PLs of the infants that had received LCP-cnrichcd formulas.
Between birth and the 35th day of life, relative levels of both 22:6n-3 (days 28 and 35:
P<0.01) and 20:4n-6 (day 28: P<0.001; day 35: P<0.0001) declined significantly less in the
LCP-enriched formula group than in the conventional formula group. At the third month of
corrected postnatal age, these differences were even more pronounced (P<0.0001 for both).
Relative 22:6n-3 and 20:4n-6 levels in LCP-enriched formula fed infants were comparable to
those of preterm infants raised on human milk (table 8.3.).
Concentrations and relative levels of the other fatty acids studied are given in tables 8.6.
and 8.7., respectively. At three months of corrected age, values for Z n-6 LCP (% (wt/wt):
P<0.001) and Z «-3 LCP (mg/1: P<0.01; % (wt/wt) total fatty acids: P<0.0001) were signifi-
cantly higher in the infants raised on the LCP-enriched formulas than in the infants given the
conventional formulas. At the same time, values for the parent EFAs 18:2n-6 (mg/1: P^O.01;
% (wt/wt): P<0.0001) and 18:3n-3 (mg/1: P<0.001; % (wt/wt): P<0.001) and for 20:3n-6
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8 Table &4. Fatty acid composition of plasma phospbolipids (absolute values for conventional artificial formula (C-AF). LCP-enriched artificialformula (LCP-AF) and human milk (HM) groups)'.
Fttyaóf"
- * *
M i l FA
ZSAFA
Z M U T A
I W A
I »-9 FUf A
18:2,-6
2O:3n-6
2O:4n-6
1,-6 IO
l8:3n-3
20:5(1-3
22:6«i-3
L d - 3 u r
C-AF (B»15)
514(461-658)
247(213-313)
74 (63-94)
195(169-241)
19(10-2 7)
45 (38-58)
22(15-26)
96(82-105)
116(108-145)
ND
129(104-170)
19 3 (15.7-27.0)
22.3 (18.2-306)
diyO
LCP-AF (B=12>
476(441-531)
225(211-257)
76 (55-87)
182(161-200)
1 7 (0 9-3.9)
35 (32-42)
16 6(14 8-20.6)
94 (85-99)
119(105-123)
ND
1 I3(ND-1.2I)
18.5 (14.8-26.4)
20 7(17.1-29.1)
HM (0=9)
632(448-729)
288(204-341)
83(63-111)
220(175-282)
2.0(1.2-2.5)
54(45-69)
27(18-34)
97(75-124)
142 (99-164)
ND
1.12 (ND-2.06)
23(17-32)
27(20-36)
C-«,n=9)
968 (857-994)
403(3*3-131)
193(167-206)
344 (301 364)
2.5 (1.7-4.1)
205(184-217)
29 (25-32)
71 (51-80)
106(82-117)
ND
1.92 (1.45-2 49)
15 6(13 1-17 7)
21.4 (17.0-22.4)
<by 35
LCT *ƒ (n-12)
1068 (1004-1216)
461 (420-517)
209(201-234)
400(369-467)'
1 53 (1 04-2.82)
216 (202-248)
25 (22-30)
107 (94-130/
136(124-162)'
ND
2.42(2.14-2.82)
29 (25-33/
34.1 (29 6-37.5/
HM (Q=7)
1176(1068-1234)
528 (466-535)
171 (150-210)
448 (420-523)
2.07 (1.57-2.23)
262 (203-301)
42 (27-44)
97(93-111)
148(120-161)
ND
3.15(1.79-4.53)
35 (21-43)
44 (27-54)
3monti
C-AF (0=14)
969(921-1134)
442 (402-509)
175 (160-202)
356 (332-413)
2-56(1.81-3.69)
233 (220-276)
219(19.9-25.1)
58(45-65)
87 (71-97)
1.58(1.18-199)
1.72(1.56-188)
14.5(11.4-19.1)
21.6(17.4-26.2)
is concern) ige
LCT-AF (11=13)
1257(1060-1482)'
564 (475-683)'
203(182-245)
486 (394-561)'
2.01 (I 41-2.91)
247 (208-284)
20 1 (17.5-25.4)
132(113-159/
161 (136-189/
1.40 (ND-1.55)
1.81 (1 44-2.22)
60 (47-67/
66 (53-74/
f
f»
"•'As in table 8.1.
Statistical difference between control and LCP-enriched formula groups (two-tailed Mann-Whitney U test, except for 22:6n-3 and 20:4n-6, day 35:
repeated-measures analysis):
* 1 , 'K0.001,''lPS0.0001.
Table 8.5. Fatty acid composition of plasma phospholipids (relative values for conventional artificial formula (C-AF). LCP-enriched artificial
formula (LCP-AF) and human milk (HM) groups)'.
Fuiy «rid" <ky35
C-AF (II-13) UCT-AF (n>12) HM(n*9) C-AF ( 0 ^ ) UT-AF (*-12) IMW-7) C-AF (a-14) UT-AF (Ml3)
ISAFA
ÏMUFA
ZFUFA
I - . 9
IS2.I-6
18.W 3
»3«-J
22:6»-3
E*-3LCT
CADI
CAS
47 6(47.1-414)
143(13 1-15 1)
36 7 (36.2-390)
0 37 (0 22-044)
19 (7 5-9 «)
47 8(46.1-49.0)
15 3(12.5-17.7)
36 9 (34.9-40.3)
036 (020-075)
7 47 (7.09-8 5»)
47 5 (45.5-W.8)
147 (12.9-15.9)
37.2 (34.7-40»)
030 (022-040)
9 6(7.7-109)
ND
0 26(0174.30)
3 79 (3 36-4 50)
441 (3 M 5 20)
0*5(069-106)
7.1(60-100)
ND
0 21 (0 12-0.26)
362a9t~4 96>
3 9* (3 42-5 60)
107(0*0-1 17)
7 6(63-9-2)
ND
023 (0 17-0.36)
4 4 (3 7-5 2)
4 83 (4 28-5 9»)
0 8» (065-103)
90(78-120)
43 3 (41.7-440)
204(1(1-21 I)
36 1 (35.4-37 2)
0 2» (0 17-0 42)
22.3 (209-23 3)
»3it-6 3 79(3 45-417) 3.62(3 17-4 30) 4.1* (3 64-4*3) 3 23(2*2-3 47)
» 4 J I - 6 175(15.9-19 3) 194(169-211) 17.7(15.5-113) 743(567-790)
ÏK-6LCF 22 79(22.03-23.39) 24 7(220-26.0) 21.» (20.9-23.4) 10*4 (9 6*-ll 6»)
ND
0.20(0 15-0 27)
1.62 (14*- ISO)
2.14(191 2 32)
1.24(1 10-149)
5 11(4 36-6 30)
42 8(42.1-43 7)
19 1 (114-202)
37.5 (36.7-3* 5)
0 13(0 10-022)
20 5(19 1-209)'
2 36(2.25-2-711'
1047(9.22-11 10/
ND
0 24<OrWl26)
064<04t-OJ*r
452 (44 5-4*0)
H-2 (17 4-190)
359 (35.5-370)
029(0 19-0 J2)
24 I (23 5-24 1)
44 2 (43 7-44 5)
144(12.217 I)
391(3*1-42 4)
019(0 13-0 21)
22 ( (201-231)
307 (251-390)
13* (7 95-199)
1306(1143-13*» 14* (» 104 15)
ND 014(011-0-21)
026(024-0-2*) 0 1 * 0 1 6 - 0 1 9 )
291(177-331) 1*2(1 19-1*6)
3 75 O34-4 06) 241(1 *7266>
097 «1*71 4«> IJO (103-13*1
1066(475-1142)
462(44 7-47 4)
16 3 (15 7-169/
37 4 (36 «-3* I)
OI6(OM-O2lr'
l».47
(IIJ4.20iM/
2-» Q 09-150) I J * (144-1 67/
( I 0 J 0 4 - I 0 9 I /
1271
(12 07-12 90/
ND(ND-OI2C
0 14 «012-0 Wf*
445(4 06-4 79/
49* (444-5 39/
064 (0 53-073/
24* (195-275/
*^As in table 8.1. in addition: CADI= cervonk acid (22:6n-3) deficiency
: ia table 8.4.
CA9= cervonic sufficieticy (22:6n-
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Figure 8.2.: 22:6n-3 and 20:4n-6 values in red blood cell (RBC) phospholipids (PL). Median and interquartile
range expressed as nig/1 (/<•ƒ/) and as % (wt/wt) of total fatty acid methyl esters fn^/i/).
Number of infants, respectively, in conventional (—•—) and long-chain polyunsaturated fatty acid (LCP)-
enriched (—O—) artificial formula groups and in human milk group (--v--) at day 0: 15/12/9; day 7:
16/13/12; day 14: 16/14/12; day 21: 14/14/9; day 28: 11/13/7; day 35: 8/12/7; 3 months corrected age
(3mc): 14/14.
Statistical difference between conventional and LCP-enriched artiflcial formula groups (repeated measures
analysis, except for 3 months of corrected age: Mann Whitney U test):
*P<0.0l. "P<0.00l. *"P<0 000l.
Difference between LCP-enriched artificial formula group and human milk group (changes irom the values
at day 0):
*0 outside 95% confidence interval.
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Table 8.6. Fatty acid composition of red blood cell phospholipids (absolute values for conventional artificial formula (c-af). LCP-enriched artificial
formula (LCP-AF) and human milk (HM) groups)".
Filly add*'
mg/1
IOUI FA
XSAFA
I MUFA
I niFA
I 11-9 PUFA
18:2(1-6
2OV-6
20:4.-6
ÏH-6U7
18:.W3
20:5-3
226-3
I-3LCT
°^AS in table
CAF In. 15)
830 (668-989)
405(340-456)
130(124-193)
269 (208-329)
7 5 (5 4-90)
35 (26-45)
15.6 (12 7-192)
118(100-147)
169(138-211)
ND
O92(ND-I9O)
34.9(24 1-407)
400(27 2-468)
8.4
d»yO
LCTAF (H-12)
901 (595-1008)
429(301-482)
175(105-201)
289(189-321)
80 (4 29 8)
35 (24-43)
139(109-18 1)
145(83-162)
200(114-219)
ND
IOO(ND-I83)
33 (22-42)
40(23-48)
HM(n*9)
832 (728-1113)
393 (353-540)
166(122-213)
270(241-355)
7 0(54-113)
395 (34 8-47 8)
17.4 (14.7-22.4)
124(107-172)
175(152-242)
ND
I.I7CND-2J6)
333 (28.0-44.9)
37 6(31.8-54 1)
CAF (n=8)
735 (624-980)
322(266-419)
180(164-232)
225(193-313)
3.30 (2 60-4 70)
76 (60-98)
13.0(119-17 6)
76(68-109)
112(100-160)
ND
1 !4(ND-2 78)
186(14 1-23 8)
26 2(200-39 6)
diy35
LCF-AF (H-I2)
714 (665-872)
313(290-380)
171 (157227)
225 (201 283)
3.29 (2.57-3 70)
65(59-79)
110(100-126)
90(75-104)
123 (104-143)
ND
1 I3 0O-I.73)
2I .5( I». | .»J)
27 6(251-34 1)
HM(a»7)
1068(1029-10*5)
498 (4*7-502)
200(184-215)
350 (346-375)
3 55 (2 76-4 20)
I I I (107120)
20 3(13 7-213)
123(120-133)
171(1*1-191)
ND
3 1* (Z25-3 72)
327 OSJ-MJ)
4SJ (400-51J)
3.~»
C-AF(I-I4)
945(713-1178)
413(322-519)
227 (179-27»)
218(213-3*3)
4 14 (3 26-507)
101 (78-130)
15 6(10 8 16 7)
95(70-117)
144(105-17*)
ND(ND-IM)
I53 0O-1I5)
134(9 5-20*)
2*8(19 0-34»)
LCT AKB-IJI
957(744-1069)
433 (347-4*2)
231 (171-2*7)
297 (225-328)
190(1 I3-112P
802(3*9-8*5^
82 (60.103)»
116(88-132)
155(114-177)
IJOI (ND-I4I)
40 4 (32 5-4* Or*
470 CP 5-54 9 /
• " * - * * — •
O
Uil-*
2» 4»-6
I n * te»
22:6n-3
InJtC?
CAIM
CASI
18.6 (17 719 3)
32 7(310-334)
0J7 (060-1*9)
4.57 (3*0-5.16)
1.91 (I 69-2.34)
1501
(1424-1563)
21.2 (I9.Ï-22.3)
ND
Oil (ND-0.19)
4 23 (3.60-4 42)
4 73(3 99-5'!)
0 27 (0.22-0 30)
4 8 (3.9-6.0)
31.7 (31-0-33 1)
093(067-104)
3 «7 (3.48-4 48)
,79(153-2 23)
1561
(1509-1615)
21.5(20.4-22 4)
ND
3 74(3 42-4 16)
4.29(4.11-5 40)
() 24 (0.23-0 27)
54 (4.4^.2)
HM<n=9)
48 4(4*8-490)
19.2 (17 9198)
32.5 (31.6-34 5)
OK (0.72-1 03)
4 54 (4.28-5.09)
2 18 (1 74-247)
15*0
(1491-1573)
216(20 2-22 5)
ND
0 15 (0.10*24)
4 26 (3 63-4 86)
49* (4 32-5 46)
025 (021-0 31)
5.5 (4.8-* 6)
•
436 (42.5-44 3)
25 2 (23 9-267)
31 5 (299-312)
OJO (O 29-0 59)
101 (9 4-112)
190(172195)
1097
(9. W-11 28)
15 8 (14.4-16.4)
ND
0 18<ND-0 29)
2 51 (2.21-282)
3 55(3 13-404)
Oil (0.I7-O.24)
4 8 (4.1-5.8)
tc?-Af (m=12)
4} 3 (42.3-M.5)
23 9(23 1-259)
313 (3016-32.2)
041 (0.316-048)
909 («.33-9.4»/'
,53 (1.33-1 66/
12.07
dl.44-IZ.C6y'
16 56US.I9-17.26)
ND
0 15 (ND-0 27)
301 (2.7-7-3.24)'
3 85 (3.72-4.27)
0.l«(0.n-0.20)
6 74 (6 2ID-7.45)'
45 5 (45.3-i6-l)
,94(17 9-21 1)
34.0 (329-35O)
0.32 (O 26-0.40)
1077 (10 18-10.9»
183(147-2.08)
1162
(1126-1230)
16 3» (16 21-17 17)
ND
0.31 (021-034)
307 (2.46-3.42)
4 38 (4.14-4.88)
0.15(0.14-0.21)
6.87 (626-9.01)
44 1 (43.6-44 6)
25 5 (25.0-26.0)
30.2(29.5-31.4)
tt44 (0.36-0.55)
10.90(10.56-1130)
,44(133-160)
971
(9.37-1041)
14.89 (14 33-15.40)
010(ND-013)
O 16 (0.14-0.20)
164(138-203)
2.95 (2.61-345)
021 (O 18-025)
2.81 (2.11-3.16)
45 2 (44 1-466)
24 2 (23 5-247)'
305 (29.9-31 1)
021 (0.12-025/
847 (8 27-890/
092 (0.75-098/
12.22
(11.81-12.77/
16.40 (15 5816.64/
ND'
0.10 (ND-0 14)'
4.22 (4.07-4.48/
499 (4.76-5.17/
0.13 (0.100.14/
12.0(112-15.8/
0 0
••'As in table 8.5.
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2(mg/l: P<0.001; % (wt/wt): P<0.0001) and 2O:5n-3 (% (wt/wt): P<0.01) were significantly
lower in the LCP-enriched formula group.
The two indices calculated confirmed the observed inter-group differences in 22:6/1-3
status, with lower values for the CADI (3 months: P<0.0001) and higher values for the CASI
(day 35: P<0.001; 3 months: P50.0001) in the RBC PLs of infants receiving LCP-cnriched
formulas.
8.5 Discussion
The present study is, to our knowledge, the first to report on the effects of long-term
feeding of artificial formulas enriched with both 22:6n-3 and 20:4n-6. Its results show that
adding these two major LCPs to formulas in balanced ratios, i.e. amounts comparable to
those found in preterm human milk, successfully raises both the 22:6«-3 and 2O:4n-6 status
of preterm formula-fed infants to values found in plasma and RBC PLs of prelcrm infants
fed on human milk. Inter-group differences in the 22:6n-3 status were also reflected by the
two indices of the functional 22:6n-3 status, with lower CADI values and higher CASI values
in the infants raised on LCP-enriched formulas.
Results of three studies that evaluated the effects of short-term feeding of an H-3 and «-
6 LCP-enriched formula on the LCP status of prctcrm infants arc available for comparison. In
1989, Koletzko and co-workers (15] reported that 17 days (day 4-21) of feeding an artificial
formula containing 22:6n-3 and 20:4«-6 in levels half those present in human milk, resulted
in plasma lipid LCP levels that were higher than those of infants fed a conventional formula,
but were still substantially lower than those of infants raised on human milk. In a more
recent study by Clandinin and colleagues [16], preterm infants fed for four weeks (1-5
weeks) on an artificial formula which contained all n-3 and «-6 LCPs within the range char-
acteristic of human milk, had plasma PL-associated LCP concentrations similar to those of
infants fed human milk. LCP levels in RBC PC and phosphatidylcthanolamine (PE) were also
evaluated, but reported not to be affected by dietary LCP supply. Preliminary results from a
study by Carnielli and co-workers [25], in which the LCP-enriched formula contained 0.60
% (wt/wt) of 22:6n-3 and 0.75 % (wt/wt) of 20:4/i-6 (comparable to levels in human
colostrum), also indicated similar plasma PL LCP levels in LCP-enriched formula and human
milk-fed infants at four weeks of age.
Enhancing the dietary intake of the parent EFA of the n-3 series, 18:3/1-3, has been
suggested to be equally effective in increasing the n-3 LCP status as adding w-3 LCPs to
formulas. This view was based on the results of two short-term (4 to 5 weeks) feeding
trials, in which RBC 22:6n-3 levels of preterm infants consuming formulas containing >
2.0% of total fatty acids of 18:3n-3 were reported not to differ from those of infants fed on
human milk [39,40]. However, longer-term studies have quite clearly demonstrated that
even higher intakes of 18:3/i-3 (up to 4.8% (wt/wt) of total fatty acids, with a ratio of
18:2/i-6 to 18:3M-3 as low as 6.4), cannot prevent n-3 LCP declines in formula-fed preterm
infants [23,24]. The artificial formulas used in the present study were designed to contain
the parent EFAs in amounts present in human milk, resulting in a maximum 18:2/1-6/18:3/i-3
ratio of 13.0.
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Three months after the initially expected date of delivery, both the 22:6n-3 and 20:4/i-6
status were considerably higher in the plasma and RBC PLs of infants that had been fed on
artificial formulas enriched with these LCPs than in those that had received conventional
formulas. Unfortunately at this age, the values of the LCP-enriched formula group could not
be compared to those of the preterm infants fed on human milk, since the far majority of
these infants had to be excluded from further follow-up due to the limited amounts of
human milk they actually received. However, the plasma levels of 22:6/i-3 and 20:4n-6 in
our LCP-enriched formula group were similar to, and RBC levels somewhat lower than those
recently reported by Luukkaincn and co-workers [41] for 10 preterm infants which were
fully breast-fed until 6 months postnatal age. This strongly suggests that the 22:6/1-3 and
20:4/i-6 levels measured in the infants fed on LCP-enriched formulas are within their physio-
logical ranges. Carlson and co-workers [23], at approximately 3 months corrected age,
observed 22:6/i-3 values in plasma and RBC PC and PE of preterm infants fed on n-3 LCP-
enriched formulas which were only twice as high as those in infants fed conventional
formulas. The ratios of 18:2/1-6 to 18:3«-3 present in these conventional formulas, however,
were smaller (6.4-6.9 compared to 9.1-11.9), and the 18:3/1-3 contents higher (3.0-4.8
compared to 1.2-1.4 % (wt/wt) of total fatty acids) than those in ours, which may account
for the somewhat smaller inter-group differences than in the present study.
After 28 to 35 days of life, the 22:6«-3 and 20:4/i-6 status of the infants fed on a
preterm formula containing these LCPs in amounts typical for human milk was indeed
comparable to that of infants receiving actual human milk. However during the study
period, the total entcral intake of the human milk-fed population, on average, consisted for
only 89.3 % (vol/vol) of human milk, while the LCP-enriched formula group consumed
almost exclusively their particular study formula. This apparently higher efficiency of
human milk in maintaining certain LCP levels, when compared to the LCP-enriched artificial
formula, is possibly related to the presence of human milk bile salt-stimulated lipase, which
is not only known to be of major importance for overall triglyccridc digestion [42], but may
also play a particular role in the release of LCPs during this process [43,44].
In the present study, a diet-induced decrease of 20:4/i-6, which was reported after
supplying only additional «-3 LCPs [23,24], was not observed. Preliminary data by Carlson
and co-workers [45] indii ated that reducing the amount of 20:5/1-3 added to the formula
(0.06 in stead of 0.3 % (wt/wt) of total fatty acids) prevents this lowering of the 20:4/i-6
status. However, considering the presence of high levels of 20:4/i-6 in neural tissue and the
potential influence of this «-6 LCP on postnatal growth [26,27], raising the 20:4n-6 status of
formula-fed preterm infants to that of infants receiving human milk may be preferable. To
achieve this, adding preformed 20:4/i-6 to the formulas appears to be necessary.
The use of an LCP-enriched formula not only resulted in higher 22:6/?-3 and 20:4/i-6
values, but also in significantly lower blood levels of 18:2/i-6 in the supplemented formula
group, when compared to the infants fed the conventional formulas. This relatively short-
term effect was also found in other LCP-supplementation studies [16,25]. The decreased
18:2/i-6 values may reflect a competition between this parent EFA and the supplemented /?-3
and /i-6 LCPs for incorporation into blood PLs.
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Effects of enhancing the LCP content of artificial formulas were not only detected in
plasma, but also in RBC PLs. The assumption that changes observed in the fatty acid profile
of the RBC membrane reflect changes occurring in the fatty acid composition of the brain
[33,46], has been subject of debate [47]. However for 22:6n-3, recent studies demonstrated
that breast-fed infants have significantly higher levels of this major n-3 LCP in their cerebral
cortex lipids than formula-fed infants [9,48,49], and that these levels are significantly
related to those in RBCs (9). The findings of these studies are supplemented by those of (he
increasing number of studies that report significant influences of the dietary LCP supply, and
the resultant LCP status, on several parameters of brain and visual function [ 40,50-531.
However, all of these studies have focused solely on the dietary intake of n-3 LCPs. Further
studies in preterm infants are needed to evaluate the potential functional consequences of
enhancing the dietary 20:4n-6 intake, other than achieving better growth.
In conclusion, adding 22:6/>-3 and 20:4n-6 to artificial formulas in balanced ratios and
in amounts similar to those found in prcterm human milk, raises both the 22:6n-3 and
20:4H-6 status of formula-fed prcterm infants to values reported for human milk-fed preterm
infants. Additional studies arc necessary to evaluate the potentially favourable effects of
feeding formulas enriched with both n-3 and n-6 LCPs on the neurodcvclopmenial outcome
of preterm infants.
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General discussion
The studies described in this thesis focused on long-chain polyunsaturatcd fatty acid'
(LCP) levels in preterm infants. One of the factors which has contributed significantly to the
decreased mortality and morbidity of these vulnerable infants, is the increase in the know-
ledge of their particular nutritional needs for achieving optimal growth anil development.
These concern not only the supplies of fluid, amino acids, vitamins, minerals and energy, but
also that of specific, essential fatty acids (EFAS), which are necessary for maintaining par-
ticular body functions.
The KFAs of main importance for preterm infants are probably not so much the parent
EFAs, linoleic acid (18:2n-6) and a-linolenic acid (18:3/1-3), but rather (heir more desaturated
and elongated derivatives (LCPs). The major LCP of the n-3 series, docosahcxacnoic acid (also
named cervonic acid, 22:6n-3), and that of the n-6 scries, arachidonic acid (20:4/1-6), arc the
most abundant polyunsaturated fatty acids (PUFAs) present in human brain | l -3] and retina
[4J. These LCPs accumulate rapidly in neural tissue during the last trimester of gestation |5-7J,
a period associated with rapid cell division, formation of synapses and dendritic spines 18,9),
and development of the photoreceptor cells. In addition, 20:4n-6 is present in considerable
amounts in membrane phospholipids (PLs) throughout the body, and, like dihomo-y-linolcnic
acid (20:3n-6) and eicosapentaenoic acid (2O:5n-3), is a precursor of proslaglandins and other
eicosanoids that have important bioregulatory functions [10-13],
Unlike term infants, preterm infants undergo third trimester growth and development
extrauterinely, and arc deprived of the substantial accretion of fat, including n-6 and n-3 LCPs,
during late pregnancy. Hence, the postnatal dietary EFA supply to preterm infants will poten-
tially have to meet specific requirements, a topic which was addressed in Chapters 6 to 8.
Besides, it is of interest to know whether preterm birth is associated with a particular prenatal
EFA supply and whether this prenatal supply has certain consequences for postnatal LCP levels
in preterm infants. These subjects were studied in Chapters 2 to 4, and 7.
9.1 Main findings
9.1.1 Supply of long-chain polyunsaturated fatty acids during intrauterine life
Information on the prenatal EFA supply and the resultant fetal EFA status is almost always
gathered from EFA levels in materials (umbilical plasma, red blood cells (RBCs), or cord
vessel walls) that were collected (shortly) after delivery [14-20]. The potential of the EFA
profile of umbilical vessel walls as a tool for studying the EFA status during intrauterine life
'Polyunsarurated fatty acids with a chain length of 20 carbon atoms or more, and derived from
the parent essential fatty acids linoleic acid (18:2/i-6) and a-linolenic acid (18:3n-3) through alternate
desaturation and elongation.
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has been discovered only recently. Since human umbilical vessels have no va.ra vasorwm, and
human tissue cannot synthesize EFAS <te now, EFAS present in the umbilical vessel walls must
have been derived from the blood flowing through them. When combined with the relatively
slow turnover of vessel wall PLS, this renders the EFA composition of the umbilical vein wall
PLs likely to be a longer-term representation of the F.FA supply to the fetus [18]. Similarly, the
EFA profile of the umbilical artery wall PLs can be considered a longer-term reflection of the
EFA content of the return flow from the fetus to the mother. Although direct comparisons with
the EFA profiles of other fetal tissues are yet to be performed, the EFA content of the um-
bilical artery wall is, therefore, regarded as an indication of the fetal EFA status [17,18].
Studies that evaluated the EFA content of umbilical vessel walls of for the most part healthy,
full-term infants, born after an uncomplicated pregnancy have raised doubts as to whether the
prenatal supply of EFAS, including LCPs, adequately covers the fetal demands [17-19,21,22].
Lo/ig-cfaiin /w/yKH.ra/urafód/a/ry add 5/afus o/preferm in/antt a/ feirr/i
To extend on the observations in full-term infants, we reported, to our knowledge, the
first extensive data on the F.FA profiles of umbilical vessel walls of preterm infants in Chapter
2. When compared to cord vessel walls of term infants, the fatty acid profiles of preterm
umbilical arteries and veins were characterized by a lower /i-6 and n-3 LCP content and by
higher values for indicators of a general EFA shortage, 20:3n-9, and the EFA deficiency index
(^EFADl. 20:3n-9/20:4n-6). and for those of an isolated 22:6n-3 shortage, Osbond acid (22:5n-
6) and the cervonic acid deficiency index [CADI, 22:5n-6/adrenic acid (22:4n-6)]. In other
words, the biochemical FFA status of downstream preterm fetal tissue (indicated by the EFA
profile of the umbilical artery walls) is substantially lower than that of the term fetus, but the
EFA supply to the preterm fetus (reflected by the EFA contents of the umbilical vein wall) is
lower as well.
In accordance with the differences observed between the mean fatty acid values in pre-
term and term cords, the EFA content of umbilical vessel walls of preterm infants was found
to increase with advancing GA (Chapters 2 and 7), while values for EFA deficiency markers
decreased (Chapter 2). Potential relations between LCP profile and GA were also studied in the
PLs of plasma collected by fetal blood sampling during pregnancy (Chapter 3) or gathered
from the umbilical cord shortly after delivery (Chapter 7). As in studies by others [16,23], n-3
LCP levels were consistently found to increase with increasing GA. Plasma n-6 levels de-
creased with advancing gestation when the blood was collected by fetal blood sampling, but
in blood collected immediately after preterm birth no correlation with GA was found. In
studies by others, the plasma n-6 LCP content at birth has been found to increase [16] with
advancing GA, or, as in Chapter 7, no significant relation was observed [23,24]. The inconsis-
tent relation between n-6 LCP levels and GA could be explained the relatively short-term
(dietary) influences which are known to affect fatty acid levels in plasma PLs, but which are
less likely to influence the EFA profiles of umbilical vessel walls.
The increasing n-6 and n-3 values observed with advancing GA can be considered a
reflection of an adequate response (increased supply) to the increasing fetal demand for n-6
and n-3 LCPS, necessary for brain and body growth, during the last trimester of pregnancy. At
the same time, the decreasing values of EFA deficiency markers found in cord vessel walls
with advancing GA might suggest an increasing adequacy of the EFA supply towards term.
Olsen and co-workers [25] have argued that the increasing n-3 EFA levels seen with increas-
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ing pregnancy duration are the result of a higher maternal dietary /i-3 intake, which leads to
the prolonging of gestation through a down-regulation of the formation of dienoic prostaglan-
dins involved in the triggering of parturition. They considered the results of their intervention
study [26] as supportive of this hypothesis. However, in their recent prospective study of the
influence of the maternal n-3 LCP intake during pregnancy on gestation length |27|. no such
influence was observed. Moreover, preliminary data reported by Al and co-workers (28] show
that the maternal n-3 LCP status during pregnancies ending in prctcrm or term delivery and
during prolonged pregnancy (GA > 42 weeks) arc not significantly different. Umbilical cord
blood /i-3 LCP values of the infants born from these pregnancies, were again higher for term
than for preterm infants, with that of infants bom after u prolonged pregnancy being even
higher than that of term infants. In addition, as mentioned before, a significant positive
correlation between plasma n-3 levels and GA was also observed in samples obtained through
fetal blood sampling during pregnancy (Chapter 3). Furthermore, when comparing the l>A
profiles of fetal and postnatal umbilical plasma PLs, the KFA status of the prctcrm newborn
infant (postnatal umbilical plasma), if anything, is higher than that of the prctcrm fetus (fetal
plasma) at similar GAS (Chapter 3). This latter observation may be regarded the most convin-
cing argument in favour of the view that the lower EFA values of prctcrm infants arc a reflec-
tion of a physiologically lower demand for EFAs, necessary for growth and development, that
is associated with less advanced gestation.
Long-c/iain po/vM/tfafurafed /af/y acid 5/arwj o/ in/an/.y born u/ter a /MM//!/?/? j»r#n«/icv
Since the human fetus must derive the necessary KFAs from the maternal circulation, the
low EFA status reported for newborn infants in this thesis (Chapter 2) and by others 118,19,
21] could very well be caused by a limiting maternal KFA supply. To check the validity of
this view, the EFA profiles of the umbilical cord vessel walls of infants born after a multiple
or after a singleton pregnancy were compared (Chapter 4), assuming that the increased
accretion of fetal and placental tissues and the resultant higher total KFA demand associated
with a multiple pregnancy would result in an even lower infant EFA status.
Indeed, the EFA status of downstream fetal tissue during a multiple pregnancy appears to
be substantially lower than that during a singleton pregnancy, as indicated by the lower levels
of 18:2/i-6 and of the major LCPs 20:4n-6 and 22:6n-3, and the higher values for markers of
a general EFA shortage (2O:3n-9, its elongation product dihomo-Mcad acid (22:3/i-9), and the
EFADl) in the cord artery vessel walls of the former. The fatty acid pattern of the supplying
umbilical vein of infants born after a multiple pregnancy, when compared to that of infants
bom after a singleton pregnancy was characterized by lower levels of 18:2/1-6 and higher
values for markers of a general EFA deficiency and a specific shortage of 22:6/J-3 (22:5n-6,
and the CADI). The one other study reporting EFA data of a limited number (3 twins) of
infants born after a multiple pregnancy [29] observed a similar trend in umbilical plasma
cholesterol esters and triglycerides.
These differences observed between the EFA profiles of infants born after a singleton and
after a multiple pregnancy do not only support the hypothesis that the maternal EFA supply to
the fetus is limiting, but also indicate that the mother has difficulty coping with the KFA
demands of the developing and growing multiple fetuses. During a singleton pregnancy,
women would have to increase their daily dietary EFA intake by about 1.5 % of energy intake
to adequately cover the EFA demands of the fetus, which amount to about 400 and 50 mg/kg
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of body weight per day for «-6 and n-3 EFAs, respectively [30] as well as those of the ac-
creting placcntal and maternal tissues [31]. This increase is roughly similar to that recom-
mended to pregnant women by the Food and Nutrition Council [32] in the Netherlands, but
no specific guidelines have been formulated in case of a multiple pregnancy. Moreover,
results of a recent longitudinal study [20] of the maternal EFA status during and after an
uneventful singleton pregnancy, indicated that these pregnant women had already drawn on
their EFA stores to supply their fetuses with the necessary quantities of EFAs, 22:6n-3 in
particular.
All in all, the above-mentioned results warrant further studies of the need for supplying
women who carry more than one infant with additional n-3 and n-6 EFAs and LCPs. An
additional argument for extra supply is the fact that multiple pregnancies result in preterm
delivery more often than singleton pregnancies do [33). The combined effect of a lower EFA
and LCP status due to preterm birth ([16], Chapter 2), and as a result of multiple pregnancy
might seriously threaten the quality of the F.FA and LCP status of preterm twins and triplets.
/ «ƒ /?remjfa/ /wi/j-c/ia/Vi /w/yunsafura/«//affy ac/d jwpp/j on
The influence of the prenatal LCP supply on parameters of prenatal growth was studied by
evaluating relations between anthropometric parameters at birth (weight, head circumference
(HC), and length), and the LCP profiles of umbilical cord plasma (Chapter 7), RBC (Chapter 7),
and vessel wall (Chapters 2 and 7) PLs. Because both the growth parameters and the fatty
acid profiles arc known to be related to GA at birth, correlations were corrected for this
confounder by multiple regression analysis. Indeed, all significant correlations between fatty
acid levels and growth parameters were significantly influenced by GA.
No significant correlations were observed for any of the anthropometric parameters with
the LCP status measured in cord plasma or RBC PLs. Perhaps, the fact that LCP levels in
umbilical plasma and RBC PLS are relatively short-term indicators of the fetal LCP status,
renders their correlation with measures of a long-term process like fetal growth likely to be
less distinct. The fatty acid composition of the PLs of walls of the supplying umbilical vein
was also unrelated to any of the parameters of prenatal growth. This could indicate that
varying amounts of the supplied LCPs are used as 'building bricks" for structural growth. In
the arterial cord vessel walls, values for n-6 LCPs were found to be positively related to birth
weight (Chapter 2), and HC at birth (Chapter 7), while 22:6n-3 quite consistently correlated
positively with all three anthropometric parameters.
Others have also reported a positive relation of both n-3 and n-6 LCP levels at birth with
weight and HC at birth, namely in preterm cord plasma [23] and in term cord blood [17] and
umbilical vessel walls [17,34]. Kolctzko and Braun [24], however, argued that LCPs of the n-
6 series arc specifically related to tissue growth in u/ero, based on a positive relation between
birth weight and relative levels of 20:4n-6 and the sum of all n-6 LCPs they observed in
plasma triglyccrides of newborn preterm infants, and the absence of such a relation for n-3
LCPs. Crawford and co-workers [35] stressed the importance of the highly significant negative
correlations they observed for the EFAD1 and the CADI measured in the umbilical artery wall
with both weight and HC at birth. Also in contrast to the findings in Chapter 2, Felton and co-
workers [341 reported significant positive correlations with growth of n-6 and n-3 fatty acid
levels in both arterial and venous cord vessel walls. The most probable explanation for the
discrepancies between our results and those of others, is that the correlations observed in the
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latter were not always corrected for GA. Correction for this main confounder proved to he of
substantial influence on the relations observed in our study population: the significant cor-
relations for percentage levels of 20:4n-6 and the sum of all n-6 LCPs with birth weight and
with HC in Chapter 7 were completely attributable to GA at birth, while strong correlations
between prenatal growth and deficiency indicators as well as venous fatty acid levels were
completely attributable to GA at birth (Chapter 2).
In addition to the striking relation between prenatal growth and 22:6n-3 status that wat
observed in the studies of Chapters 2 and 7, the only significant difference observed between
the EFA profiles of the lightest and heaviest infants of the sets of twins or triplets studied
(Chapter 4), was the lower 22:6n-3 level in the umbilical vein wall of the lightest infants. In
contrast to 20:4n-6, which is present in considerable amounts in membrane PLS throughout
the human body, 22:6n-3 has a highly specific distribution, being present in high con-
centrations in brain, retina, spermatozoa and mitochondria [36|. Consequently, the explanation
for the seemingly important influence of 22:6n-3 on prenatal growth must perhaps be sought
in the high 22:6/1-3 concentration in milochondrial membrane PLs and its potential influence
on mitochondrial metabolic functions (37). In isolated liver mitochondria of KFA deficient
rats, partial uncoupling of the oxidalive phosphorylalion has been observed |38|. This un-
coupling will result in a decreased efficiency of the conservation of the energy available from
the oxidation of dietary substrates.
9.1.2 Postnatal long-chain polyunsaturated fatty acid status of pretcrm infants
The two enteral dietary EFA sources available for newborn infants arc human milk, which
contains small but significant amounts of 22:6n-3, 20:4n-6 and other LCPs, or commercially
available artificial formulas, the majority of which did not contain any but trace amounts of
LCPs when the studies described in this thesis were initiated [39-41). The presence of the
parent EFAS 18:2n-6 and 18:3«-3 in these formulas will possibly not fully compensate for the
absence of LCPs, considering the limited desaturase capacity of prcterm newborns [42,43],
The findings that pretcrm infants have very limited fatty acid stores [30,42,44) and arc born
with a lower EFA status than infants carried to term (116], Chapter 2) will potentially provide
an additional challenge to their postnatal LCP status.
Indeed, when the postnatal LCP status of preterm infants fed on conventional artificial
formulas was compared with that of pretcrm infants raised on their own mother's milk during
the first four weeks of life (Chapter 6), a number of significant differences were observed.
After 21 to 28 days of postnatal life, absolute (mg/1) and relative (% (wt/wt) of total fatty
acid methyl esters) 22:6n-3 values and the absolute amount of 20:4n-6 had become substan-
tially and significantly lower in the plasma PLs of the formula-fed infants. Effects on the
22:6/1-3 status were supported by the changes in the sum of all n-3 LCPs and by a higher
value for the marker of an isolated 22:6n-3 deficiency, the CADI, in the formula-fed infants.
In RBC PLs, the postnatal decreases of 22:6n-3 and 20:4/i-6 in the formula-fed pretcrm infants
were approximately twice those in the human milk-fed group, but like in other recent short-
term studies [45,46], these inter-group differences did not reach significance. The slower
turnover rate of RBC PLs than of plasma PLs may have contributed to the less apparent nutriti-
onal effects on this tissue over a relatively short period of time.
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The results described in Chapter 6, as well as those of other studies [45-48], provided a
strong indication that the conventional artificial formulas that contain the parent EFAS but lack
their longer-chain derivatives, are unable to maintain the postnatal biochemical LCP status of
prctcrm infants at levels that can be obtained when feeding with preterm human milk. There-
fore, a long-term study (until three months of corrected age, that is three months after the
initially expected date of delivery) on the consequences of feeding preterm infants on preterm
formulas, containing both 22:6/i-3 and 20:4n-6 in amounts typical for preterm human milk,
was initiated (Chapter 8). The usefulness of this approach was supported by the results of the
first short-term studies on the effects of increasing the dietary intake of preterm infants of /i-3
LCPs [47,49) or both n-3 and n-6 LCPs [48].
After four weeks of postnatal life, the plasma PL 22:6/i-3 and 20:4/j-6 contents in preterm
infants fed on the LCP-enrichcd preterm formula were significantly higher than those in
infants which had received a conventional formula, and were comparable to those of preterm
infants raised on their own mother's milk. These differences between the two formula-fed
populations continued to increase, resulting in average 22:6/i-3 and 20:4/i-6 values that were
up to four and two times higher, respectively, in the LCP-enriched formula group than in the
conventional formula group at three months of corrected age. In RBC PLs, differences between
the two formula-led groups reach significance as early as after 28 days of life only for
relative (weight %) levels of 22:6n-3 and 20:4/i-6. These were again higher, and comparable
to those of human milk-fed infants, in the group raised on an LCP-enriched formula. Three
months after the expected date of delivery, these inter-group differences were even more
pronounced and also significant for the absolute (mg/1) 22:6/i-3 amount. Both in plasma and
RBC PLs, inter-group differences found for the 22:6n-3 status were also reflected by the two
indices of the functional 22:6/i-3 status: CADI values were significantly lower in the infants
raised on LCP-enrichcd formulas, while values the cervonic acid sufficiency index (CASI,
22:6/1-3/22:5/1-6) [50] were significantly higher.
The results of this study, supported by those of two short-term (up to four weeks) studies
[46,48], show that feeding preterm infants with artificial formulas enriched with both 22:6n-3
and 2():4n-6 in balanced ratios and in amounts approximating those found in preterm human
milk, is a successful approach to raising both the 22:6/i-3 and 20:4/i-6 status of preterm
formula-fed infants to values found in plasma and RBC PLs of preterm infants fed on human
milk. A diet-induced decrease of 20:4/i-6, as reported after supplying only additional /i-3 LCPs
[45,50], was not observed.
Another main finding of the studies described in Chapters 6 and 8 was that the changes
with time after birth were strikingly different when fatty acid values were expressed as
absolute amounts or concentrations (mg/1 plasma) or as relative levels (% (wt/wt) total fatty
acid methyl esters). Details of these differences, as well as the advantages and disadvantages
of each form of expression and the specific information they may yield, are discussed in the
section on methodological considerations of this general discussion.
/ii/7iM7i<r «ƒ />rcfujfri/ /<>«#-<7I«I/I po/vun&irur<ir?<//afrv acid supp/v
All in all, the substantial influence of the postnatal LCP supply on the biochemical post-
natal LCP status of preterm infants is quite well established. However, to what extent postnatal
LCP levels arc also affected by the intrauterine LCP supply has hardly been studied. Prelimi-
nary data by Leaf and co-workers [51] did reveal a positive correlation between plasma LCP
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levels at birth (reflecting the prenatal LCP status) and those at term postconccptional age (40
wks GA). The relation was reportedly independent of the type of postnatal diet, and as such
was considered to indicate that the inlrautcrine experience of the fetus may set the pattern for
postnatal LCP levels [52]. This observation may be of particular relevance, considering the
widely divergent LCP levels with which infants arc bom (|16) Chapters 2. 4 and 6). There-
fore, it gave rise to the study in Chapter 7, in which the nature of the relation between the
LCP status at birth and that in the term period (37-42 wks GA) in a group of prctcrm infants
was explored more extensively by studying LCP levels in plasma, RBCs, as well as umbilical
artery walls.
In this study, the postnatal diet was the only significant determinant of absolute and
relative plasma levels of 22:6/i-3 and relative plasma levels of 20:4n-6 at term postconccp-
tional age, with lower postnatal levels in the infants raised on formula than in those fed their
own mother's milk. The absolute 20:4n-6 amount in plasma PLS at birth was the only ex-
planatory variable (positive correlation) for the absolute 20:4n-6 amount at term. The 22:6n-3
and 20:4n-6 contents of the walls of the umbilical arteries of the prclcrm infants were positi-
vely related to the 22:6/i-3 and 20:4n-6 contents of RBC PLs collected at the time when these
infants were expected to be born. These results quite clearly demonstrate that (he biochemical
LCP status at term is determined, not only by the postnatal diet, hut also by the l.ci' status at
birth, with higher LCP levels at birth resulting in higher postnatal levels. This finding stresses
the significance of an appropriate prenatal LCP supply (a major determinant of the Lev status
at birth), particularly for infants who are born preterm, or after a multiple pregnancy, or both.
Since the only potential way to achieve a change in this prenatal LCP supply is through an
adaptation of the fatty acid content of the maternal diet during pregnancy, these results may
warrant further studies of the effects of EFA-enriched maternal diets during pregnancy on the
infant LCP status at birth. Such studies should also include an evaluation of the functional and
clinical consequences of such an intervention, a subject which will be addressed more exten-
sively later in this general discussion.
9.2 Methodological considerations
9.2.1 Is Mead acid a deficiency indicator in umbilical vessel walls?
When the infant EFA status at birth was studied in Chapters 2 (preterm compared with
full-term infants) and 4 (infants of multiple and of singleton pregnancies), KFA profiles of the
umbilical vessel walls were focused on, for they are considered to give a longer-term reflec-
tion of intrauierine EFA levels than those of umbilical plasma or RBCs [17,18]. Apart from the
EFA content, values for EFA deficiency indicating fatty acids, such as 20:3/i-9, were compared.
However, these EFA deficiency indicating fatty acids are regarded as such based on biochem-
ical reactions in adult material, which leaves room for debate about the applicability of these
deficiency indicators to fetal cells and tissues.
In this respect, Sanders and Reddy (53] have postulated that the presence of 20:3n-9 in
cord artery walls may not reflect an EFA deficiency, but rather a high activity of the conver-
sion system (overactive A6-desaturase) in the arterial wall, resulting in the formation of
20:3n-9 even in the presence of adequate EFA levels. Yet, the information presently available
on fetal fatty acid biochemistry indicates that the desaturase activity in fetal liver microsomes
is low [43], and that in (fetal) placental tissue is low [54] or even not detectable [43,55], In
addition, the higher 20:3/i-9 content of preterm than of full-term cord vessels (Chapter 2)
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would indicate a decreasing activity of the fatty acid desaturation system during progressing
pregnancy. However, microsomal synthesis of LCPs was shown to increase with advancing GA
in piglet liver and brain [56], Moreover, in case of a highly active desaturase system, the
conversion of oleic acid (18:ln-9) to 20:3n-9 would be accompanied by an even higher
conversion of the preferred desaturase substrates 18:2n-6 and 18:3n-3, leading to a positive
relation between H-9 and n-6 or n-3 LCPs. Nevertheless, when relating cord levels of 20:3n-9
to those of 20:4n-6 (the major n-6 LCP), significant negaf/ve correlations between these two
fatty acids were observed both in our preterm and in our full-term study populations (Chapter
2). Finally, the higher 20:3n-9 content, combined with a lower EFA content, of cord arterial
vessel walls of infants born after a multiple pregnancy, when compared to those born after a
singleton pregnancy, support the validity of 20:3n-9 as an indicator of EFA deficiency, rather
than of desaturase activity.
Another explanation given for the high cord artery vessel wall levels of 20:3n-9 and other
EFA deficiency indicating fatty acids is that these vessel walls serve as a dustbin for the infant
to store unnecessary fatty acids. If this is the case, the 20:3n-9, 22:n-9, and 22:5«-6 contents
of umbilical vessel walls would be expected to increase with advancing GA. However, values
of these fatty acids were found to be stable (umbilical artery walls) or to even decrease
(umbilical vein wall) with increasing pregnancy duration (Chapter 2).
All in all, the information currently available from studies described in this thesis or from
the literature docs not refute the supposition that fatty acids that are established F.FA deficien-
cy indicators in adult tissues, can also be used as such in fetal or infants tissues. However,
additional studies that provide more information on fetal and infant fatty acid biochemistry
are necessary to indisputably establish whether this assumption is justified.
9.2.2 Comparability of fatty acid profiles of venous and capillary plasma and red
blood cell phospholipids
In the studies of dietary influences on the LCP status of preterm infants in plasma and RBC
PLS (Chapters 6 and 8), the necessary blood samples were collected in connection with
diagnostic punctures. As a result, the longitudinal sample sets consisted of blood samples of
venous or capillary origin in a random order. To ensure that such a set of blood samples
would provide reliable information on dietary influences, the comparability of the fatty acid
profiles of venous and capillary plasma and RBC PLS was studied, for ethical reasons, in eight
healthy adult volunteers (Chapter 5).
Fatty acid profiles of venous and capillary plasma PLS were found to be comparable,
which directly enabled an accurate evaluation of dietary influences in this substance, without
imposing the burden of extra blood punctures on the participating infants. The comparability
of the fatty acid profiles of venous and capillary RBC PLS was good when lipids were extrac-
ted within one week after blood collection. However, when the RBCs were stored for four
weeks at -20 °C, considerable differences were observed that resulted from substantial fatty
acid losses in the capillary samples. These losses mainly concerned the PUFAS, the concentra-
tion of which decreased to some 10% of the initial value, and the highly unsaturated LCPs in
particular.
This loss of PL-associated PUFAs from RBCs as a consequence of storage at temperatures
below 0 °C has also been reported by others [57-59], with autoxidation of PUFAS as the
obvious major cause, since the process of lipid peroxidation, both in the initiation and propa-
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gation stages, uses iron, which is largely present in haemoglobin, as a catalyst [60-641 In
Chapter 5, the multiple significant fatty acid losses were observed in the capillary', rather than
in the venous RBC samples. This could be the result of more extensive loss of membrane
integrity caused by the considerable manual pressure by which the blood is driven into a tube
during a capillary blood collection. This RBC membrane damage may enhance RBC suscep-
tibility for lipid peroxidation through the release of otherwise sequestered iron, which thus
becomes available for the radical reactions involved in autoxidation [64|. Besides, the struc-
tural insulation that proteins give to autoxidisable lipids [65] as well as the protective struc-
tural organization of the lipids themselves [66] are disturbed.
In any event, to obtain reliable information on dietary influences on the fatty acid profile
of RBCs attempts ought to be made to prevent the PUFA losses observed in this tissue. One
potential strategy is storage of RBC suspensions at very low temperatures, e.g. at -50°C or
even -80°C, but this appeared only to delay and not to prevent lipid loss (unpublished obser-
vation). Another option is removing the oxidation-promoting haemoglobin from (he RIK' lipids
by preparing red cell ghosts or lipid extracts from the RBCS within one week after blood
sampling. If all steps of the analyses arc to be simultaneous for a scries of consecutive RBC
samples, autoxidation may be prevented by handling and storing the RHC samples in the
presence of an iron-binding chclating agent, preferably desfemoxamine [67], which has been
demonstrated to effectively prevent or at least reduce lipid pcroxidalion in various in w'fro
and />» w'wo studies [67-70]. That desfcrrioxaminc is also effective in preventing lipid loss
from RBC samples stored for longer periods at temperatures below 0 °C, as will be the case in
many dietary studies, is illustrated by figure 9.1. It shows the preliminary results of a study
initiated by that of Chapter 5, in which 0.25 mg of desfcrrioxamine per ml RBC suspension
was added to RBCS stored for up to 4 months, and clearly demonstrates the protective effect
of this addition on lipid loss.
9.2.3 Information obtained from absolute and relative fatty acid values
In all but one of the studies presented in this thesis, the fatty acid content was expressed
as absolute amounts or concentrations (mg/1 plasma or RBC suspension, or mg per g of dry
weight tissue), next to or instead of relative levels (% (wt/wt) total fatty acid methyl esters).
The impression obtained from these absolute data was sometimes quite different from that
obtained from relative values.
In Chapters 6 and 8, absolute LCP amounts in plasma F-Ls of preterm infants showed an
initial increase during the first week of life, followed by a gradual decline (conventional
formula) or stabilization (human milk or LCP-enrichcd formula) during the following weeks,
while percentage values declined steadily from the first day of life onward. These different
patterns resulted from a considerable increase in the total amount of PL-associated fatty acids
in plasma. In RBC PLs, the total amount of fatty acids present did not change markedly and,
consequently, the postnatal changes in absolute and relative LCP values were more or less
similar. In Chapter 5, absolute amounts of PUFAS, but also of saturated fatty acids (SAFAS) and
monounsaturated fatty acids (MUFAS) were shown to decrease in capillary RBCs stored for
four weeks. Due to a 50% reduction of the total amount of PL-associated fatty acids, which
was mainly caused by the decrease in PUFAS, relative levels of SAFA and MUFA were increas-
ed in stead of decreased. This would suggest a shift in the fatty acid profile of the RBCs,
rather than a loss of all types of fatty acids, which is what really happened. So when pool
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Figure 9.1. Protection against lipid loss from the phospholipid (PL) fraction of stored capillary red blood
cells (RiK's) by the addition of 0.25 mg desferrioxamine per ml RBC suspension.
Storage timc= time between blood collection and extraction of total lipids; SAFA= saturated fatty acids,
MUFA= monounsaturated fatty acids, PUFA= polyunsaturated fatty acids.
sizes change markedly over time, or when pools sizes are different, as is the case in com-
parisons between maternal and fetal blood (Chapter 3, [52]), absolute fatty acid data provide
information, that is at least additional to, but sometimes even more adequate than that ob-
tained from relative values. Absolute LCP amounts also seem to correlate better with parame-
ters of prenatal growth, than relative levels (Chapters 2 and 7).
The particular importance of relative fatty acid levels is evident, when considering that,
with fatty acid reactions occurring in a lipid environment, it is the amount of a given fatty
acid relative to that of the others that determines the rate of these reactions. Besides, the
measurement error of the analytical procedure is usually smaller when calculating relative
values, as is illustrated by the inter-group differences for RBC LCP levels in Chapter 8, which
reached significance for relative data earlier than for absolute data.
So, ideally, both absolute and relative fatty acid data should be reported. However, when
comparing absolute amounts of PL-associated LCP levels in plasma reported in Chapters 6 and
8 to those reported by others [45,46,71,72], considerable differences (up to a factor ten) are
observed, even when relative levels are comparable. Although these discrepancies may be
caused by varying study designs and population characteristics, they could also result from
methodological differences. For example, the addition of the internal standard (the amount of
which absolute amounts of the other fatty acids are based on) not at the start of the fatty acid
analysis (lipid extraction) but at some point in time thereafter, will result in artefactually
lower absolute values for the fatty acids present, because fatty acid losses during the pre-
ceding steps of the analysis arc not accounted for. On the other hand, an overestimation of
actual fatty acid amounts could be the result when the lipid fraction studied (e.£ PLS) is not
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separated to near homogeneity, hut contaminated with other fractions (rj? triglyccrides and
cholesteryl esters). All in all, analytic procedures need to he standardized to enable a better
comparability of absolute data from various research groups.
9.2.4 Blood LCP status as a reflection of neural tissue I.CP status?
When studying the effects of the LCP supply on the fetal or infant 22:6n-3 and 20:4n-6
status, the actual tissue of interest is neural tissue, especially that of the brain and retina.
Blood LCP levels have been adopted as an alternative to the direct measurement of the t.CP
composition of these target organs in living human infants. In this respect, changes in plasma
fatty acid levels are regarded to reflect the dietary LCP supply, while those in RHC membrane
were considered to reflect changes occurring in the fatty acid composition of the brain. Until
recently, this latter assumption was based on direct correlations of brain and RBC lipid fatty
acid distribution found in animal studies in rats (73) and rhesus monkeys [74], and its validity
has been subject of debate (75]. However, recent studies demonstrated that breast-fed infants
have significantly higher levels of 22:6/i-3 in their cerebral cortex lipids than formula-fed
infants (76-78), and that 22:6n-3 levels in RBC and cortex arc even significantly related |78).
The findings of these studies are supplemented by those of the increasing number of studies
that report significant influences of the dietary n-3 LCP supply, anil the resultant ;i-3 LCP
status measured in blood lipids, on several parameters of brain and visual function [79-82],
which will be considered in more detail later in this discussion.
9.3 Supplementation of essential fatty acids, the longer-chain deriva-
tives in particular, during pre- and postnatal life
The majority of the studies described in this thesis evaluated the LCP status of especially
preterm infants, and to what extent this is influenced by the prc- and postnatal I-:FA supplies
under the prevailing dietary conditions for pregnant women (Chapters 2 to 4, and 7), and for
newborn infants (Chapters 6 and 7), respectively. The results from these studies, combined
with those of studies by others, indicate that the KFA supplies resulting from the current diets
do not lead to an optimal fetal and infant LCP status, and that supplementation of n-6 and n-3
LCPs to both the maternal and the infant diets may be beneficial.
9.3.1 Supplementation during prenatal life
The results in Chapter 2 showed that the EFA status at birth of preterm infants is signifi-
cantly lower than that of infants carried to term. In addition, the MA status at birth of infants
born after a multiple pregnancy is significantly lower than that of infants born after a single-
ton pregnancy of equal duration (Chapter 4). The results of the study described in Chapter 3
indicated that this impression of the fetal EFA status given by the Kf-'A profile of material
collected shortly after delivery is fairly reliable, since it is reasonably consistent with that
given more directly by fetal blood.
As stated earlier, the lower preterm EFA values probably arc a reflection of a physio-
logically lower demand for LCPs, necessary for brain and body growth and development, of
the preterm fetus when compared to the term fetus. Yet, this lower LCP status at birth will
result in a lower postnatal LCP status (Chapter 7). Preterm infants are bom during the period
of most rapid brain growth, which is associated with a high demand for EFAs and the LCPs in
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particular. As a result, these infants are deprived too early from their intrauterine source of
LCPs, which, based on the results in Chapter 7, may be more adequate than the dietary
exlrautcnnc supply. First, however, it is of interest to discuss why the EFA status of healthy,
term infants, bom after an uneventful pregnancy, which is widely considered to represent the
'normal' situation, may not be an optimal one. As mentioned earlier in this chapter, this dis-
cussion was initiated by the discovery of relatively high 20:3n-9 levels in the umbilical
(artery) vessel walls of these infants, and the information currently available indicates that
this and other established KFA deficiency indicators in adult 'issues, can also be used as such
in fetal or infant tissues.
A number of years ago, a study on the composition of the diet of our paleolithic ancestors
and its potential effects on current diet-related health problems was published [83]. It descri-
bes how alterations in the human genetic constitution have been relatively small over the last
4(),(KM) years, while the dietary patterns have changed substantially in the last millennia as a
result of the many developments in food production and processing. The transition from a
huntcr-gathcrcr society to an agricultural society, was associated with an increased intake of
SAFAs through the currently high consumption of edible fats and diary products [84], which
were lacking from the paleolithic diet, and a reduced dietary intake of n-6 and n-3 LCPs,
which arc present in larger amounts in wild animals than in domestic livestock [83,85].
Indeed, the major HHA present in the diet of pregnant women participating in a study [86] that
was conducted in the same period, region, and hospitals as the studies reported in this thesis,
was 18:2/1-6 (> 80% of the total PUFA intake). To obtain information on the intake of other
EFAs, duplicate food portions were collected by a subset of 48 women during four days in the
second trimester of pregnancy. Fatty acid analysis of these food portions revealed that the
mean daily intakes of the major LCPs 20:4n-6 and 22:6n-3 were 0.13 and 0.01 % of the total
daily fatty acid intake, respectively (R.P. Mcnsink, unpublished data). These preliminary
results tire in agreement with the combined 20:4/i-6 and 22:6/i-3 intake of less than one
percent of the total dietary fat intake, which was reported for British pregnant women [17].
Thus, it is conceivable that the combination of a developing human body and brain, which
arc genetically still adjusted to a relatively high PUFA and LCP supply, and a maternal diet
which has meanwhile evolved to contain less of these fatty acids, leads to a relative EFA
deficiency, accompanied by the presence of EFA-deficiency indicators, during apparently
normal pregnancies.
Based on the data discussed above, an increase of the prenatal supply of EFAS, and LCPS
in particular, may have potential beneficial effects on the fetal and (newborn) infant LCP
status. Of course, the only way to achieve this is through a maternal dietary intervention. The
highly significant positive correlations observed at delivery between EFA values in umbilical
and maternal venous plasma PLs [19,20] support the potential effectiveness of such an inter-
vention. Moreover, the intake of increased amounts of 18:2n-6 [87] and n-3 LCPs [88,89] was
reported to result in a. respectively, higher «-6 and n-3 LCP status of the newborn infant.
However, the increase in LCP levels of the n-6 series was accompanied by a decrease in n-3
LCPs [87] and vice versa [89]. Since both n-6 and n-3 arc of importance for proper body
function, growth, and development (which will be discussed in more detail later in this
section), these additional decreases should be considered undesirable. Consequently, EFAs of
both series should be supplemented in balanced ratios. Yet. controlled clinical intervention
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studies are indispensable to the determination of the optimal ratio and content of n-6 and n-3
EFAS in the maternal diet during or even before pregnancy.
9-3.2 Supplementation during postnatal life
Clearly, conventional artificial formulas, which lack LCPs, are unable to maintain (he
postnatal LCP status of preterm infants al levels obtained after feeding on prctcrm human milk
([45-48], Chapter 6). Consequently, to establish al least comparable 22:6n-3 and 2():4/»-6
blood levels in formula and human milk-fed preterm infants, alterations to the KFA com-
position of the formulas arc in order. A number of strategies are available (o achieve this
goal.
Many of the conventional artificial formulas do not only lack LCPs, but also contain levels
of 18:2/1-6 that are extremely high when compared to those of the other parent I-:I-A !8:3n-3,
with the ratio of 18:2/i-6 to 18:3n-3 reaching 50:1 (Chapter 6). Basically, the substrate
affinity of A6-desaturase, which is the limiting enzyme for the rate of synthesis of I.CPS from
their parent EFAS 190] is higher for 18:3n-3 than for 18:2/i-6 |911 However in these formulas,
the 18:2n-6 content is that much higher than the 18:3n-3 content, that the tonner displaces
the latter from the enzyme sites, which results in a decreased n-3 LCP synthesis. Therefore,
some researchers have tried to increase the n-3 LCP status of preterm infants by enhancing the
dietary intake of 18:3n-3 in short-term (4 to 5 wks) feeding trials [79,92). In these studies,
RBC 22:6n-3 levels of preterm infants consuming formulas containing > 2.0% of total fatty
acids as 18:3n-3 were apparently similar to those of infants fed on human milk. Nevertheless,
longer-term studies demonstrated quite clearly that even higher intakes of 18:3/1-3 (up to
4.8% of total fatty acids, with a ratio of 18:2n-6 to l8:3n-3 as low as 6.4), cannot prevent /t-3
LCP declines in formula-fed preterm infants [45,50], indicating that the biosynthesis of «-3
LCPs cannot meet the n-3 LCP demand.
Another approach used is the addition of marine oils to the diet of preterm infants, which
increases only their n-3 LCP intake [45,47,49,50], However, besides the desired enhancement
of 22:6/i-3 levels, this type of intervention also resulted in decreased 20:4n-6 levels [45,50].
Reducing the amount of 2O:5n-3 added to the formula e.g. from 0.3 % to 0.06 % of total
fatty acids, may prevent this diet-induced lowering of the 20:4n-6 status [93]. Yet, in view of
the presence of high levels of 20:4n-6 in neural tissue and the influence of this n-6 LCP on
postnatal growth [94], raising the 20:4n-6 status of formula-fed preterm infants to that of
infants receiving human milk may be preferable.
The third possible strategy is the addition of both n-6 and n-3 LCPs to the prctcrm infant
formulas, as was done in the long-term study described in Chapter 8. In accordance with (he
findings of two short-term studies [46,48], this approach successfully raised both the 22:6n-3
and 20:4n-6 status. Three months after the initially expected date of delivery, the LCP status
of the LCP-formula group could not be compared to that of preterm infants raised on their
own mother's milk, as most of these did not receive enough human milk any more by that
time. However, the considerably higher values for 22:6n-3 and 20:4n-6 in the LCP-cnriched
formula group, when compared to infants fed on conventional formulas, appear to be within
their physiological ranges, since they were similar to (plasma) or somewhat lower than (RBCs)
those recently reported by Luukkainen and co-workers [95] for 10 preterm infants which were
fully breast-fed until 6 months postnatal age. In addition, in two long-term studies in which
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only n-3 LCPs were supplemented [45,50], differences between the 22:6n-3 status of the two
formula-fed study groups similar to those in Chapter 8 were reported.
However, levels of two other important LCPs which were not added, 20:3n-6 and 2O:5n-3,
were significantly lower in the supplemented formula group than in the infants fed the
conventional formulas, even at 35 days postnatal age. At the same time, 20:3n-6 and 20:5n-3
values in infants receiving human milk, were at least comparable, but usually higher than
those in the conventional formula group. Clandinin and co-workers [46], who studied an LCP-
enriched formula containing all LCPs at levels typical for human milk, did not observe a
decreased 2O:5n-3 concentration (20:3n-6 was not reported separately) in the infants receiving
this formula. In view of the potentially important physiological function, particularly of
20:3n-6, as a precursor of prostaglandins and other eicosanoids, studies of further 'fine-
tuning' of the LCP content of LCP-cnrichcd artificial formulas may be in order, for example by
copying the entire LCP profile of preterm human milk. However, whether human milk is able
to maintain an optimal LCP status in preterm infants, during a period of (brain) growth and
development that actually ought to have been spent in utero, is open to debate. In Chapters 6
and 8, relative 22:6n-3 and 20:4n-6 levels decreased significantly after birth, which resulted
in values sometimes well below those measured in cord blood of infants bom after normal
lull-term pregnancy [19], also in human milk-fed infants.
9.3.3 Influence of long-chain polyunsaturated fatty acid status on functional and
anthropometric parameters
Initially, studies of the effects of various dietary LCP supplies on preterm human infants
had biochemical end-points, usually blood LCP levels that were used as a reflection of the LCP
status elsewhere in the body, particularly in the neural target organs. Faced with significant
differences in infant LCP status resulting from the various diets, researchers then sought to
evaluate the influence of the differences in LCP supply and status on infant development by
adding clinical and functional outcomes to the biochemical data.
/uncf/on
So far, functional studies in preterm infants have focused on the influence of the supply
of n-3 KFAs, and have mainly and most thoroughly evaluated dietary effects on early visual
function [79-82], This preference for studying the visual system can be considered logical for
a number of reasons. Firstly, within the human body, amounts of the major n-3 LCP, 22:6n-3,
are particularly high in the retina (60% of total fatty acids in photoreceptor outer segment
membranes [96]) and the brain (grey matter of the cerebral cortex). Secondly, the retina,
particularly the fovca, and the primary visual cortex of the cerebrum are relatively immature
at birth, and undergo substantial development, including active synaptogenesis, thereafter [97-
100]; this renders these tissues and their function particularly vulnerable to nutritional mani-
pulation, especially in preterm infants. Thirdly, effects of the dietary n-3 EFA supply on visual
function had already been demonstrated in several animal studies [101-105].
The two measures of visual function used in preterm human infants are the electroretino-
gram (KRG) and visual acuity. The KRG is an electrophysiologic response of the retina to light,
and provides a non-invasive measure of retinal function. The a-wave of the ERG provides
information on photoreceptor function [106]. while the b-wave originates from the inner
retinal neurons that arc activated by the input from the photoreceptors. Responses generated
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by the rods (photoreceptors responsible for night vision) can be differentiated from those
arising from the cones (daylight and colour vision, and high visual acuity) Performance on
ERG is quantified by a number of parameters that are either measured directly or calculated.
Those of most relevance are the threshold (the minimum intensity to elicit a small criterion
amplitude), the implicit time, or peak latency (the lime from the eliciting brief flash of light
to the response peak), V^, (the maximum amplitude), and K, or sensitivity (the intensity (hat
elicits a response half the amplitude of V^,). The latter two parameters arc determined using
the so-called Naka-Rushton method [107).
The amount of n-3 LCPs present in the entcral diet, was demonstrated to significantly
influence ERG measures of retinal function in healthy prcterm infants by Birch, Uauy. and co-
workers [79,80]. Up to 71 formula-fed infants were randomly allocated to receive cither a
corn oil-based artificial formula (low in all n-3 fatty acids), a soy oil-based formula (con-
taining a relatively high level (2.7%) of the parent n-3 EFA. 18:3#i-3. but no n-3 LCPs), or a
soy and marine oil-based formula (containing 0.35% of total fatty acids as 22:6n-3, and
0.65% as 2O:5n-3). Of these and of 10 human milk-fed infants, full-field BROS were obtained
at 36 and 57 weeks after conception. In addition. 10 infants bom at 35 weeks after concep-
tion were tested at one week of age; these intrautenne nurtured infants, and those raised on
human milk, were considered to provide 'gold standards' for prcterm retinal development. At
36 weeks after conception, infants raised on (he n-3 fatty acid-lacking corn oil-based artificial
formula had significantly lower plasma and RBC 22:6n-3 levels, a higher rod b-wave thresh-
old, and a lower maximum amplitude (V^,) and sensitivity (K) of the rod ERG b-wave than
those receiving preformed dietary n-3 LCP from the soy and marine oil-based formula, human
milk, or intrauterine nutrition. Infants fed on the soy oil-based formula had intermediate
thresholds that were significantly higher than those of infants receiving intrauterine nutrition.
Similar differences among groups in a-wavc amplitude suggested that dietary effects on the
rod b-wave originated primarily at the photoreceptor level. The I-:RG parameters were also sig-
nificantly related to plasma and RBC /i-3 LCP levels, with higher values for blood n-3 LCPs
being associated with better ERG performances [79]. At 57 weeks after conception, the above-
mentioned inter-group differences were no longer present [80]. The authors considered these
results to be consistent with delayed rod development rather than permanent rod damage.
Cone-ERGs were similar for all study groups both at 36 and 57 weeks poslconccption, pos-
sibly as a result of the earlier morphological and functional maturation of cxtrafovcal cones,
when compared to rods [108], which renders them less susceptible to dietary manipulation.
Yet at 57 weeks postconception, a delay in retinal development was seen in infants fed the
corn oil-based formula, in that they had significantly prolonged implicit times of the so-called
'oscillatory potentials' [80]. These are generated by circuits in the inner retina and presum-
ably reflect ganglion cell-amacrine cell interactions [109].
While an ERG provides valuable information on retinal physiology, it does not actually
indicate how well an infant can see, for vision is a process which is affected not only by the
activity of the retina, but also by that of the central visual system. The quality of vision is
usually evaluated by measuring visual acuity, which indicates the maximum spatial resolution
of the visual system. In young preterm infants, resolution acuity, and how this is influenced
by the dietary n-3 EFA supply, have recently been evaluated by the forced-choice preferential
looking method [81], the Teller acuity card procedure [82], and by measuring cortical visual
evoked potentials (VEPS) [81]. The preferential looking method and the acuity card procedure
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are both behavioral measures of grating acuity, which is a form of resolution acuity that
indicates the Finest stripes that can be discriminated from a homogeneous grey stimulus. They
are both based on an infants' inherent visual preference for a patterned rather than a homoge-
neous surface, with the acuity card procedure being a concise, less time-consuming version of
the preferential looking method [110,111]. Results of both methods correspond well with one
another [111,112]. With VEPs, the infant gazes at grating or checkerboard patterns on a video
display in which the light elements change to dark, and vice versa. The VEPS monitor the
responses from neurons in the primary visual cortex to each change. The acuity threshold is
estimated by extrapolating the linear relationship between response amplitude and the size of
the stripes or squares to zero amplitude. Compared with preferential looking acuity, VEP
acuity develops more rapidly [111-113]. This is probably related partly to differences in
stimuli and ways of threshold determination used, and partly to slower maturation of neural
systems involved in levels of visual processing beyond the primary visual cortex or in the
behavioral response, which both also determine preferential looking acuity.
Birch and co-workers [81] reported on the influence of the dietary n-3 fatty acid supply
on both VEP and preferential looking visual acuity development of preterm infants (GA at
birth: 29-35 weeks). Among 73 formula-fed healthy preterm infants which were randomly
assigned to one of three dietary groups (identical to those in the studies of Birch, Uauy, and
colleagues on retinal function), they found that preterm infants raised on a corn oil-based
artificial formula had significantly poorer VEP and preferential looking acuities at 36 (VEP
done) and 57 weeks (both done) after conception than infants fed a soy and marine oil-based
formula. Infants that received a soy oil-based formula had intermediate values for the meas-
ures of visual acuity, with their mean VEP acuity at 57 weeks postconceptional age being
significantly poorer than that of the soy/marine oil group. Additionally and interestingly, only
the acuities of the soy/marine oil group were comparable to those of the two (non-ran-
domized) groups that were considered to represent 'gold standards' for visual acuity develop-
ment in preterm infants, namely preterm infants raised on human milk, and infants born and
tested 35-36 weeks after conception. Results for acuity measures also correlated significantly
with the 22:6n-3 status, evaluated through the ratio of 22:6n-3 to 22:5n-6 (CASl), with higher
CAS1 values being associated with better visual acuity. Comparisons with VEP and preferential
looking acuities of full-term infants suggested that physical maturation (represented by
postconceptional age at measurement) rather than visual experience (indicated by postnatal
age) is the major determinant of acuity development.
Carlson and colleagues [82] studied the effects of marine-oil supplementation (0.2%
22:6«-3, 0.3% 2O:5n-3) until 9 months postterm on visual acuity in 67 healthy preterm
infants. They used the Teller acuity card procedure to measure visual acuity at term date and
2, 4, 6.5, 9, and 12 months thereafter. Their findings were in accordance with those of Birch
and co-workers, in that infants randomly assigned to receive a standard soy oil-based formula
had significantly poorer resolution acuity than infants raised on a marine-oil supplemented
(but otherwise similar) formula at 2 and 4 months after term, and tended to do so at term
date. In addition, visual acuity was correlated positively with RBC phosphatidylethanolamine
22:6n-3 and postnatal age, and negatively with hours of supplementary oxygen received by
the infants. When the n-3 formula was given until 2 months postterm, differences in early
visual acuity were found until that time but not thereafter [114]. The decreased VEP and
preferential looking acuities are consistent with the relative immaturity of oscillatory poten-
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bals reported for preierm infants fed an artificial formula lacking n-3 KFAS |80| They may all
reflect a relative 22:6n-3 shortage at an age when functional connections in the retina are
developing rapidly.
Although inter-group differences in n-3 LCP status persisted, many of the apparently diet-
induced variations in visual function appear to be temporary: effects on rod-KRG found at 36
weeks postconccption were no longer detectable some 5 months thereafter, ami infants that
did and did not receive dietary n-3 LCPs had comparable preferential looking acuities at least
at 6.5 months postterm and thereafter. Perhaps, the infants eventually manage to accumulate
adequate amounts of 22:6n-3 for undisturbed visual development from dietary l8:3n-3. rj?.
through increasingly efficient mechanisms for delivery and sequestering of 22:6n-3 in rod
outer segments [80]. On the other hand, dietary and body levels of 22:6/i-3 may continue to
influence aspects of vision other than those studied so far. There is also evidence that al-
terations in the maturation during early infancy of a sensory process like vision may (almost
irreversibly) affect later development: in primates, the development of the primary visual
cortex was shown to be guided by normal retinal input during an early sensitive period 1113].
Other functional end-points of interest are cognitive and psychomotor development, and
the resultant early behaviour. Similar to the primary visual cortex, the frontal and temporal
cortex of the brain (association areas involved in higher cognitive processes such as learning
and memory) are still relatively undeveloped at birth. Their eventual function is, therefore,
prone to be affected by dietary manipulation. However, to what extent intellectual perfor-
mance is actually influenced by levels of 22:6/i-3, 20:4n-6, and other LCPs, is probably even
more difficult to establish conclusively than for visual function, for a number of reasons. For
one thing, substantial LCP levels are present in neural membranes throughout (he brain, so
many neural systems and functions (sensory and motor systems, activity, motivation, atten-
tion, learning, memory) arc potentially susceptible to dietary influences. Moreover, these
systems and functions, which are all of importance for intellectual development, interact with
one another in many complex ways. Consequently, conclusive evidence on the importance of
LCPs for appropriate cognitive and psychomotor development is rather limited, if not almost
lacking. So far, only Carlson and colleagues [114,116] have reported on studies of specific
effects of n-3 LCP supplementation on these functional end-points. Up to 54 prctcrm infants
were fed either a conventional LCP-lacking formula (identical in studies I and 2) or a marine-
oil supplemented formula, which provided 0.2% of total fatty acids as 22:6n-3, and 0.3%
(study 1) or 0.06% (study 2) as 2O:5/i-3. The functional outcomes measured at twelve months
after the initial term date were the Baylcy Scales of Mental and Psychomotor Development
[117], and the Fagan Infantest.
The Bayley Mental Development Index (MDI) is aimed at measuring perception, memory,
learning, problem solving, abstract thinking, vocalization, and early verbal communication.
The Bayley Psychomotor Development Index (PDl) is designed to assess gross motor abilities
and hand and finger manipulation. In study 1, Bayley MDls of both study populations were
comparable, while the Bayley PDl tended (P<0.09) to be significantly lower in the marine-oil
group. The latter observation was suggested to be associated with a negative effect of marine-
oil supplementation on linear growth [116]. However in study 2 [114], psychomotor develop-
ment was similar in both populations, while the MDI was significantly (P<0.03) higher in the
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supplemented infants. These discrepancies between the results of both studies were con-
sidered to be an effect of an improvement in the nutritional status by a prolonged provision
of nutrient-rich preterm study formulas. When interpreting results for Bayley Indices, it is
important to realize that these give an overall reflection of performances in several sensory,
motor, and cognitive domains, and that deficits in one particular domain may be masked by
otherwise normal development.
The Fagan Infantcst is a test of infant looking behaviour, which uses an infant's inherent
tendency to look at novel stimuli (faces) as a means to assess visual recognition memory
(118]. With this test, the infant's memory of the familiar faces is measured by his or her
preference for novel ones. Novelty preference scores of the marine-oil supplemented infants
of studies 1 and 2 were similar and, surprisingly, lower than those of the control groups
(P<0.()2, and P<().()75, for studies 1 and 2, respectively). Yet, infants in the marine-oil group
had more discrete looks to novel and familiar faces (study 1), and this number of discrete
looks was positively correlated to values for Bayley MDl (study 2) [114]. In addition, sup-
plemented infants had shorter visual Fixation, or look duration, when tested at 6, 9, and 12
months after the initial term date [119].
Researchers have also evaluated the influence of the dietary LCP intake of preterm infants
on anthropometric parameters. Associations between the intrauterine LCP supply and prenatal
growth ((17,23,24,34,35], Chapters 2 and 7) have been addressed in an earlier subsection of
this general discussion. With respect to postnatal growth achievements, the intake of n-3 LCP
containing formula was found to be associated with poorer first year growth (concerning
weight, length, as well as HC) in preterm infants [120]. Furthermore, the 20:4n-6 status in
plasma phosphatidylcholine was reported to be positively correlated with the above-men-
tioned measures of postnatal growth in preterm infants through 12 months corrected postnatal
age, irrespective of the dietary n-3 LCP intake [94]. Therefore, attempts were made to prevent
significant declines in 20:4n-6 status by making two changes to the dietary regime of the
preterm infants: the amount of 2O:5n-3 added to the marine-oil supplemented formula was
reduced from 0.3 % to 0.06 % of total fatty acids, and the time-span during which this
formula was given was reduced from until 9 to until 2 months after term date [93]. Prelimi-
nary data suggest that this approach did indeed result in comparable growth performances of
infants receiving an n-3 LCP supplemented or a standard formula [114].
All of the above-mentioned studies of influences of the dietary LCP supply, and the
resultant LCP status, on several parameters of brain and visual function have focused primarily
on the dietary intake of n-3 LCPS. Both 22:6n-3 and 20:4n-6 account for a substantial propor-
tion (some 25% each) of the total fatty acids in the cerebral cortex. Consequently, potential
beneficial effects on brain function of dietary n-3 LCP supplementation, might well be undone
by the associated decrease in 20:4n-6 status; a view supported by the different effects on
Bayley MDl of two types of n-3 LCP suppletion discussed earlier [114]. Thanks to recent
technological advances, artificial preterm formulas can be designed to meet both n-3 and n-6
LCP needs by using so-called 'single-cell oils'. These oils that are produced by single-celled
organisms, such as microalgac and fungi, are highly purified and lack undesirable con-
tamination with other LCPs. Further studies in preterm infants are needed to evaluate the
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potential functional and clinical consequences of these formulas, which simultaneously
enhance the dietary n-3 and n-6 LCP intake.
9.4 Perspectives for future research
As described earlier in this discussion, further studies are in order to determine the
optimal ratio and content of n-6 and n-3 KKAS in the diets of both pregnant women and
preterm infants, and the optimal starting-points, durations, and types of possible adaptations
in particular. On the one hand, these studies will have to be of a biochemical nature. This
will include the use of stable isotope labelled fatty acids, which may clarify yet uncertain or
unknown aspects of maternal, fetal, and infant KKA metabolism. On the other hand, the
biochemical data will have to be supported by studies of the effects on functional parameters.
Apart from extending the current knowledge of effects on visual function of prctcrm formulas
supplemented with n-3 LCPs. with those of formulas providing both «-3 and n-6 UTs. much
attention and effort ought to go out to conclusively establishing pre- and postnatal dietary
influences on higher mental function. These influences might not always be beneficial, as is
indicated by preliminary results by Janowsky and co-workers [121], which suggest a possible
negative effect of 22:6/i-3 on language development in healthy term infants.
Guidelines for choosing methods appropriate for assessing cognitive development have
been described in a recent brief review article by Ncuringer and colleagues [122]. They are
based on studies aimed at understanding the neural basis of specific cognitive functions and
the effects of neurotoxins [123,124]. Since no single test can fit these guidelines, the pre-
ferred strategy is to perform a set of tests that provide useful comparisons and, in this way,
can indicate dietary effects on specific aspects of cognition. Firstly, effects on a given cog-
nitive function should be measured by several tests and their results should be consistent:
convergent validity. Secondly, when testing other, unrelated abilities, no effects ought to be
found: divergent validity. Thirdly, the tests chosen should have the power to predict later
outcomes: predictive validity. Fourthly, tests should preferably be able to detect develop-
mental delays as well as deviances from normal performances. Consequently, the normal
course of development should be known, and performances on the tests should change
qualitatively with age.
As mentioned earlier, Bayley scales do not meet most of these criteria, but a visual com-
parison test like the Fagan Infantest does. Other potentially suitable tests arc [122]: the so-
called 'AnotB tasks' that measure short-term memory of infants [125] as well as their ability
to inhibit preferred responses [126], which may possibly depend on a late developing frontal
lobe system [127], and 'delayed-matching-to-sample', another way of measuring visual
recognition memory. Valuable information may also be obtained from so-called 'infant
habituation scores' [128], which indicate an infant's efficiency at processing and memorizing
information. Unlike the development assessment scores from standard tests such as the
Bayley scales, habituation scores obtained during the first year of life correlate reasonably
well with later childhood intelligence scores [129]. Recently, early infant habituation was
reported to be affected by the dietary LCP content in a randomised study in term infants
1130].
With all of the functional research to be performed, aiming for a long-term follow-up is
of great importance. As stated earlier, dietary effects during early infancy, which appear to be
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transient, may have important implications for later development. Moreover in higher, more
complex functions, dietary effects may not emerge until these functions actually mature.
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The long-chain polyunsaturatcd fatty acids (LCPs: essential fatty acids (EFAs) with 20 or
more carbon atoms and at least 3 double bonds) docosahexaenoic acid (cervonic aicid,
22:6n-3) and arachidonic acid (20:4/i-6) arc the predominant structural fatty acids in the
human brain and retina. An adequate supply of these LCPs during the period of their most
rapid accumulation (the last months of gestation and (he first months of postnatal life) is
believed to be of major importance for appropriate growth and development of these
organs. In addition, 20:4n-6, dihomo-y-linolcnic acid (20:3/1-6) and eicosupcntacnoic acid
(20:5/1-3) arc precursors of prostaglandins and other cicosanoids, which have important
bioregulatory functions. Preterm infants undergo 3rd trimester growth and development ex-
trauterinely and are deprived of the substantial accretion of fat, including /i-6 and >i 3 LCPs,
during late pregnancy. The studies described in this thesis were designed to extend the
existing knowledge on the biochemical LCP status of preterm infants and on how this status
is influenced by the supply of EFAs, and LCPs in particular, during intiautermc and early
postnatal life. In addition, some methodological aspects were considered.
First, the EFA status at birth of 43 preterm infants was compared with that of 43 infants
carried to term (Chapter 2). To obtain an indication of the fetal I:IA status over a longer
period of time, the EFA composition of umbilical vessel wall phospholipids (PLs) was studi-
ed. Generally, n-6 and w-3 LCP levels were lower, while levels of EFA deficiency markers,
such as Mead acid (20:3/1-9), the EFA deficiency index (20:3/1-9/20:4/1-6), Osbond acid
(22:5/1-6), and the cervonic acid deficiency index (CADI: 22:5n-6/22:4/j-6), were higher in
preterm cords. This lower biochemical EFA status of the preterm fetus was reflected by fatly
acid values in both the draining arteries and the supplying vein. Yet, /i-6 and n-3 l-l'A levels
in preterm cords correlated significantly and positively with gestational age (GA) at birth,
which indicates that the lower preterm EFA values could merely be a reflection of a physiol-
ogically lower demand for EFAs, necessary for growth and development, of the pretcrm
fetus. The negative correlations found between GA and values for EFA deficiency markers
suggest an increasing adequacy of the EFA supply towards term. For the preterm infants,
arterial LCP levels were also found to be related to prenatal growth: significant, positive cor-
relations between umbilical cord n-6 and /i-3 LCP levels and birth weight, and between
22:6/i-3 and length at birth were supported by a number of positive relations between «-6
and n-3 LCP levels and head circumference (HC), or length, which tended to be significant.
All correlations were corrected for the confounding effect of GA at birth.
As in Chapter 2, studies on the fetal EFA or LCP status arc usually based on materials
collected (shortly) after delivery (umbilical plasma, red blood cells (RBCS), or cord vessel
walls), but whether the EFA profile at birth accurately reflects fetal EFA values is actually
unknown. To obtain some insight into this, the EFA profiles of fetal plasma samples
obtained by transabdominal puncture during pregnancy (n=86, GA: 18-39 weeks) were
studied (Chapter 3). The fetal plasma EFA profile was found to change with increasing
pregnancy duration in a fatty acid specific way: the linoleic acid (18:2/1-6) level increased
slightly, values for 20:4/i-6 decreased, while those for 22:6/»-3 increased. The overall f-.FA
status increased with advancing GA, which is in agreement with the observations in Chapter
2. However, increasing values for the markers of a specific 22:6 /J-3 shortage (22:5/i-6 and
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CADI) and the decreasing value for the cervonic acid sufficiency index (CASI: 22:6«-3/22:5/i-
6) indicated that the functional 22:6«-3 status declined. This may suggest that the increased
availability of 22:6w-3 (fetal plasma 22:6/i-3 values increased) is still insufficient to cover
the high fetal 22:6n-3 demand associated with rapid (neural) tissue growth and development
during late gestation. Compared with plasma samples (n=51) that were collected from the
umbilical cord immediately after birth at similar GAs (28-39 weeks), EFA levels in the fetal
samples were alike or slightly lower (18:2«-6, Z w-6 EFAS). This observation supports the
assumption that the relatively low EFA status of pretcrm infants at birth (Chapter 2) is
dcvclopmcntally related. Besides, it indicates that the plasma EFA status measured after
delivery is a reasonably adequate reflection of the actual fetal plasma EFA status.
Although higher than (hat of prcterm newborns (Chapter 2), the EFA status of term
infants born after an uneventful, singleton pregnancy may still be considered marginal
because of the high 20:3n-9 levels that arc present in their umbilical artery vessel walls. If
this low EFA status is caused by a limiting maternal EFA supply, the higher total fetal EFA
demand associated with a multiple pregnancy would result in an even lower infant EFA
status. Hence, we compared the EFA status at birth of 30 pairs of twins, 7 sets of triplets,
and I set of quintuplets with that of 94 infants (51 prcterm, 43 term) born after a singleton
pregnancy (Chapter 4). Again, PL-associated EFA profiles of the umbilical vessel walls were
studied. At similar GAs, arterial and venous levels of n-6 and n-3 EFAs were generally
lower, while those of EFA-dcficiency indicating n-9 polyunsaturated fatty acids (PUFAs) were
significantly higher for infants born after a multiple pregnancy. The EFA profiles of twins
and triplets were comparable, but the average EFA status of the set of quintuplets was lower
than that of twins and triplets. All in all, the observation of a lower EFA status of infants
born after a multiple pregnancy supports the view that the maternal EFA supply to the fetus
is limiting. Considering the importance of particularly LCPs for proper growth (Chapter 2)
and development, this finding warrants further studies of the adequacy of the maternal EFA
intake during pregnancy in general. Moreover, multiple pregnancy is a major cause of
prcterm delivery which is also associated with a lower EFA status. Considering the added
effect of a lower EFA and LCP status as a result of multiple pregnancy, the adequacy of the
EFA and LCP status of prcterm twins and triplets may be a subject of particular concern.
Effects of the pre- and postnatal LCP supplies on the postnatal LCP status of preterm
infants were studied in plasma and RBC PLs of blood samples collected at regular intervals
alter birth (Chapters 6 to 8). To reduce the burden placed on the participating infants, the
required blood samples were to be collected in conjunction with venous or capillary
diagnostic punctures. The comparability of the fatty acid profiles of plasma and of RBC PLs
isolated from both types of blood is described in Chapter 5. In addition, the effects of
storage at -20 °C for a maximum of 4 weeks were evaluated, since all blood samples of a
preterm infant were to be analyzed simultaneously to ensure uniformity of analytic condi-
tions. For ethical reasons, this study was not performed in young infants but in 8 healthy
adult volunteers. Plasma fatty acid profiles from venous and capillary blood were compar-
able and not affected by up to 4 weeks of storage. RBC fatty acid concentrations from
venous and capillary blood were comparable after up to 1 week of storage before lipid
extraction. However after 4 weeks of storage, the total amount of PL-associated fatty acids
in capillary RBCS was decreased to half the initial value. This decline was mainly caused by
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a decrease of almost 90% in the concentration of PITAS and was not observed in venous
RBCs. Consequently, highly significant differences developed between the fatty acid profiles
of venous and capillary RBCs. Loss of membrane structural integrity may have added to the
higher susceptibility to lipid loss of RBCs collected by capillary puncture. The iron-induced
oxidation of PUFAs can possibly be prevented by prepiiring RBC ghosts or lipid extracts from
the capillary RBCs within 1 week after blood sampling, or by adding an iron-chelating
agent, preferably desferrioxamine. during handling and storage of the RBCs.
Preterm infants arc dependent on their own dietary HFA supply to handle the demands
associated with the rapid brain and body growth which normally takes place during the hist
trimester of pregnancy. The two enteral dietary EFA sources available to newborn infants are
human milk, which contains small but significant amounts of 22:6/i-3. 20:4n-ft and other
LCPs, or commercially available artificial formulas, which did not contain l.CPs when the
studies described in this thesis were initiated. Considering the facts that pretenn infants
have very limited fatty acid stores and arc born with a lower l.CP status Ihan infants carried
to term (Chapter 2), feeding prcterm new horns on an artificial formula will potentially
threaten their postnatal LCP status. Indeed, when the LCP status of 12 human milk-fed
prcterm infants (birth weight < 1800 g) was compared with that of 27 formula-fed infants
during the first 4 weeks of life (Chapter 6), a number of significant differences were
observed. After 21 to 28 days, absolute (mg/1) and relative (% (wt/wt) of total fatty acids)
22:6n-3 values and the absolute 20:4n-6 amount had become substantially lower in (he
plasma PLs of the formula-fed infants. Effects on the 22:6/i-3 status were supported by the
a higher value for the CADI in the formula group. In RBC PLs, the postnatal decreases of
22:6n-3 and 20:4n-6 in the formula group were approximately iwicc those in (he human
milk-fed group, but these differences did not reach significance. The slower turnover rate of
RBC PLs than of plasma PLs may have contributed to the less distinct nutritional effects on
these cells over a relatively short period of time. Apparently, the presence of the parent
EFAs 18:2«-6 and a-linolenic acid (18:3w-3) in the formulas was unable to fully compensate
for the absence of LCPs, which may be related to the limited desaturase capacity of prcterm
newborns. Therefore, for formula-fed infants to achieve postnatal plasma l.CP values at least
similar to those found in infants fed on human milk, both «-3 and M-6 LCPS should be added
to prcterm infant formulas. Another main finding of this study (and that of Chapter K) was
that, in plasma PLs, the changes with time after birth were markedly different when fatty
acid values were expressed as absolute or as relative values, which illustrates the additional
importance of measuring absolute fatty acid amounts. However, analytical procedures need
to be standardized to enable effective comparison of results from various research groups.
After having found a substantial effect of the postnatal LCP supply on the biochemical
postnatal LCP status of preterm infants (Chapter 6), the influence of the intrautcrinc IX'P
supply on postnatal LCP values was assessed in 28 prcterm infants (average GA at birth: 32
weeks; Chapter 7). Such an influence could be of importance, considering the widely
divergent LCP levels with which infants are born (Chapters 2, 4 and 6). The LCP status at
birth (measured in the umbilical artery wall PLs, and in umbilical plasma or RBC PLs) which
results from the prenatal LCP supply, and the postnatal diet (human milk or conventional
artificial formula), representing the postnatal LCP supply, were related to the LCP status
measured in plasma or RBC PLs collected from the preterm infants in the period during
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which they were actually due to be born (37-42 weeks GA). Indeed, the biochemical LCP
status some 2 months after preterm birth was determined not only by the postnatal diet, but
also by the LCP status at birth: a higher plasma 20:4/j-6 concentration at birth resulted in a
higher plasma 20:4n-6 concentration 'at term', and higher 22:6n-3 and 20:4n-6 values in the
walls of the umbilical arteries lead to higher postnatal RBC 22:6n-3 and 20:4n-6 contents.
These findings stress the significance of an appropriate prenatal LCP supply (a major
determinant of the LCP status at birth), particularly for infants who are born preterm, or
after a multiple pregnancy, or both. Since this prenatal LCP supply can only be changed by
adapting the maternal fatty acid intake, these results warrant further studies of the effects of
EFA-cnrichcd maternal diets during pregnancy on the infant LCP status at birth. Besides in
the study of Chapter 7, the exploration of the relations among EFA status, GA, and growth
parameters at birth (Chapter 2) was extended by also studying LCP levels in umbilical
plasma and RBC PLs. However, after correction for GA at birth, significant relations were
only observed between anthropomctric measurements at birth (weight, HC, and length) and
LCP levels in the umbilical artery wall. Perhaps the fact that LCP levels in umbilical plasma
and RBC PLs are relatively short-term indicators of the fetal LCP status, renders their correla-
tion with measures of a long-term process like fetal growth likely to be less distinct.
'Flic results of a randomized controlled intervention study of the effects on the LCP status
of supplying formula-fed preterm infants (birth weight < 1800 g) with an artificial formula
containing both 22:6n-3 (0.3%) and 20:4n-6 (0.6%) in levels present in human milk were
described in Chapter 8. Blood LCP levels of 15 infants fed on the LCP-enriched study
formula were compared with those of 16 infants receiving a conventional formula (lacking
LCPs), and with those of 12 preterm infants raised on human milk. Weekly postnatal blood
samples were collected until the 35th day of life and, for the formula-fed infants, at 3
months alter their initial term date (3 months of corrected age). After 4 weeks of postnatal
life, the plasma and RBC PL 22:6«-3 and 20:4n-6 levels in preterm infants fed on the LCP-
enriched preterm formula were significantly higher than those in infants which had received
a conventional formula, and were comparable to those of preterm infants raised on their
own mother's milk. The differences between the two formula groups continued to increase,
resulting in average plasma 22:6«-3 and 20:4n-6 values that were up to 4 and 2 times
higher, respectively, in the LCP-enrichcd formula group at 3 months of corrected age. Both
in plasma and RBC PLs, inter-group differences found for the 22:6n-3 status were also
reflected by the two indices of the functional 22:6n-3 status: CADI values were significantly
lower in the infants fed on LCP-enriched formulas, while CASl values were higher. The
results of this relatively long-term study show that feeding preterm infants on artificial
formulas enriched with both 22:6n-3 and 20:4n-6 in balanced ratios, i.e. in amounts found
in preterm human milk, is a successful approach to raising both the 22:6n-3 and 20:4n-6
status of preterm formula-fed infants to values found in blood PLs of preterm infants fed on
human milk. Additional studies are necessary to evaluate the potentially favourable effects
of this combined addition on the (neuro)developmental outcome of preterm infants.
In Chapter 9, the major findings of the above-mentioned studies and their implications
for current views and future research are discussed. In particular, the purpose of supplemen-
ting the maternal, fetal and infant diet with «-6 and n-3 EFAs. and the importance of adding
clinical and functional outcomes to the biochemical data are considered.
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Het centrale zenuwstelsel (CZS) van de mens is rijk aan zogenaamde langketcnige
meervoudig onverzadigde vetzuren ('long-chain polyunsaturated fatty acids'. l.(Ts). Oil zijn
voor het lichaam essentiële vetzuren ('essential fatty acids', EFAS) met een kctenlcngte van
20 koolstofatomen of meer en tenminste 3 onverzadigde bindingen. De belangrijkste
bouwstenen van de celmembranen van het CZS zijn de LCPs docosahexaeenzuur (cervon-
zuur, 22:6/1-3) en arachidon/uur (20:4n-6). Met name tijdens de laatste maanden van de
zwangerschap en de eerste maanden na de geboorte neemt het CZS zeer snel in omvang toe.
en een toereikende aanvoer van 22:6n-3 en 20:4«-6 in die periode wordt geacht van groot
belang te zijn voor een ongestoorde groei en ontwikkeling van dit orgaan. Daarnaast dienen
20:4«-6, dihomo-y-linolecnzuur (20:3n-6) en cicosapcntacenzuur (2O:5n-3) als substraat
voor de vorming van prostaglandines en andere cicosanoiden, die belangrijke regulerende
laken hebben. Te vroeggeboren kinderen maken de bij het laatste trimester van de zwanger-
schap horende groei en ontwikkeling buiten de baarmoeder door; zij zijn derhalve verstoken
van de belangrijke opslag van vetten, waaronder n-6 en n-3 LCl's, die normaal aan het einde
van de zwangerschap plaatsvindt. Het in dit proefschrift beschreven onderzoek had tot doel
de reeds aanwezige kennis van de biochemische LCP status van premature zuigelingen uil te
breiden dan wel te verdiepen. Hierbij werd met name bestudeerd hoc deze status wordt
beïnvloed door de voorziening van EFAs, en met name van LCPs, tijdens het intra ulcrienc
en vrocg-postnatale leven. Ook werden een aantal methodologische aspecten onderzocht.
Ten eerste werd de EFA status bij de geboorte van 43 premature zuigelingen vergeleken
met die van eenzelfde aantal voldragen kinderen (Hoofdstuk 2). Hierbij werd de KlA
samenstelling van de fosfolipiden (FLs) in de navclstrcngvaatwandcn beoordeeld, omdat die
een indruk geeft van de foetale EFA status over een langere termijn. Over het algemeen
waren de gehaltes aan EFAS van de «-6 en «-3 families lager en de gehaltes aan lil-A defi-
ciëntie-indicatoren [waaronder Meadzuur (20:3n-9), de EFA deficiëntie index (20:3/i-9/20:4n-
6), Osbondzuur (22:5/i-6), en de cervonzuur deficiëntie index (CADl: 22:5/i-6/22:4w-6)|
hoger in de navelstrengen van premature kinderen. Deze lagere biochemische HFA status van
de premature foetus werd weerspiegeld in de vctzuurgchaltcs van zowel de afvoerende
navelstrengarteriën als de aanvoerende -vcne. De gehaltes aan «-6 en «-3 EFAs bleken echter
positief gecorreleerd te zijn met de zwangerschapsduur ten tijde van de geboorte. Dit zou
erop kunnen duiden dat de lagere EFA waarden zoals gemeten bij het te vroeggeboren kind
slechts een afspiegeling zijn van een fysiologisch lagere behoefte aan EFAS van de prematu-
re foetus, wiens CZS en lichaam zich nog in een relatief vroege fase van groei en ontwikke-
ling bevinden. De negatieve correlaties die werden gevonden tussen de zwangerschapsduur
en de gehaltes aan EFA deficiëntie-indicatoren geven aan dat, naarmate de zwangerschap
vordert, de EFA aanvoer steeds beter in de aanwezige behoefte voorziet. Artcriëlc LCP
gehaltes van premature pasgeborenen bleken ook nauw samen te hangen met de foctalc
groei: significante, positieve correlaties werden gevonden tussen n-6 en n-3 LCP waardon en
het geboortegewicht, en tussen 22:6n-3 en de gcboortelengtc. Daarnaast werden een aantal
nagenoeg significante, positieve correlaties gevonden tussen /i-6 en n-3 LCP gehaltes
enerzijds en schedclomtrek en lengte bij de geboorte anderzijds. Al deze correlaties werden
gecorrigeerd voor de invloed van de zwangerschapsduur bij de geb<x)rtc.
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Zoals ook in Hoofdstuk 2, wordt bij onderzoek naar de foetale EFA of LCP status
doorgaans gebruik gemaakt van materialen die (kort) na de geboorte worden verzameld
(navelstrengplasma, -erytrocyten ('red blood cells', RBCs), of -vaatwanden). Het is echter
onbekend of de EFA samenstelling bij de geboorte een juiste afspiegeling is van foetale EFA
gehaltes. Om hier enig inzicht in te krijgen, werd de EFA samenstelling van plasma uit
foetaal bloed dat via een transabdominale punctie tijdens de zwangerschap werd afgenomen
(n=86, zwangerschapsduur: 18-39 weken) bestudeerd (Hoofdstuk 3). Naarmate de zwanger-
schap vorderde, veranderden de gehaltes van de diverse EFAS in foetale plasma FLs op
verschillende manieren: linolzuur (l8:2n-6) vertoonde een geringe stijging, het 20:4n-6
gehalte nam af, dat van 22:6«-3 nam toe. De algehele EFA status steeg bij een toenemende
zwangerschapsduur, hetgeen overeenkomt met de bevindingen in Hoofdstuk 2. De stijgende
waarden voor de indicatoren van een specifiek tekort aan 22:6/i-3 (22:5«-6, CADi) en de
daling van de waarde voor de cervonzuur 'sufficiëntie' index (CASI: 22:6n-3/22:5/i-6)
duidden echter op een vermindering van de functionele 22:6n-3 status. Wellicht is de
verhoogde beschikbaarheid van 22:6«-3 (foetale 22:6n-3 plasmawaarden stegen met toene-
mende zwangerschapsduur) nog steeds onvoldoende om te voorzien in de, door de snelle
wccfselgroei en -ontwikkeling, grote foetale behoefte aan dit vetzuur tijdens de laatste
maanden van de zwangerschap. Wanneer de foetale plasmamonsters werden vergeleken met
plasmamonstcrs uit bloed dat bij de geboorte uit de navelstreng was afgenomen (n=51,
zwangerschapsduur: 28-39 weken), bleek dat, op hetzelfde moment in de zwangerschap, de
EFA gehaltes in het foetale plasma hetzelfde of enigszins lager (18:2«-6, Z n-6 EFAS) waren.
Deze bevinding ondersteunt onze veronderstelling dat de relatief lage EFA status van
premature pasgeborenen (Hoofdstuk 2) een fysiologisch verschijnsel is dat samenhangt met
hun vroegere ontwikkelingsfase. Daarnaast blijkt hieruit dat de EFA status zoals gemeten in
na de geboorte afgenomen navclstrengplasma een redelijk betrouwbare weergave is van de
EFA status in foetaal plasma.
Hoewel de EFA status van gezonde, voldragen kinderen hoger is dan die van te vroeg-
geboren zuigelingen (Hoofdstuk 2), zouden hun EFA waarden nog steeds als 'krap' be-
schouwd kunnen worden, met name vanwege de aanzienlijke 20:3n-9 gehaltes (EFA defi-
ciëntie-indicator) in de wanden van de navelstrengarteriën. Indien deze krappe EFA gehaltes
het gevolg zijn van een beperkende EFA voorziening door de moeder, dan zou de hogere
gezamenlijke foetale EFA behoefte bij een mcerlingzwangerschap tot nog lagere EFA
waarden bij de kinderen moeten leiden. Of dit inderdaad het geval was, werd onderzocht
(Hoofdstuk 4) door de EFA status bij de geboorte van 30 tweelingen, 7 drielingen, en 1
vijfling te vergelijken met die van 94 eenlingen (51 prematuur, 43 voldragen). Net zoals in
Hoofdstuk 2, werd de EFA samenstelling van de FLs in de wanden van de navelstrengvaten
beoordeeld. Bij eenzelfde zwangerschapsduur bevatten de navelstrengarteriën en -vene van
meerlingen over het algemeen significant lagere EFA gehaltes en significant hogere waarden
voor de op een EFA-deficiëntie wijzende «-9 meervoudig onverzadigde vetzuren ('poly-
unsaturated fatty acids', PUFAs). Twee- en drielingen hadden een vergelijkbare EFA status,
maar de gemiddelde EFA status van de vijfling was beduidend lager dan die van de andere
meerlingen. Alles in ogenschouw nemend, lijken deze bevindingen er inderdaad op te
duiden dat een beperkende moederlijke EFA voorziening aan de zich ontwikkelende foetus
een oorzaak voor de krappe EFA status van pasgeborenen is. Aangezien EFAs, en LCPs in het
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bijzonder, worden geacht van groot belang zijn voor een goede groei (Hoofdstuk 2) en
ontwikkeling, geven deze resultaten aanleiding tot meer en uitgebreider onderzoek naar de
kwaliteit van de moederlijke inneming van EFAs tijdens zwangerschap in het algemeen. Hen
meerlingzwangerschap resulteert bovendien vaker dan een cenlingzwangcrschap in een
premature geboorte, die ook gepaard gaat met een lagere EFA status (Hoofdstuk 2). IX' als
het ware 'dubbel-verlaagde' EFA en LCP status van premature meerlingen verdient derhalve
bijzondere aandacht.
De invloed van de pre- en postnatale LCP voorziening op de postnatale LCP status van
premature zuigelingen (geboortegewicht < 1800 g) werd bestudeerd in de plasma en RBC
FLs van bloedmonsters die na de geboorte wekelijks werden afgenomen (Hoofdstuk 6 tot en
met 8). Om de participerende zuigelingen zo min mogelijk te belasten, werd de afname van
de benodigde bloedmonsters steeds gecombineerd met vencuze, dan wel capillaire diagnosti-
sche puncties. In Hoofdstuk 5 wordt de vergelijkbaarheid van de vct/uursamenstclling van
de FL-fractie van veneus en capillair plasma en van vcneuzc en capillaire RBCs beschreven.
Hierbij werd ook de invloed van een bewaartijd van maximaal 4 weken bij -20 °C onder-
zocht, aangezien alle bloedmonsters van een premature proefpersoon tegelijk, en dus onder
dezelfde omstandigheden, geanalyseerd dienden te worden. Om ethische redenen werd dit
onderzoek niet gedaan bij (premature) zuigelingen, maar bij 8 gezonde volwassen vrijwilli-
gers. De vctzuurprofielen van plasma van vencuze en capillaire origine bleken goed overeen
te komen en niet te worden beïnvloed door een bewaarperiode van 4 weken. De vct/.uurpro-
fielen van RBCs afkomstig uit veneus en capillair bloed waren vergelijkbaar indien de
vetextractie op de dag van bloedafname of 1 week daarna werd verricht. Echter, na 4
weken bewaren was de totale hoeveelheid vetzuren in capillaire RBCs gedaald tot de helft
van de uitgangswaarde. Deze daling was grotendeels het gevolg van een vermindering van
de absolute hoeveelheid PUFAs met 90%, en werd niet waargenomen voor de RBCs van
veneuze oorsprong. Dientengevolge ontstonden er aanzienlijke verschillen tussen de vct-
zuurprofielen van veneuze en capillaire RBCs. De grotere gevoeligheid voor vetzuurverliezen
van RBCs die via een capillaire punctic zijn verkregen, zou het gevolg kunnen zijn van een
verstoring van de structurele integriteit van hun membranen door de bloedafname. De met
ijzer als katalysator optredende oxydatie van PUFAs kan wellicht voorkomen worden door
binnen 1 week na hun afname het hemoglobine uit de capillaire RBCs te verwijderen, dan
wel door hun lipiden te extraheren, of door een ijzer-chelator, liefst desferrioxaminc, tijdens
de bewerkings- en bewaarfase aan de RBCs toe te voegen.
Premature pasgeborenen zijn aangewezen op hun eigen voeding om te voorzien in de
grote EFA-behoefte die het gevolg is van de snelle groei van het CZS, die normaal gesproken
tijdens de laatste 3 maanden van het intra-uteriene leven plaatsvindt. De twee soorten
enterale voeding die geschikt zijn voor zuigelingen zijn enerzijds moedermelk, die geringe
hoeveelheden 22:6n-3, 20:4AI-6 en andere LCPs bevat, en anderzijds de kunstmatige zuigc-
lingenvoedingen ('flesvoeding'), waarvan het merendeel (nagenoeg) geen LCPs bevatte toen
het onderzoek zoals beschreven in dit proefschrift werd gestart. Prematuur geboren zuigelin-
gen hebben zeer beperkte vetvoorraden en komen bovendien met een lagere LCP status ter
wereld dan voldragen kinderen (Hoofdstuk 2). Het geven van flesvoeding aan premature
pasgeborenen zou derhalve bij deze kinderen tot relatief lage LCP gehaltes kunnen leiden.
Om deze hypothese te toetsen werd, gedurende de eerste vier levensweken, de LCP status
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van 12 met moedermelk gevoede prematuren vergeleken met die van 27 flesgevoede
kinderen (Hoofdstuk 6). Hierbij werden een aantal significante verschillen gevonden tussen
beide groepen: na 21 tot 28 dagen waren de absolute (mg/l) en relatieve (gewichts % van
totaal vetzuur) 22:6n-3 waarden en het absolute 20:4n-6 gehalte aanzienlijk lager in de
plasma FLs van de flesgevoede kinderen dan in die van de moedermelk-groep. De invloed
op de 22:6«-3 status bleek ook uit een hogere CADI-waarde in de flesvoeding-groep. In de
RBC FLs was de daling van de 22:6n-3 en 20:4n-6 gehaltes in de flesvoeding-groep on-
geveer tweemaal zo groot als in de moedermelk-groep, maar deze verschillen waren niet
significant. De, op korte termijn, minder uitgesproken verschillen in de RBC FLs zouden het
gevolg kunnen zijn van hun, vergeleken met plasma FLs, lagere vervangingssnelheid.
Blijkbaar kunnen de zogenaamde 'mocder-EFAs' 18:2/i-6 en a-linoleenzuur (18:3n-3), die
wel in de flesvoeding aanwezig zijn, het ontbreken van de LCPs niet volledig compenseren;
door hun nog niet volledig ontwikkeld enzymsysteem zijn de premature zuigelingen
onvoldoende in staat om 18:2«-6 en 18:3n-3 zelf om te zetten in, respectievelijk, 20:4n-6 en
22:6«-3. Om de postnatale LCP status van flesgevoede prematuren op het niveau van de
status van met moedermelk gevoede premature zuigelingen te brengen, zullen derhalve n-3
en «-6 LCPs aan de premature zuigelingcnvoeding moeten worden toegevoegd. Een andere
belangrijke bevinding van dit onderzoek (en dat van Hoofdstuk 8) was dat hei postnatale
vct/uurverloop in plasma FLs opvallend anders was, afhankelijk van of de vetzuurwaarden
als mg/l (absoluut) of percentueel (relatief) werden uitgedrukt. De (doorgaans niet gepresen-
teerde) absolute vctzuurwaarden kunnen dus aanvullende informatie geven. De analytische
methodieken van de diverse onderzoeksgroepen in de wereld dienen echter op elkaar afges-
temd te worden om tot een zinvolle vergelijking van eikaars resultaten te kunnen komen.
Nadat de postnatale LCP voorziening duidelijk van invloed was gebleken op de bioche-
mische postnatale LCP status van premature zuigelingen (Hoofdstuk 6), werd de invloed van
de intra-uteriene LCP aanvoer op postnatale LCP waarden onderzocht in 28 premature
kinderen (gemiddelde zwangerschapsduur: 32 weken; Hoofdstuk 7). Aangezien kinderen
met zeer uiteenlopende LCP gehaltes ter wereld komen (Hoofdstuk 2, 4 en 6), kan een
dergelijke invloed van groot belang zijn. Derhalve werd de LCP status bij de geboorte (ge-
meten in de FLs van de arteriële navclstrengvaatwand en van navelstrengplasma of RBCs)
die wordt bepaald door de LCP voorziening tijdens de zwangerschap, gerelateerd aan de LCP
status die werd gemeten in plasma of RBC FLs uit bloed dat bij de premature kinderen was
afgenomen in hun oorspronkelijke 'a tcrme periode' (37-42 weken zwangerschapsduur).
Hierbij werd ook rekening gehouden met de enterale voeding (moedermelk of flesvoeding)
als vertegenwoordiger van de LCP voorziening na de geboorte. Uit de resultaten van dit
onderzoek bleek duidelijk dat de biochemische LCP status, in ieder geval tot 2 maanden na
een premature geboorte, wordt bepaald door zowel de postnatale enterale voeding als de
LCP status bij de geboorte: een hogere 20:4/i-6 concentratie in navelstrengplasma resulteerde
in een hogere 20:4n-6 plasmaconcentratic in de a terme periode, en hogere 22:6n-3 en
20:4/i-6 gehaltes in de arteriële navelstrengvaatwanden gingen gepaard met hogere 22:6n-3
en 20:4«-6 RBC-gehaltes in de a terme periode. Deze bevindingen onderstrepen het belang
van een toereikende LCP voorziening tijdens het intra-utericne leven, met name wanneer er
sprake is van een premature geboorte, een meerlingzwangerschap, of beiden. Aangezien
deze prenatale LCP aanvoer alleen veranderd kan worden door de vetzuurinneming van de
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zwangere vrouw aan te passen, dient nader onderzocht te worden welke invloed een met
EFAs verrijkte voeding tijdens de /wangerschap op de LCP status van het kind heeft. Bij het
onderzoek van Hoofdstuk 7 werd tevens de studie van Hoofdstuk 2 naar de relaties tussen
de EFA status, de zwangerschapsduur, en groeiparameters bij de geboorte verder uitgebreid
door ook de LCP gehaltes in navelstrengplasma en -RBC Fl.s hierbij te betrekken. Na
correctie voor de zwangerschapsduur bij de geboorte bleken gewicht, schedelomtrck en
lengte bij de geboorte echter alleen samen te hangen met LCP waarden in de wand van de
navelstrengarteriën. Wellicht vertonen de LCP-gehaltcs in navclstrcngbloed geen duidelijke
relatie met een langdurig proces als groei, omdat zij een indruk geven van de foetale LCP
status op de kortere termijn.
Tenslotte werd via een dubbel blind gerandomiseerd onderzoek bestudeerd hoc het geven
van een met LCPs verrijkte flesvoeding de postnatale LCP status van te vn>eggcborcn
kinderen beïnvloedt (Hoofdstuk 8). De verrijkte flesvoeding bevatte zowel 22:6M-3 (0.3%)
als 20:4«-6 (0.6%) in hoeveelheden zoals die ook aanwezig zijn in premature moedermelk.
De LCP gehaltes in het bloed van 15 kinderen die de met LCPs verrijkte flesvoeding kregen,
werden vergeleken met die van 16 kinderen die een standaardflesvocding (/.onder LCPs)
kregen, en met die van 12 met moedermelk gevoede prematuren. Tot en met de 35ste
levensdag werd wekelijks een bloedmonster afgenomen en van de flesgevoede zuigelingen
werd ook een monster verzameld 3 maanden na hun aanvankelijke a tcrme datum. Na 4
weken waren de 22:6n-3 en 20:4n-6 gehaltes in plasma en RBC FLs significant hoger in de
met LCP-verrijktc flesvoeding gevoede groep dan in de met standaardflesvoeding gevoede
kinderen. Bovendien waren de bloedwaarden van de verrijkte flesvocdinggrocp vergelijk-
baar met die van de prematuren die moedermelk hadden gedronken. De verschillen tussen
de twee flesvoedinggroepen namen steeds verder loc, hetgeen 3 maanden na de a terme
datum resulteerde in respectievelijk 4 en 2 maal zo hoge gemiddelde plasmawaardcn voor
22:6n-3 en 20:4n-6 in de verrijkte flesvoedinggroep. Zowel in de plasma als in de RBCs,
bleken de verschillen in 22:6/i-3 status ook uit de twee indicatoren van de functionele
22:6«-3 status: CADl waarden waren significant lager en CASl waarden significant hoger in
de met LCPs verrijkte flesvoedinggroep. De bevindingen van deze relatief langdurige
interventie-studie geven aan dat het toevoegen aan premature /.uigclingcnvocding van 22:6/j-
3 en 20:4«-6 in een uitgebalanceerde verhouding, i.e. in gehaltes zoals aanwezig in prema-
ture moedermelk, een geschikte manier is om zowel de 22:6/i-3 als de 20:4n-6 status van
premature flesgevoede zuigelingen te verhogen tot in het bloed van met moedermelk
gevoede prematuren gemeten waarden. De mogelijk gunstige gevolgen van deze gecombi-
neerde LCP-toevoeging voor de algehele ontwikkeling van te vroeggeboren kinderen en die
van hun CZS in het bijzonder, zullen in aanvullende studies nader moeten worden onder-
zocht.
De belangrijkste bevindingen van bovengenoemde studies en hun betekenis voor de
huidige inzichten en toekomstig onderzoek worden besproken in Hoofdstuk 9. Hierbij wordt
in het bijzonder aandacht besteed aan het potentiële nut van een met n-6 en n-3 EFAs
verrijkte voeding voor zwangere vrouwen, foetussen en zuigelingen, alsmede aan het grote
belang van het bepalen van de klinische en functionele relevantie van de biochemische
resultaten.
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